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Abstract
From association to function: elucidating the role of G Protein Signaling
Modulator 3 and variants in its gene locus in rheumatoid arthritis
Bryan Gall

Rheumatoid arthritis (RA) is an autoimmune disease that is estimated to affect
1% of Americans. RA causes significant morbidity as a result of autoimmune stimuli
inducing pro-inflammatory leukocyte recruitment to the joint. Despite the large effect on
quality of life and significant research into RA pathophysiology, there is still much that is
not known about the etiology of RA. Although effective treatment options do exist for RA,
many of them carry significant risks of compliance-limiting adverse effects, high costs,
and a subset of patients do not respond to treatment. This work attempts to respond to
the limitations of current therapeutics by characterizing GPSM3 as a potential genetic
marker and pharmaceutical target for RA through genetic and ex vivo modeling.
Based on data from compelling genome-wide association studies (GWAS), and
supporting evidence from knockout mouse inflammatory arthritis models, we
hypothesize that the G protein signaling modulator-3 (GPSM3) gene and protein play a
significant role in the pathogenesis of RA. Current literature has identified two singlenucleotide polymorphisms (SNPs) in humans, rs204989 and rs204991, associated with
protection from multiple autoimmune diseases including RA. We show that qRT-PCR
analyses of whole blood-isolated RNA from volunteers homozygous for the GPSM3
SNPs show a decrease in GPSM3 transcript abundance compared to volunteers without
the minor SNP alleles. Results from reporter gene studies support rs204989 as the
causal SNP in decreasing GPSM3 promoter activity. In cell line models of neutrophil and
monocyte physiology, GPSM3 deficiency results in disrupted migration patterns toward
LTB4 and MCP-1, respectively. We hypothesize the minor allele of rs204989 represents
a genetic factor contributing to the pathogenesis of RA, acting by decreasing GPSM3
expression and disrupting normal migration toward pro-inflammatory chemoattractants.
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Chapter 1
General Introduction

1

1.1 – Rheumatoid arthritis clinical introduction
1.1.1

– Background
Rheumatoid arthritis (RA) is a chronic, autoimmune polyarthritis that, if left untreated,

leads to deformity, chronic pain, and disability for patients through a process of synovial
inflammation, synovial cell proliferation with angiogenesis, and joint destruction. Clinically, RA is
characterized by chronic inflammation of the synovial tissue of multiple joints, and may manifest
in severe joint deformity2. Additional extra-articular disease co-morbidities, such as vascular
disease from unchecked inflammation, further lead to increased mortality3–5. Improved
understanding of immune system-mediated RA pathogenesis has led to new biologic treatments
that target selective elements of the RA inflammatory response; however, there are still patients
who are non-responders or experience adverse effects limiting their treatment6,7. This is likely a
result of disease variability between the pathology of RA in different patients, characterized by
differences in the frequency and severity of inflammation, duration of inflammation, and
frequency of inflammatory bouts. This variability can be characterized by defining three
subclasses of RA: monocyclic, polycyclic, and progressive RA. A minority of patients present
with monocyclic RA, where a single inflammatory episode occurs and then remission follows.
Polycyclic RA is defined as patients presenting with a continuously fluctuating level of disease
activity, while progressive RA will continue to increase in severity and does not resolve2.

1.1.2 – Treatment Options

1.1.2a – Non-steroidal anti-inflammatory drugs (NSAIDs):

NSAIDs are typically used to treat mild to moderate rheumatoid arthritis as a first-line therapy.
The anti-inflammatory capabilities of non-selective NSAIDs are due to their antagonism of
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cyclooxygenase preventing the conversion of arachidonic acids to prostaglandins. The primary
effect of NSAIDs is likely due to inhibition of cyclooxygenase-2. Conversely, cyclooxygenase-1
is involved in platelet aggregation, gastric protection, and renal regulation. Therefore, inhibition
of cyclooxygenase-1 in non-selective NSAIDs results in many of the reported adverse effects.
Selective NSAIDs have been developed with selectivity for cyclooxygenase-2, and have similar
effects to non-selective NSAIDs with lower risks of adverse effects with prolonged use
(reviewed in 8). Drugs of this class have protective benefits over placebo in patients with RA,
and show improvements in pain and stiffness scores9. At clinical dosages, NSAIDs do not
reduce acute-phase proteins in the serum or inhibit progression of radiographic joint damage8.

1.1.2b – Non-biologic disease-modifying antirheumatic drugs (DMARDs):

Methotrexate (MTX): MTX is currently the first-line therapy for RA. The classical mechanism of
action of MTX in malignancies is the competitive inhibition of the enzyme dihydrofolate
reductase, responsible for the reduction of folic acid to metabolically active forms10. However, in
the treatment of RA the weekly low-dose treatment is approximately three orders of magnitude
lower than the weekly dosing in oncology11, and supplementation of MTX treatment with
metabolically active folates apparently does not disrupt the anti-inflammatory properties of
MTX12. Despite the approval of MTX by the FDA, researchers have yet to fully elucidate its
mechanism of action for low-dose RA therapy. Some proposed hypotheses for this action
include the release of anti-inflammatory adenosine13,14, growth arrest, and impaired adhesion15.
Although most patients respond well to low dose MTX treatment, a number of adverse effects
are noted including bone marrow depression (e.g., anemia, leukopenia), hepatotoxicity, and
immunosupression16.
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Azathioprine: Azathioprine is a purine synthesis inhibitor, disrupting the functions of
amidophosphoribosyltransferase17. The adverse effects of azathioprine are similar to those seen
in MTX treatment18.

Leflunomide: Leflunomide is a pyrimidine synthesis inhibitor, disrupting the functions of
dihydroorotate dehydrogenase19. The adverse effects of Leflunomide are similar to those seen
in MTX treatment, with the addition of hepatotoxicity, and a higher risk of diarrhea. Additionally
Leflunomide is contraindicated during pregnancy, and inhibits the activity of the metabolically
relavent proteins cytochrome P4502C8 and organic anion transporter 320.

Hydroxychloroquine: Hydroxychloroquine treatment results in a decrease in a number of
proinflammatory cytokines including interleukin-1β (IL-1β), IL-6, and tumor necrosis factor alpha
(TNFα). This effect is the result of a poorly understood mechanism of action that may include
inhibition of toll-like receptors21 and alkalization of intracellular vacuoles (disrupting pH sensitive
enzymes and antigen processing)22.

Sulfasalazine: The mechanism of action of sulfasalazine is poorly understood in the context of
RA. Both sulfasalazine and its metabolite are poorly absorbed in the bloodstream23.
Sulfasalazine has been shown to function in isolated colon epithelial and T-lymphocyte
immortalized cell lines through inhibition of IκB kinases. By inhibiting IκB kinases, sulfasalazine
indirectly disrupts proinflammatory Nuclear Factor κB activity24,25. Although sulfasalazine
treatment is generally well tolerated, immunosuppression and megaloblastic anemia can be side
effects due to inhibitory effects on folate synthesis26.
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1.1.2c – Biologics

TNFα Inhibitors (TNFi): TNFi are a drug class that functions by inhibition of TNFα, and result in
marked decreases in inflammatory markers27. There are currently five TNFi approved for
treatment of RA. These are divided into four subcategories: humanized mouse monoclonal
antibodies (infliximab), fully human monoclonal antibodies (adalimumab and golimumab), a
recombinant soluble TNFα receptor-IgG Fc region fusion protein (etanercept), and polyethylene
glycolated humanized Fab fragment (certolizumab)28. Phase III clinical trials with each of the five
TNFi resulted in more than half of patients experiencing a reduction in American College of
Rheumatology (ACR) scores of ≥20% (ARC20) versus placebo, except golimumab
monotherapy (44%)29–32. In head-to-head comparisons between TNFi and MTX, meta-analytic
data show that when administered as a monotherapy, TNFi and MTX are equally efficacious in
reaching ACR20 criteria; however, when TNFi are administered in combination with MTX, TNFi
elicit a significant improvement in ACR20 over MTX alone33. Noted TNFi side effects include
increased risk of serious infections34,35, and of lymphomas36, due in part to the systemic
immunomodulatory role of TNFα37–39. Additionally, the immunogenicity of TNFi can lead to
increased adverse reactions and treatment failure in patients40.

T cell co-stimulatory signal inhibitor – abatacept: Abatacept is a fusion protein composed of the
Fc region of immunoglobulin G (IgG) and cytotoxic T-lymphocyte-associated protein-4 (CTLA4). In order for T-cells to become activated by antigen presenting cells, they require interaction
of the major histocompatibility complex with T-cell receptor and a co-stimulatory interaction
between CD80 or CD86 and CD2841. Conversely interaction between abatacept and CD80/86
inhibits the required co-stimulatory signal and results in decreased activity of T-cells41. In headto-head comparisons of co-administration of MTX with adalimumab or abatacept, the efficacies
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of these two treatments were not statistically different, although abatacept-treated patients did
report fewer adverse effects and a greater number completed the 12-month treatment42.

Anti-CD20 antibody – rituximab: Rituximab is a monoclonal antibody targeting CD20, a cell
membrane-localized phosphoprotein expressed on B-cells but not plasma cells. RituximabCD20 binding results in B-cell cytotoxicity via antibody- and complement-dependent
mechanisms43. Another effect seems to be the inhibition of anti-apoptotic signaling pathways,
further reducing circulating B-cells44. These mechanisms are believed to reduce the production
of B-cell-derived autoantibodies. In a meta-analysis of rituximab monotherapy, it was shown to
have similar efficacy to other non-TNFi biologics with 51% of patients meeting ACR20 criteria45.

Interleukin 1 (IL-1) inhibitor – anakinra: Anakinra is a recombinant form of the endogenous
human IL-1-receptor antagonist. Anakinra functions by binding to and inhibiting IL-1, which acts
as a proinflammatory cytokine in RA. In brief, IL-1 has several functions related to RA
pathogenesis including stimulating bone resorption46, cartilage degradation, and leukocyte
activation47. A phase III trial of MTX non-responders reported mild improvements in percent of
patients receiving anakinra and MTX meeting ACR20 criteria compared to MTX monotherapy
(38% vs. 22%)48. The most frequently reported serious side effect in anakinra therapy is severe
infectious episodes, when compared to placebo49, however head-to-head comparisons are
needed to assess if this is more severe than in TNFi therapy.

IL-6 receptor inhibitor – tocilizumab: Tocilizumab is a humanized monoclonal antibody targeting
the IL-6 receptor, thus disrupting its signaling. Activation of the IL-6 receptor in RA promotes the
pro-inflammatory differentiation of Th17 cells (with Transforming Growth Factor-β), the
production of acute phase proteins50, osteoclast differentiation51, and matrix metalloproteinase
production (with IL-1)52. ACR20 responses in combination with MTX were reported at 61%53,
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and tocilizumab treatment is uniquely effective at decreasing degradation of joint tissue as
well54,55. Treatment with tocilizumab has been shown to increase the risk of infection56 and
immunogenicity57, without the risk of malignancies over placebo56.

1.1.2d – Glucocorticosteroids (GC):
Glucocorticosteroids:

GC

exerts

multiple

anti-inflammatory

effects

relevant

to

the

pathophysiology of RA. One of the effects is to inhibit NF κ B-induced transcription of
proinflammatory genes, such as cyclooxygenase-2, IL-1β58, IL-659, IL-1760, and TNFα61. GC
treatment is most effective prior to onset of tissue damage in early stages of RA (i.e., 1-2 years
post onset), when in combination with a DMARD, GC significantly reduced radiographic bone
erosion62. The primary limitation of GC treatment is off-target effects in the adrenal gland (e.g.,
adrenal hypertrophy), cardiovascular system (e.g., dyslipidemia), kidney (e.g., sodium
retention), and nervous system (e.g., glucocorticoid-induced psychoses) (reviewed in 63)

1.1.3 Treatment Approach

The most common treatment approach for RA follows “treat-to-target” recommendations,
which were initially proposed in 201064, and are now recommended by the American College of
Rheumatology

(ACR)65.

In

summary,

the

overarching

principles

of

“treat-to-target”

recommendations are to maintain either remission or low disease activity by careful monitoring
of disease activity and modifying treatments as deemed necessary by the rheumatologist and
patient64. The ACR has since adapted this principle into their guidelines for the treatment of RA
(Fig. 1.2).
Under the ACR 2015 guidelines, the primary goal for patients presenting with early RA is
disease remission, with disease activity monitored every 1-3 months. If over-the-counter non-
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steroidal anti-inflammatory drugs do not control disease activity, patients are typically prescribed
a non-biologic DMARD monotherapy. Of the classical non-biologic DMARDs, methotrexate
(MTX) is recommended (purine synthesis inhibitor). Other non-biologic DMARDs available to
rheumatologists include azathioprine, leflunomide, sulfasalazine, and hydroxychloroquine. The
goal of this treatment is to enter disease remission. If patients continue to present with high
disease activity following this initial treatment, then combination therapy can be prescribed.
Combination therapy involves the addition of another non-biologic DMARD, a TNFi, or a nonTNF biologic DMARD at the patient and rheumatologist’s discretion. In the event that remission
cannot be attained, the ACR 2015 guidelines recommends an alternative goal of attaining low
disease activity (Fig. 1.1)65. Once the patient’s disease activity meets the criteria for either
remission or continued low disease activity, the treatment goal becomes the maintenance of the
lowest possible disease severity. Typically disease activity will be monitored every 3-6 months,
and treatments will be adapted as required (Fig. 1.1)64,65.

1.1.4 Rheumatoid arthritis risk factors

The mechanism of RA pathogenesis remains elusive, although it is hypothesized that it
is a result of both genetic and environmental factors2. A non-inclusive list of RA risk factors
includes age, sex, smoking, physical activity level, and genetics. It is generally accepted that
onset of RA is most frequently seen in patients greater than 60-years old, with the incidence
rate in women 2-3 times greater than what is seen in men. Smoking is one of the greatest
modifiable risk factors with a reported risk ratio between 1.3-2.42.
The genetic risk factors for RA may have an even more important role in RA
pathogenesis, as indicated by a concordance rate 4.3 times greater among monozygotic twins
relative to dizygotic twins66. Another study in twins confirms this report, estimating genetic
factors contribute 60% of the risk of developing RA67. The introduction of genetic references,
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like the human genome and HapMap projects, has led to significant advances in technologies
such as genome-wide association studies (GWAS). These technologies have contributed
greatly to the understanding of the genetic risk factors involved in RA; however, much of the
complex genetic contributions to RA pathogenesis have yet to be elucidated. An example of the
complexity of this disease is reflected in the results from one of the largest GWAS metaanalyses performed to date. This study analyzed 22 different RA GWAS studies with a total of
>10 million single nucleotide polymorphisms (SNPs) in >100,000 volunteers, and identified 101
risk alleles that were conserved across multiethnic individuals of Asian and European
ancestries68. Another database reports 123 risk alleles that have been confirmed in multiple
independent GWAS69. Among the identified risk alleles, some of the most significantly
associated with RA include haploblocks of HLA-DRB170–72, PADI473, PTPN2274, TNFAIP375,
TRAF1/C576, REL77, and CCR678 (reviewed in ref.72). Despite the advances in GWAS,
conclusions from these studies are strictly limited to disease association. To validate many of
these findings, much more research needs to be performed to better understand the
physiological consequences of many identified genetic variants.

1.2

Neutrophils in Rheumatoid Arthritis

This work is currently being edited for submission as a review publication in: Arthritis and
Rheumatism

1.2.1 Introduction to Neutrophils

Neutrophils represent a terminally differentiated leukocyte population derived from
myeloid progenitor cells, which also give rise to monocytes, basophils, and eosinophils. In
humans, neutrophils are the most common circulating leukocyte in peripheral blood (40-60%)41.
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These cells have multiple granules containing preformed inflammatory mediators and
antimicrobial substances that are tightly regulated to ensure they are not inappropriately
released. In healthy individuals, neutrophils exist in a resting state where they require additional
signals to prime and subsequently release these compounds. Neutrophils require a three-step
process to release pre-formed granules: (1) priming, (2) migration, and (3) activation. Priming of
resting neutrophils is mediated by pathogen-associated molecular patterns (PAMPs; e.g.,
lipopolysaccharides)79 and cytokines (e.g., TNF-α, GM-CSF, IL-8, and IFN-γ)80–82. Primed
neutrophils rapidly mobilize intracellular granules, containing pre-formed receptors, to the
plasma membrane, and priming agents also affect transcription of many genes to alter
neutrophil function and increase lifespan (discussed in detail later). Primed neutrophils can then
migrate to the site of inflammation via chemotaxis and are the first leukocytes to arrive in
inflamed or injured tissues83. Once within the inflamed tissue, neutrophils are activated by autoreactive immunoglobulin complexes, cytokines, and complement, inducing the release of
granule contents (Table 1.1; reviewed in ref. 84).

Once within the inflamed tissues, additional granules containing oxidant-producing
enzymes and proinflammatory compounds are released into the extracellular space and
contribute significantly to tissue damage in chronic disease processes like RA (Table 1.2)85,86.
This non-specific release of cytotoxic mediators is amplified as activated neutrophils continue to
release cytokines that induce further neutrophil and pro-inflammatory leukocyte recruitment in a
positive feedback loop. This positive feedback recruitment must therefore be prevented prior to
any repair of tissues and resolution of the inflammatory response. In healthy individuals the
acute stage of inflammation is followed by the recruitment of anti-inflammatory macrophages
that inhibit neutrophil migration to tissues and removes apoptotic and necrotic cells via
phagocytosis. These macrophages then continue to secrete anti-inflammatory cytokines
promoting the repair of damaged tissues, and resolution of inflammation.
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This review will focus on neutrophil physiology as it pertains the pathophysiology of RA,
covering the recruitment to inflamed synovial tissues, the common presence of neutrophilderived anti-granulocyte and anti-citrullinated protein antibodies in RA patients87, the disruption
of induced arthritic inflammation in transgenic mouse models88, and the ability of neutrophils to
affect other leukocytes.

1.2.2 Recruitment of neutrophils to synovial tissues and fluid

In RA, sterile tissue damage or autoantibody complexes can disrupt tissue homeostasis
resulting in the production of damage-associated molecular pattern molecules (DAMPs) that can
be recognized by resident antigen-presenting cells (e.g., macrophages, dendritic cells) or
resident stromal cells89,90. The activated resident cells then release a number of proinflammatory mediators including IL-1β, TNF-α, lipid mediators (e.g., leukotriene B4), and
chemokines. This process results in recruitment of circulating neutrophils into the synovial
tissues, thereby initiating the tissue inflammation that is a hallmark of RA91.

The cascade of events by which neutrophils are recruited toward pro-inflammatory
mediators includes (1) adhesion to vascular endothelial cells, (2) transendothelial migration, and
(3) migration through tissue along chemokine gradients. (1) Neutrophil adhesion to vascular
endothelial cells is a complex process, which can be further subdivided into (a) vascular
neutrophil activation, (b) rolling adhesion, and (c) tight adhesion. (a) The activation of circulating
neutrophils results in preferential association with vascular endothelial cells. Induction of this
activation state is not completely characterized, but it may be the result of elevated serum
TNFα, IL-1, chemoattractants (e.g., formylated peptides, C5a), or anti-neutrophil autoantibodies
(e.g., ANCA, ACPA)

80,92

. (b) Neutrophil rolling adhesion is a process mediated predominantly

11

through TNFα- and IL-1-activated93 endothelial cell E- and P-selectin interaction with neutrophil
adhesion molecules (e.g., P-selectin glycoprotein ligand-1 [PSGL-1], cluster of differentiation 44
[CD44], and E-selectin ligand 1 [ESL1])94. These weak interactions result in neutrophil “rolling”
in the post-capillary venules at shear stress between 1-10 dynes per cm2 (95), and the process is
mediated by sequential weak binding and vascular shear stress-mediated release of
complementary binding molecules. While neutrophils are rolling across the vascular
endothelium, they are “sampling” chemokines and cytokines from the underlying tissue that are
transported and bound to the apical/vascular surface of endothelial cells by negatively-charged
glycoaminoglycans96. Chemokine receptors on “rolling” neutrophils recognize endothelial-bound
chemokines, resulting in a conformational change of β-integrins increasing their affinity and
promoting (c) firm adhesion of neutrophils to activated endothelial cells proximal to the site of
inflammation97,98. This activation of β1- (e.g., VLA-4) and β2-integrins (e.g., LFA-1, MAC1) occurs
via intracellular signaling networks – believed to be mediated through the actions of G protein βγ
subunits99,100. Once activated, firmly adhered neutrophils can begin the process of
transendothelial migration (reviewed in ref. 94).
(2)

Neutrophil

transendothelial

migration

occurs

following

adhesion;

however,

neutrophils do not frequently transmigrate at the site of initial adhesion. Often neutrophils extend
pseudopods and appear to ‘probe’ the vascular endothelial cells without moving from the initial
anchor point. Under in vivo flow conditions, neutrophils then proceed to slowly migrate along the
endothelial cells, in a MAC-1-dependent process101, perpendicular to forces of shear stress102.
This migration pattern likely increases the odds of a neutrophil recognizing a ‘transmigration
point’, because neutrophils are moving across endothelial cell axis that is elongated by vascular
shear stress and therefore encounter more endothelial junctions103. To leave the vasculature,
neutrophils must first cross the endothelial cell layer through paracellular (i.e., between cells) or
transcellular (i.e., through cells). Because paracellular migration presents the fewest barriers to
migration and occurs more rapidly, neutrophils preferentially use this pathway101,104,105.
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Transcellular migration is observed, but is less efficient and more time consuming104. The
paracellular route typically occurs at endothelial tricellular junctions, where junctional proteins
are at the lowest density105,106. Transmigration involves the interaction of a number of neutrophil
surface molecules (e.g., LFA-1, MAC-1, VLA-4, CD99, PECAM1) with endothelial surface
molecules (e.g., ICAMs, VCAM1, CD99, junctional adhesion molecules) (reviewed in 92).

(3) Following adhesion and transmigration, neutrophils must next migrate through a
number of barriers, including the vascular basement membrane, vascular pericytes, and tissue
matrix. Neutrophils preferentially migrate where the extracellular matrix is least dense107, then
are induced by chemoattractants108 within the basement membrane to release matrix
metalloproteinases (e.g., MMP-9) and proteases (e.g., elastase, collagenase; table 1.4)109.
These enzymes make the basement membrane more porous and allow neutrophils to migrate
toward the vascular pericytes, which are less densely packed in regions with porous basement
membranes, thus are readily circumnavigated110. Migration through additional tissue
extracellular matrix is less dependent on enzymes to degrade matrix, due to the decreased
density of matrix polymers. Migration through additional extracellular matrix is primarily
mediated by chemokine gradients92. The final barrier to entry of neutrophils into the synovial
tissues in early RA is a poorly vascularized layer of cartilage. This process is not well
characterized, but is likely a result of the actions of neutrophil collagenase, elastase, and MMP9
(Table 1.2). There is less of a necessity to migrate through cartilage late in the RA inflammatory
response, because of the formation of a neovascularized pannus, formed by synoviocyte
hyperplasia, within the synovial tissues111. The additional blood vessels within the synovial
tissues likely increase leukocyte recruitment by decreasing the distance and barriers to
migration.
In RA, the process of neutrophil migration through these barriers to the site of
inflammation is mediated by a number of chemoattractant gradients. Chou et al. highlights the
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complexity of neutrophil recruitment by hypothesizing that a temporal cascade of leukotriene B4
(i.e., LTB4 or 5,12-diHETE), IL-1β, then CXCR2 agonists (e.g., CXCL1/GROα, CXCL2/GROβ,
CXCL8/IL-8)112 and complement orchestrates leukocyte recruitment in RA112–114, a hypothesis
that is widely accepted by others in the field86,115,116. Initially, lipid mediators like LTB4, a highly
potent chemoattractant for neutrophils, are produced at a low concentration by activated
resident leukocytes. The low concentration of LTB4 induces in a mild recruitment of circulating
neutrophils, which are activated in synovial tissue, leading to the release of additional LTB4,
thus establishing a positive feedback loop and markedly increasing the number of neutrophils
recruited. One study has shown this positive feedback on neutrophil-derived LTB4 results in
concentrations as high as 400 ng/ml (1.2 µM) in synovial fluid samples of a cohort of
seropositive RA patients during inflammatory bouts117. The role of LTB4 in rheumatoid arthritislike inflammation is apparent in leukotriene B4 receptor 1 (Ltb4r1 or Blt1)-deficient mice that
exhibit a profound lack of detectable inflammation in both serum-transfer (K/BxN)112 and
collagen-induced (CIA)118,119 models of inflammatory arthritis. Similar protection from models of
arthritis are also afforded to mice deficient in enzymes involved in LTB4 synthesis, including 5lipoxygenase activating protein (Flap)120, 5-lipoxygenase (Alox5)121, and leukotriene A4
hydrolase (Lta4h)121; protection was also reported in mouse models utilizing pharmaceutical
inhibitors of many of these enzymes122–124. Of note, inhibition of LTB4 receptor with the orallyactive competitive antagonist, BIIL 284, did not significantly improve ACR20 scores in a 3 month
clinical trial performed in patients with RA125. Although not reported in the literature, an
additional LTB4 receptor inhibitor (CP-195,543

126

; clinicaltrials.gov) also failed in clinical trials

due to a poor tolerability profile. These results from human trials are discrepant from positive
effects seen in mouse models, but may be a result of a elevated concentrations of LTB4
outcompeting the antagonist or the confounding requirement that patients cease their
therapeutic regimens prior to these studies. An alternative approach to inhibit LTB4 signaling
may be to target an enzyme involved in LTB4 synthesis, which had been attempted in clinical
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trials with a soluble phospholipase a2 inhibitor, LY333013, but was speculated to be hampered
by poor uptake into synovial fluid and tissues127. An additional LTB4 synthetic enzyme to target
may be LTA4 hydrolase, which would decrease levels of LTB4 secreted and prevent the
inflammatory response in RA. Despite the inconclusive human clinical trial data, the previous
mouse model studies and the elevated LTB4 levels detected in human synovial fluid suggest a
role for LTB4 as an obligate mediator of early recruitment of neutrophils.

Following LTB4-induced recruitment, additional chemoattractant signals are important in
the continued recruitment of neutrophils. Recruited LTB4R1-positive neutrophils are then
stimulated to release IL-1β in response to the increased synovial concentration of DAMPs (e.g.,
antibody complexes, purine metabolites, hyaluronan monomers, nucleic acids, interferons), and
consequently, autocrine IL-1β signaling upregulates neutrophil synthesis and secretion of
proinflammatory mediators, including LTB4, CCR1 agonists, and IL-8112,128. The clinical
importance of IL-1β in arthritis is highlighted by the utility of Anakinara, an FDA-approved
therapeutic synthesized from human recombinant interleukin 1 receptor antagonist (IL-1Ra)49.
Of note, mouse strains deficient in IL-1β production (i.e., pro-Il1b-deficient and caspase-1deficient) are not protected from K/BxN serum transfer-induced acute paw swelling; however,
these mice are protected from cartilage damage, proteoglycan depletion, and cell influx to
synovial tissue in Streptococcal cell wall-induced chronic arthritis129. However, the role of IL-1β
is highlighted by the exogenous administration of recombinant IL-1β to Ltb4r1-deficent mice
restoring K/BxN serum transfer-induced acute arthritis, presumably via by-passing the
requirement for LTB4-signaling to initiate this IL-1β production112. Therefore, it may be that the
innate immune-driven models of acute arthritis may be capable of inducing inflammation
primarily through lipid mediators (e.g., LTB4), but prolonged recruitment and activation of
leukocytes is driven through IL-1β signaling.
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In the pathophysiology of rheumatoid arthritis, recruitment of additional lymphocytes is
required, and is believed to be partially mediated by IL-1β inducing the release of neutrophil
extracellular traps (NETs)130. NETs have been shown to contain various targets for lymphocytederived autoantibodies, including neutrophil cytoplasmic and histone proteins that have been
citrullinated by enzymes like protein arginine deaminase 4 (PADI4). Anti-citrullinated protein
antibodies (ACPA) and anti-neutrophil cytoplasmic antigen (ANCA) are hallmark RA
autoantibodies that target these entities released from NETs131–133. Additionally, NET release
from neutrophils releases a number of lymphocyte activating components (described in detail
later). Although the complete mechanism of IL-1β in acute and chronic arthritis requires
additional study; however, at least part of the role for IL-1β is the formation of NETs, which in
turn release auto-antigens necessary for the chronic inflammatory state of RA.

IL-1β also stimulates the release of resident leukocyte-derived CXCR2 agonists,
including CXCL1 (GRO-α), CXCL2 (GRO-β), and CXCL8 (IL-8), all of which amplify the
recruitment of neutrophils to continue the inflammatory response within synovial tissues112. In
Cxcr2-deficient mice K/BxN serum-induced inflammatory arthritis does not appear to be different
from the wild-type mice over the first 5 days. After that time, there is significant decrease in
ankle swelling in the Cxcr2-deficient mice134; furthermore, mice treated with a synovial injection
of a dominant-negative form of CXCL8 also exhibited only partial decreases in nociception in a
methylated bovine serum albumin-induced model of inflammatory arthritis135. These data may
reflect the temporal relationship of CXCR2 ligand signaling to the inflammatory process, i.e.,
primarily involved in late phase inflammation in RA113. Therefore, the CXCR2-deficient and blocked models of disease may develop early LTB4- and IL-1β-dependent inflammation but be
protected from prolonged inflammation that is not reliably demonstrated in acute inflammatory
arthritis models112,134. IL-1β may also increase recruitment of monocytes/macrophages, given
that treatment of human monocyte-derived macrophages with IL-1β induces production of CCL2
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(MCP-1)136 as well as endothelial cell CX3CL1 (fractalkine) expression137, both of which are
monocyte/macrophage chemoattractants138–140. The influence of CCL2-induced monocyte
recruitment may however be a minor component of arthritic inflammation. This notion is
supported by the lack of protection in Ccr2-deficient mice and moderate protection in Cx3cr1deficient mice in K/BxN serum-induced inflammatory arthritis134, as well as blockade of CCR2
and CCR5 failing to inhibit primary human monocyte recruitment in vitro or offer therapeutic
benefits in clinical trials141.

Beyond the LTB4/IL1β/CXCR2 axis, recruitment of neutrophils to synovial tissues in RA
also occurs as an indirect result of autoimmune antibodies (e.g., ANCA, ACPA) or acute phase
proteins (e.g., C-reactive protein) that activate the complement cascade, and additionally
produce anaphlyatoxins like complement component 5a (C5a)142,143. The role of C5a in RA
pathophysiology is supported by C5ar-deficient mice exhibiting protection from K/BxN serum
transfer arthritis114, while C5a144 and C5a receptor145 antagonism by monoclonal antibodies
protects wild type mice from collagen-induced arthritis models. Furthermore, mutations in the
human C5 gene, which enhance the rate of proteolysis of the inert C5 protein into the
anaphylatoxin C5a146, are risk alleles for RA76,147. These and other findings have led Novo
Nordisk to develop a therapeutic C5a receptor inhibitor, which is currently in clinical trials145.
However, it has yet to be fully elucidated how C5a signaling is incorporated into the proposed
temporal chemokine cascade.

In summary, these aforementioned data support the sequential recruitment of
neutrophils and other leukocytes through the sequential functions of LTB4, IL-1β, CXCR2, and
complement, which emphasizes the importance of each in the pathogenesis of RA. Lack of RA
protective phenotypes detected in Ccr1-9, Cxcr3, and Cxcr5-deficient mouse strains further
support a central role for this LTB4/IL-1β/CXCR2 chemokine axis in the development of
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inflammatory arthritis134. However, there has been recent mild success in clinical trials of the
CCR1 antagonist CCX354-C148. In this study, relative to placebo, patients naïve to traditional
biologic medications saw an improved ACR20 response (≥20% improvement in 3 of 5 diseaserelevant criteria; placebo - 26% vs. CCX354-C - 62%) and a trend toward improvement of
ACR50 response (≥50% improvement in 3 of 5 disease-relevant criteria; 15% vs. 35%) following
placebo or CCX354-C treatment, respectively148. The greatest mRNA expression of CCR1 is
seen in both neutrophils and monocytes, important innate immune cells in RA pathogenesis149,
and therefore may support the additional complexity of human rheumatoid arthritis versus
mouse models thereof.

Furthermore, the LTB4/IL-1β/CXCR2 model may not completely explain neutrophil
chemotaxis, as no mouse models of arthritis completely replicate human rheumatoid arthritis. It
is also noteworthy that differences in physiology exist between human and mouse neutrophils.
For example neutrophils only represent 10-25% of circulating leukocytes in mice150 compared to
the 40-80% that human neutrophils represent41. Additionally, protein expression of the CXCR2
sister receptor, CXCR1 – that shares many agonists with CXCR2, is absent in mouse
neutrophils150; moreover, production of some cytokines including IL-6116 and IL-10151 is shown in
mouse neutrophils, but in human neutrophils remains controversial. Furthermore, different
models of inflammatory arthritis in mice may disproportionately represent certain arms of the
immune response. For example, acute models of arthritis include K/BxN serum transfer and
collagen antibody-induced arthritis (CAIA) that primarily model the innate immune response to
autoantibody deposition. Chronic models of arthritis include as collagen-induced arthritis (CIA)
and Streptococcal cell wall-induced arthritis (SCW), that involve both the innate and adaptive
immune responses to develop autoantibodies. Stating these differences is not meant to suggest
that the mouse models are non-translatable to the features of human RA, but rather these and
other differences must be taken into account when interpreting mouse data. Therefore, although
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a fair amount is known in human RA pathogenesis as a result of clinical studies, the need for
additional clinical trials, in vitro, and genomic studies cannot be understated.

1.2.3 Neutrophil degranulation

Upon migration into the synovial tissues, cytokine-primed neutrophils can recognize both
soluble and tissue-deposited antibodies (e.g., ACPA) via one of 3 highly expressed receptors
(FcγRI, FcγRII, and FcγRIIIb), and activation of these receptors on primed neutrophils can
initiate degranulation. Disruption of the normal physiology of each of these receptors may be
involved in RA pathogenesis. (1) FcγRI (CD64) is a high-affinity receptor for IgG antibodies.
FcγRI is not expressed at the cell surface in unprimed neutrophils from healthy individuals, but
is expressed in neutrophils isolated from the synovial fluid of RA patients. The expression of this
high-affinity antibody receptor may increase the sensitivity of RA neutrophils to antibody
complexes resulting in increased degranulation152.

(2) FcγRII (CD32) is a low-affinity

constitutively expressed receptor that exists in two isoforms, the activating FcγRIIa153 and
inhibitory FcγIIb154 receptor. The importance of the balance between these isoforms is illustrated
by the nearly doubled rate of radiologic joint damage in RA patients homozygous for the loss of
function non-synonymous 695T>C polymorphism in the FcγRIIb gene154. Further evidence of
the importance of the balanced expression of these two isoforms is represented by infliximab
(TNFi) treatment, which induces a shift in expression favoring the inhibitory isoform and may
contribute to some of its therapeutic benefits in RA153. Finally, (3) FcγRIIIb (CD16) is a low
affinity receptor shown to play a role in reactive oxygen species production155. This receptor is of
particular interest as an RA therapeutic target, because individuals completely deficient in
FcγRIIIb transcript do not have impairment in bacterial phagocytosis156, but exhibit a functional
deficit in antibody complex-mediated cytokine release154. Therefore, therapeutic inhibition of

19

FcγRIIIb may prevent leukocyte recruitment via disruption of reactive oxygen generation and
cytokine release, but not affect host defense responses to bacteria.

Following activation by immune complexes, neutrophils then degranulate and produce
reactive oxygen species O2-, OH-, and H2O2 (via NADPH oxidase) and HOCl (via
myeloperoxidase). Normal resting neutrophils have little capacity to produce reactive oxygen
species, because (1) the NADPH oxidase enzyme is multimeric and assembled at the plasma
membrane during priming157 and (2) myeloperoxidase is contained within azurophilic granules
and inactive without NADPH oxidase production of its substrate H2O2158. Following neutrophil
activation in RA, NADPH oxidase enzyme is assembled and produces substrates for
myeloperoxidase, resulting in the oxidative burst that increases oxidative stress in the synovial
tissues. Increases in reactive oxygen species have been partially implicated in the pathogenesis
of RA159, and RA patients display increased NADPH oxidase activity compared to controls160,161.
The effects of reactive oxygen species in RA are likely mediated through a number of processes
that result in synovial cell and tissue damage. Synovial cell damage follows oxidation of cell
components and activation of NFκB transcription, both of which results in the transcription of
proinflammatory genes (e.g., COX-2, PLA2, IL-1β, TNFα) and propagate the inflammatory
response162. Reactive oxygen species also induce tissue damage directly through of catalysis of
cartilage proteoglycans by HOCl and H2O2

85,163

, and HOCl can promote cartilage degradation

by activation neutrophil collagenase and gelatinase163.
The oxidative burst also occurs concurrent to neutrophil degranulation, which positively
correlates with severity of synovial tissue inflammation and damage in RA patients164. Neutrophil
degranulation results in release of preformed granule enzymes that degrade structural
components of the synovial tissues (Table 1.2). When neutrophils are activated these granule
components are released into the synovial fluid, while autoantibodies deposited on synovial
tissues result in release of granule components directly on tissues in a process known as
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frustrated phagocytosis81,86 (Fig. 1.3). The neutrophil granule proteases, metalloproteases,
catabolic enzymes, and reactive oxygen species act in concert to degrade high-molecular
weight components of cartilage85,161,165. Elastase166, collagenase166, matrix metalloprotease
9167,168, and gelatinase168 are all present within neutrophil granules (Table 1.2), and have all
been shown to degrade the cartilage matrix. The activity of these enzymes results in the direct
tissue damage of arthritic synovial tissues, a hallmark of RA histopathology.
In summary, the role for antibody complex-induced activation and degranulation of
neutrophils has been revealed by in vitro experiments in which co-culture of cell-free synovial
fluid from RA patients with primary circulating neutrophils resulted in a significant increase in
NADPH oxidase activity over those treated with synovial fluid from patients with other joint
arthropathies. In the same study, depletion of synovial fluid antibodies resulted in a marked
decrease in NADPH oxidase activity169, and blockade of neutrophil FcγRIIIb and FcγRIIa
disrupted reactive oxygen species formation in response to soluble and insoluble antibody
complexes, respectively155. These observations support the role of RA autoantibody complexes
in the production of neutrophil reactive oxygen species and degranulation (Table 1.1 and 1.2)
leading to the hallmark non-specific tissue damage that ensues86.

1.2.4 Neutrophil extracellular traps in rheumatoid arthritis

Formation of neutrophil extracellular traps (NETs), first described by Brinkmann et al.170,
represents a unique form of neutrophil cell death distinct from apoptosis and necrosis
(reviewed171) that may be involved in the pathophysiology of RA. Correlative evidence shows
neutrophils isolated from RA patients more readily undergo the formation of NETs than
neutrophils isolated from patients with other forms of arthritis132. NET release results from the
deimination of histone arginine to citrulline by PADI4 and degradation of the nuclear
envelope172. Chromatin, in association with multiple anti-microbial granule components such as
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myeloperoxidase, elastase173, and LL37131,174, is then released into the extracellular space175.
The excessive release of citrullinated chromatin and numerous citrullinated antigens present in
NETs, including elastase, cathepsin G, proteinase 3, α-defensins, and LL37131,176,177 act as
potential autoantigens; therefore, NETs have been proposed to be a primary source of
citrullinated peptides that can induce formation of ANCA autoantibodies132. The importance of
this process in the development of inflammatory arthritis is demonstrated by protection from
collagen-induced arthritis inflammation via therapeutic inhibition of a citrullinating enzyme
present within NETs, PADI4178. Together these findings support a role for NET formation in RA
pathogenesis by presenting potential autoantibody targets during the conversion of acute
inflammation into an adaptive humoral immune response that is the hallmark of autoimmune
RA. Further explanation of the development of autoantibodies specific for NET-released
antigens is reviewed in depth by Darrah & Andrade179, and the role of NETs in autoimmunity is
reviewed in depth by Dwivedi & Radic180.

1.2.5 Neutrophil modulation of immune cells

Innate immune cells are a subset of leukocytes classically described by their ability to
respond to generic molecular patterns (e.g., DAMPs and PAMPs) immediately but innate
immune cells are incapable of inducing long-term immunity for the host, like adaptive immune
cells can. Classically, neutrophils, basophils, eosinophils, macrophages, dendritic cells (DCs),
natural killer (NK) cells, and mast cells comprise the innate immune cell class of leukocytes41.
Innate immune cells, like neutrophils, help to establish the chronic inflammatory response in RA
and activate the adaptive immune response. Neutrophils are typically the initial leukocytes
recruited, and therefore affect recruitment and activation of additional cells including
macrophages, DCs, and lymphocytes (described later, reviewed in refs.86,115,181).
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Neutrophil-macrophage interaction: Macrophages are a subset of leukocytes derived
from circulating monocytes or from tissue macrophage mitosis. Their canonical function is to
recognize and phagocytize moieties that are considered dangerous, then present antigen to
lymphocytes to induce an adaptive immune response41. Neutrophils and macrophages share
several common functions (e.g., phagocytosis, production of reactive oxygen species, cytokine
production), possibly due to their common origin from myeloid progenitor cells; however, unlike
short-lived neutrophils, macrophages have a lifespan on the scale of months and reside within
tissues41. While resident synovial macrophages induce the recruitment of neutrophils,
neutrophils in turn recruit additional circulating monocytes through the release of chemokines
like CCL2 (MCP-1), CCL3 (MIP-1α), and CCL4 (MIP-1β)136,137,182. Neutrophils then release a
number of cytokines that affect macrophage responses to inflammation. For example, activated
neutrophils82 can produce interferon-γ183,184, which promotes polarization of monocytes toward
proinflammatory M1 macrophage physiology185,186. In RA the activation of macrophages can
induce pathogenic generation of reactive oxygen species, cytokines, and activation of
lymphocytes of the adaptive immune response41,187.

Beyond the production of cytokines, neutrophils can also affect macrophages through
the release of myeloperoxidase188, which can directly damage synovial tissues and, in the
context of alveolar inflammation, interacts with the macrophage mannose receptor to increase
reactive oxygen species, TNF-α, and IL-1β production189. TNF-α and IL-1β at sites of
inflammation increase survival of recruited neutrophils, potentially prolonging and exacerbating
inflammation190. Further work suggests Mpo-deficient (myeloperoxidase-deficient) mice are
protected from the inflammatory phenotypes seen in collagen-induced arthritis, although it is
difficult to determine if these effects are the result of a reduction of direct tissue damage or a
reduction of myeloperoxidase activation of macrophages191. In the rheumatic arthritic joint, this
interaction between neutrophils and macrophages may both augment tissue damage via
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release of proinflammatory mediators (e.g., cytokines, reactive oxygen) and further recruit
additional leukocyte subsets, thereby affecting RA pathophysiology.

Neutrophil and dendritic cell (DC) interaction: DCs are another antigen-presenting cell
type that functions to process antigens, migrate to proximal lymph nodes, and present antigens
to lymphocytes to induce adaptive immune responses. Once activated by antigens, in this case
RA-related autoantigens, DCs migrate through the lymphatic system. This process allows
transport of antigen from distal sites of inflammation to lymphoid organs, which contain
lymphocytes required for the establishment of adaptive immune responses41. Neutrophils are
seen to co-localize with DCs when cultured together192, and their interaction is able to activate
DCs naïve to antigen, which in turn elicits lymphocyte activation193. Neutrophils also produce a
number of chemokines capable of recruiting mature DCs to sites of inflammation, the most well
characterized being CCL21194 (see Table 1.3; neutrophil cytokine production). This capacity to
recruit DCs suggests that initial neutrophil recruitment to inflammation zones may result in
recruitment of local tissue DCs allowing their collection of antigens for presentation to adaptive
immune cells. If this is the case, neutrophils would play an integral role in the conversion of an
acute synovial inflammatory response to a chronic pathology like RA.
Activated neutrophils also release granules and NETs containing a number of alarmins
(e.g., HMGB1, α-defensins, LL-37) that are capable of affecting DC migration and maturation.
HMGB1-DNA complexes are one example of a neutrophil-derived alarmin that influences both
migration and activation of DCs via the TLR9 receptor195; this process results in the activation of
a cytotoxic TH1 response196. Additionally, neutrophil granule-derived α-defensins (Human
Neutrophil Peptide-1 and -2) are capable of recruiting immature DCs toward sites of
inflammation197, and a cathelicidin, LL-37, from neutrophil granules is observed at a higher
concentration in RA synovial fluid compared to healthy controls. LL-37-targeted autoantibodies
have also been detected in rat models of arthritis198. Additionally, in the presence of DNA, LL-37
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acts via a TLR7- and TLR8-dependent manner in DC maturation, and expression of lymphocyte
co-stimulatory membrane proteins131,174,199. Thus, LL-37 may be a target of pathogenic
autoantibodies in RA, and neutrophil-derived alarmins influence the function of DCs in RA
inflammation.
Beyond cytokine signaling, the physical interaction of neutrophils and DCs also plays a
role in RA pathophysiology. Under inflammatory conditions, neutrophil cell surface expressed
Mac-1 (CD11b/CD18) interacts with DC cell-surface expressed DC-SIGN resulting in (1)
activation of DCs and (2) presentation of antigens to DCs192. The activation of DCs in a
neutrophil-DC complex will result in DC expression of lymphocyte co-stimulatory molecules
(e.g., CD80, CD86, CD40, and HLA-DR192,193), that are required for activation of lymphocytes,
and therefore an adaptive immune response. Another neutrophil cell surface molecule, CECAM1 (CD66a), is also capable of interacting with DC-SIGN, resulting in a delay of neutrophil
apoptosis and a prolonged inflammatory response152. In summary, an important role exists for
neutrophil and DC interactions in the progression of RA.

Neutrophil activation of adaptive immune response: The adaptive immune response is
defined by the activation and responses of B- and T-lymphocytes, a specialized subset of
leukocytes capable of recognizing specific antigenic signals. In contrast to the innate immune
response discussed until this point, the adaptive immune response requires 1-2 weeks to be
fully activated, recognizes highly specific antigens (not non-specific molecular patterns), and
can generate a memory response for rapid mobilization during subsequent antigenic
challenges41. Activated neutrophils can affect the adaptive immune response by promoting the
migration of both B- and T-lymphocytes (Table 1.3). However, the canonical role for neutrophils
in adaptive immunity is indirect via the activation of antigen-presenting cells (e.g., macrophages
and DCs). This activation induces expression of co-stimulatory molecules that are capable of
activating antigen specific lymphocytes.
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Neutrophils are also capable of expressing MHC class II molecules and thereby directly
activating lymphocytes. In vitro, synovial fluid neutrophil activation by GM-CSF and IFN-γ has
been shown to induce cell surface expression of MHC class II with low expression of costimulatory molecules CD80 or CD86200. Furthermore, in vitro treatment of peripheral
neutrophils with GM-CSF, IL-4, and TNF-α increases cell surface protein localization of MHC
class II molecules (e.g., HLA-DR and HLA-DQ), CD80, and CD86201. Primary synovial fluid
neutrophils from RA patients exhibit a similar expression profile and are capable of activating
primary T-lymphocytes in co-culture202,203. The activation of CD4+ T helper 2 (Th2) cells can
promote antibody production, which can result in the production of additional autoantibodies. In
summary, the MHC class II and co-stimulatory molecule expression by neutrophils appears to
be context-dependent and present within RA inflammatory attacks. The extent of MHC class II
presentation may also be a factor in individual susceptibility to various autoimmune diseases.
Therefore, activated RA synovial neutrophils and recruited T-lymphocytes probably interact
cooperatively to propagate antibody production and inflammation in RA.

1.2.6 Resolution of neutrophil recruitment

Resolution of a normal inflammatory response, within the synovial tissues, is a highly
regulated process that protects the host from prolonged inflammation and prevents the
establishment of a chronic inflammatory response. A chronic disease, like RA, is the result of a
decreased ability to stop the acute inflammatory response. An integral cell type involved in RA
pathophysiology is neutrophils, thus prolonged lifespan of RA neutrophils and disrupted egress
from inflamed tissues may lead to chronic inflammatory responses. Many recruited neutrophils
enter apoptosis following a normal inflammatory response, and then are cleared from the
tissues by anti-inflammatory macrophages. Apoptosis in healthy peripheral blood neutrophils
typically results in a short lifespan, with a half-life of between 18 and 90 hours as shown by in
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vivo labeling studies204, and cultured neutrophils from RA patients exhibited a delay of apoptosis
between 6-22 hours compared to healthy controls205. The lifespan of neutrophils increases
significantly in the pro-inflammatory RA synovial tissues, where changes in dissolved oxygen
and pH significantly delay apoptosis and resolution of inflammation206,207. There are also
populations of neutrophils in RA that avoid apoptosis and return to the vasculature by reverse
transmigration. As many as 2% of peripheral blood neutrophils from RA patients may have
undergone reverse transmigration, in contrast this population make up only 0.25% of peripheral
blood neutrophils are seen in healthy donors208. The implications of this process are not known,
but it could be a protective mechanism to decrease the neutrophil load in synovial tissues, or a
pathogenic mechanism that establishes a systemic state of inflammation. Although the process
of neutrophil apoptosis versus reverse migration is not completely characterized, some
hypotheses for the delay in neutrophil apoptosis include disrupted lipid mediator class
switching209,210, elevated serum and synovial fluid concentration of GM-CSF in RA
patients207,211,212, elevated synovial fluid lactoferrin concentrations213, and hypoxic conditions
within the inflamed synovial tissue206. Regardless of the cause, it appears there is a significant
role of the anti-apoptotic protein myeloid cell leukemia sequence 1 (Mcl-1) in neutrophil
apoptosis, as mRNA levels of Mcl-1 positively correlate to GM-CSF levels in RA synovial
neutrophils211 and treatment of peripheral neutrophils with GM-CSF stabilizes Mcl-1 protein
following cycloheximide treatment207. Additionally treatment with Seliciclib, an inhibitor of cyclindependent kinases (CDKs), was shown to increase neutrophil apoptosis, decrease Mcp-1
mRNA expression, and improve clinical scores in mouse models of arthritis214. Of note,
methotrexate treatment also restored normal rates of apoptosis in isolated neutrophils205, which
may represent an additional mechanism of action in preventing RA pathophysiology.

In

summary, the prolonged lifespan of activated neutrophils in the synovial tissues may contribute
to increased tissue damage.
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Another mechanism to resolve acute inflammation is hypothesized to be initiated by a
class switching of secreted lipid mediators (i.e., eicosanoids), although the mechanisms and cell
sources of this process are incompletely understood209. Part of class switching of lipid mediators
is the decrease in production of neutrophil-derived proinflammatory lipids like LTB4 and PGE2,
and

an

increased

synthesis

of

lipoxins.

Lipoxins

antagonizes

continued

neutrophil

recruitment209,215, and promote recruitment of anti-inflammatory subsets of macrophages to
remove apoptotic neutrophils, release anti-inflammatory cytokines, and initiate tissue repair210.
Additionally, endogenous glucocorticoids promote resolution of inflammation. Endogenous
glucocorticoids (e.g., cortisol) cause neutrophils to increase cell surface localization of annexin
1, which inhibits continued neutrophil adhesion and transmigration216. Neutrophil-derived
annexin 1 rich microparticles are released by the cell to inhibit continued neutrophil adhesion217.
In RA, the activation of endogenous glucocorticoids is decreased by lower enzymatic activity of
11β-hydroxysteroid

dehydrogenase

type

1

and

an

increase

of

11β-hydroxysteroid

dehydrogenase type 2, a glucocorticoid inactivating enzyme218. In summary, impaired neutrophil
apoptosis and response to pro-resolving molecules in RA are likely involved in the development
of a chronic disease state.

1.2.7 Conclusions

Neutrophils are classically associated with the host response to pathogenic microbes,
but they also are becoming more accepted as an important modulator of sterile inflammatory
diseases such as arthritis. Neutrophils represent the first class of circulating immune cells to be
recruited to synovial tissues in RA, and continue to recruit additional neutrophils through a
cytokine positive-feedback loop. Continued recruitment and activation of neutrophils allows the
release of granule products capable of damaging local tissues. Further propagation of
inflammation is exerted by neutrophil interaction with additional immune cells via cytokines or
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cell-cell interactions. This process supports neutrophils as a key regulator of RA inflammation,
and the therapeutic potential of disruption of neutrophil physiology in RA and other sterile
inflammatory diseases.
1.3 GPSM3 in cell physiology
This work below was published in ref.219:
Billard, M. J., Gall, B. J., Richards, K. L., Siderovski, D. P. & Tarrant, T. K. G protein signaling
modulator-3 : a leukocyte regulator of inflammation in health and disease. Am J Clin Exp
Immunol 3, 97–106 (2014).
1.3.1 Signaling interactions
Elucidating the function and regulation of G protein coupled receptors (GPCRs) was
recently recognized with a 2012 Nobel Prize, and these proteins continue to be the largest class
of cell-surface receptors successfully targeted for the treatment of human disease220,221. GPCRs
are functionally associated with heterotrimeric G proteins composed of Gα, Gβ, and Gγ
subunits. When the receptor is inactive, Gα is bound to guanosine diphosphate (GDP) in its own
inactive state; GDP binding to Gα promotes its association with the Gβγ dimer, which inhibits
spontaneous GDP release by Gα and also assists in receptor coupling. After ligand binding, the
GPCR acts as a guanine nucleotide exchange factor (GEF) promoting the replacement of GDP
with guanosine triphosphate (GTP) and leading to conformational changes that result in
dissociation of Gβγ from the heterotrimeric complex. Both GTP-bound Gα and free Gβγ initiate
signal cascades to downstream effectors. Hydrolysis of GTP to GDP returns Gα to its inactive
state, allowing re-association with Gβγ and signal termination222,223.
Chemokine receptors are GPCR family members that signal through Gαi-containing
heterotrimers to regulate cellular migration, survival, and angiogenesis in inflammatory
conditions224,225. However, as drug therapy targets in autoimmunity, chemokine receptors have
had disappointing results in various neutralization strategies141,226 and, in particular, in the
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development of chemokine signaling inhibitors as rheumatoid arthritis (RA) therapeutics227,228.
This failure has been attributed, in part, to redundancy of chemokine receptor/ligand interactions
in inflammation224, and so it has been proposed that a more efficacious strategy should target a
shared pathway regulator of chemokine receptor signaling rather than neutralization of a
specific chemokine or its receptor(s) per se229.
GoLoco motif-containing proteins are regulators of GPCR signaling that share a
signature 19-amino-acid sequence230,231, as well as a hallmark biochemical activity of inhibiting
Gαi release of GDP223,232–234. One such member of this protein family with a highly-restricted
expression pattern (Fig. 1.4), GPSM3 (a.k.a. AGS4235 or G18236), possesses three GoLoco
motifs (but only two are functional236) and an additional LSL motif required for Gβ subunit
binding237. The functional GoLoco motifs of GPSM3 allow the protein to bind Gαi·GDP and act
as a GDP dissociation inhibitor (GDI)235,236 independent of Gαi·GDP interaction with the Gβγ
dimer234,238, while the LSL motif interaction with monomeric Gβ subunits is suspected to regulate
GPCR/G-protein heterotrimer association at the level of Gβγ dimer assembly237 (Fig. 1.5). The
cellular and biologic effects of GPSM3 continue to be explored as recent research points to its
important regulatory functions in chemokine receptor signaling, monocyte phenotypes, and
autoimmune disease development.
Recent studies by Giguere et al. have illustrated that GPSM3 deficiency affects the
chemotactic response of myeloid cells activated through the chemokine receptors CCR2,
CX3CR1, and CMKLR1239. Ongoing biochemical and cell biological research is helping to define
the specific role that GPSM3 plays in the intracellular sequelae of chemokine receptor signaling
and how this role ultimately affects cellular chemotaxis and viability.
Not only does GPSM3 interact with Gαi·GDP and monomeric Gβ subunits, but from
studies of local energy transfer between fusion proteins expressed in cells, it is hypothesized
that GPSM3 may also help position Gα subunits at the cell membrane, proximal to GPCRs, and
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thereby help provide a signaling substrate to ligand-activated receptors240; however, these latter
results from ectopic overexpression of recombinant fusion proteins have yet to be confirmed in
an endogenous expression context. More controversial is the suggestion that GPSM3 may
regulate GPCR signaling pathways via GoLoco motif interactions that directly promote the
dissociation of Gα and Gβγ independent of GPCR/ligand-stimulated GEF activity232; evidence
from both structural biology studies234 and electrophysiological recordings of Gβγ-gated ion
channels238 suggest that the GoLoco motif/Gαi·GDP interaction is mutually exclusive to the
assembly of a traditional Gαi·GDP/Gβγ heterotrimer, but that the GoLoco motif cannot itself
displace a preformed Gαi·GDP/Gβγ heterotrimer.
A common outcome of chemokine receptor signaling is the mobilization of internal
calcium stores via Gβγ-mediated activation of phospholipase-Cβ (PLCβ) (Fig. 1.5). Ectopic
GPSM3 expression is seen to negatively affect GPCR signaling by decreasing PLCβ-mediated
generation of the second messenger inositol trisphosphate (IP3)239. This inhibitory effect
requires GPSM3 interaction with Gβ subunits, given that a specific loss-of-function mutation to
the Gβ-interaction site within GPSM3 (i.e., mutation of the “LSL” motif) abrogates inhibition of
IP3 accumulation after agonist stimulation; it is important to note that mutation to the LSL
mutation does not affect the GPSM3/Gαi·GDP interaction239. Indeed, endogenous Gβ subunits
are seen to co-immunoprecipitate with the endogenous GPSM3 expressed in the human
monocytic THP-1 cell line; moreover, endogenous Gβ subunits co-localize with endogenous
GPSM3 at the plasma membrane in THP-1 cells239. This plasma membrane colocalization is
consistent with the proteomic detection of GPSM3 within cholesterol-rich, detergent-resistant,
plasma membrane fragments from bovine leukocytes241, as well as an independent report of
ectopically-expressed GPSM3 being able to form a G protein-dependent complex in proximity to
membrane-delimited GPCRs240. Additional evidence that GPSM3 interacts with Gβ has been
obtained by examining the direct activation of PLCβ2 via co-expression of free Gβ1γ2 subunits;
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overexpression of wild-type GPSM3 (but not the loss-of-function LSL mutant) is seen to inhibit
PLCβ2 activation by Gβ1γ2239.
Another common Gβγ-mediated signaling effector is activation of the pro-survival kinase
PKB/Akt pathway (Fig. 1.5) - an event that is often measured by serine-473 phosphorylation
status242. When GPSM3 levels are decreased by RNA-interference in the monocytic THP-1 cell
line, activation of PKB/Akt by treatment with fetal bovine serum is diminished239. The decrease
in pro-survival PKB/Akt signaling in GPSM3-depleted THP-1 cells mirror the increased precence
of early apoptotic markers observed in etoposide-treated GPSM3-deficient THP-1 cells239 and
are consistent with the known role of GPCR/Gβγ-mediated activation of class IBPI3K and
resultant PIP3-dependent activation of PKB/Akt and downstream survival signaling in
leukocytes242,243 (Fig. 1.5).

1.3.2 GPSM3 in Immune Cell Function and Cancer

Myeloid-derived inflammation mediators and suppressors: GPSM3 expression is highly
regulated during monocyte/macrophage differentiation ex vivo, and GPSM3 deficiency reduces
monocyte

survival

as

well

as

migration

to

specific

chemokine

ligands239.

Ly6ChighCD11b+ monocytes are known to mobilize rapidly in response to infection and
inflammation244; flow cytometry of splenocytes from GPSM3-deficient mice indicates that this
population of Ly6ChighCD11b+ monocytes is significantly reduced in comparison to wild-type
mouse controls239. Therefore, a role for GPSM3 in survival and/or differentiation of particular
myeloid-lineage cells is likely, but the molecular mechanisms underlying this role remain to be
elucidated.
Myeloid cells, particularly macrophages and neutrophils, are known mediators of
inflammation; conversely, a heterogenous, immature myeloid cell population, termed “myeloid-
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derived suppressor cells” (MDSCs) are able to suppress T cell and macrophage responses in
inflammatory disease245,246. Work by Yan et al. revealed that in lysosomal acid lipase (lal)
knockout mice, which exhibit expanded MDSC development, GPSM3 transcript abundandance
is upregulated two-fold (along with other G protein-related genes) as part of a broader
perturbation of myeloid development and homeostasis247. MDSCs have been shown to expand
as a functional cell population in multiple pathological conditions including infection,
autoimmunity, inflammation, and cancer246. In the mouse collagen-induced arthritis (CIA) model
of rheumatoid arthritis (RA), MDSCs are seen to accumulate in the spleen concurrent with the
apex of developed paw swelling, inhibit production of the inflammatory cytokines IFN-γ, IL-2,
TNF-α, and IL-6, and suppress T helper 17 (Th17) pathogenic T cells248.
MDSCs also affect tumor angiogenesis and metastasis, as well as promote the
development of FOXP3+ regulatory T-lymphocytes (Tregs)249. MDSCs expand in numbers in
many tumors and are believed to be recruited from the bone marrow by tumor-derived
factors250; these increased levels of MDSCs can interfere with innate and adaptive anti-tumor
responses by depressing immune responses to tumor burden, leading to the advancement of
malignancy251. Data from mouse tumor models suggest that two populations of CD11b+ MDSCs
predominate: “granulocytic” Ly6G+/Ly6Clo MDSCs and “monocytic” Ly6G-/Ly6C+ MDSC246. Both
of these MDSC subsets are decreased in the spleens of GPSM3-deficient mice239. The ablation
of GPSM3 protected mice from a monocyte-driven model of acute inflammatory arthritis239;
however, it remains unknown whether these GPSM3-deficient mice possess a differential
response to tumor burden.
Although GPSM3 appears to be most highly expressed in developing monocytes and is
also expressed in MDSCs, Lapan et al. have shown that prostatic cancer cells also
increase GPSM3 expression greater than two-fold when co-cultured ex vivo with endothelial
cells, in a model mimicking angiogenesis within the tumor microenvironment252. As a regulator
of GPCR and G protein function, GPSM3 could therefore also influence invasive or migratory
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phenotypes in different cancers, or their responses to survival or angiogenic factors that might
be secreted as tumors grow. Therefore, whether tumor progression in GPSM3-deficient mice
may be influenced by the decreased prevalence of MDSCs or by changes that occur in adaptive
immune cells or the tumor cells themselves needs to be further examined.

Lymphocytes: Although GPSM3 has its highest expression in monocytes, B- and Tlymphocytes also have detectable GPSM3

235,239

, suggesting that GPSM3 could also regulate

GPCR/G protein signaling that mediate outcomes such as survival and chemotactic trafficking
within these key lymphocyte classes required for full immune function. For example, in a study
by Reif and Cyster253, activated B cells dynamically regulated the expression of multiple different
regulators of G protein signaling altering responses to local chemokine gradients.
Lymphocyte involvement in inflammatory diseases also involves the development of
ectopic (tertiary) lymphoid structures. The architecture of these germinal center-like structures
requires chemokine-driven organization and intercellular interactions254 likely to be impacted by
GPSM3 function on GPCR signaling in vivo. While it is currently unknown exactly how GPSM3
functions to regulate GPCR signaling in lymphocytes, the activity of this GPCR signaling
modulator could influence inflammatory function, adaptive immune responses, and/or be
involved in the protection against or exacerbation of lymphocyte-mediated inflammatory
disease.

1.3.3 GPSM3 Gene Variants in GWAS of Immune Diseases

Compelling genome-wide association studies (GWAS) identified protective alleles
located within the GPSM3 gene locus that are significantly less prevalent in patients with
several autoimmune diseases76,255,256. In the most notable examples to-date, protective alleles of
two GPSM3 single-nucleotide

polymorphisms

(SNPs

rs204989,

rs204991)

have

been
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associated with a decreased incidence of RA76,255,256. Importantly, these same SNPs associate
significantly with decreased incidence of developing other autoimmune diseases that share
similar immunologic mechanisms with RA: namely, ankylosing spondylitis (AS), systemic lupus
erythematosus (SLE), and multiple sclerosis (MS)76,255,256. Conversely, GPSM3 SNPs show risk
association with type I diabetes and autoimmune thyroid disease255,256, and GPSM3 genetic
polymorphisms have also been linked with atopic dermatitis and childhood obesity, two
diseases also characterized by chronic inflammation257,258. The GPSM3 locus on chromosome 6
is located very near to the Notch4 gene locus and is found within the densely-packed and
disease-relevant human leukocyte antigen (HLA) region76,255,256, raising the possibility
that GPSM3 SNP variants mark functional polymorphisms in other closely associated genes.
However, increasing research into GPSM3 transcript abundance and function is revealing a
consistent pattern of potential physiological involvement in immune cell types relevant to
inflammatory diseases. Therefore, it is conceivable that sequence variation within GPSM3 could
alter transcript expression or splicing, and/or GPSM3 protein sequences that could contribute
directly to immune disease pathogenesis.
Two different protein isoforms of GPSM3, with different N-terminal polypeptide
sequences (Fig. 1.6), have been predicted to date in the human genomic sequence database
curated

by

Ensembl

(http://ensembl.org)259,

as

encoded

by

three

different GPSM3 transcripts: GPSM3-001, -002, and GPSM3-004. It is presently unclear
whether these different isoforms exert differential effects on GPCR signaling, cellular function,
or disease. However, Zhao et al.260 reported that GPSM3 differentially affects the nucleotide
state of Gαi vs Gαo subunits via its N-terminal proline-rich region - a region significantly different
in the open-reading frames encoded by transcripts GPSM3-001 and-002 versus GPSM3004 (Fig. 1.6).
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1.3.4 GPSM3 in Autoimmune Arthritis

Pre-clinical evidence suggests that neutralization of proinflammatory, monocyteattracting chemokines, or their cognate cell-surface receptors, would be beneficial for the
treatment of RA224,261; however, clinical trials have revealed disappointing results both for
neutralization of chemokines or for antagonism of their GPCR counterparts141,228,262–264. One
explanation for this apparent discrepancy between pre-clinical evidence and clinical trial results
has uses the known functional redundancy of the chemokine system in the inflammatory
response, whereby many chemokines within a structural class can bind to multiple chemokine
receptors sharing similar structural motifs224,225. Thus, targeting monocyte/macrophage
recruitment in RA may be desirable, but current strategies using single chemokine or chemokine
receptor blockade have produced limited results.
GPSM3 appears restricted in its tissue transcript and protein concentration to
leukocytes235,239,265, therefore may play role in inflammatory cell function. In particular, monocyte
viability and chemotaxis are found to be affected in a GPSM3-deficient acute inflammatory
arthritis model239, and GPSM3 SNPs are associated differentially between healthy persons and
those with inflammatory arthritis from either RA, SLE, or AS76,255,256. Thus, understanding the
regulatory roles of GPSM3 as a GPCR signaling modulator may help to promote this protein as
a desirable therapeutic target for patients with autoimmune arthritis.
In an acute, collagen antibody-induced arthritis (CAIA) mouse model, GPSM3-deficient
mice (those either homozygous or heterozygous for the ablated GPSM3 allele) exhibit
decreased clinical disease scores, paw swelling, as well as reduced histopathology with less
inflammation in cartilage, less synovial damage, and less bone erosion239. Additionally, a
decreased disease incidence was observed in Gpsm3-/- mice (34% for Gpsm3-/- mice vs 95%
for control mice)239. Independent studies by Schmidt et al. report that GPSM3 expression
decreases in the joints after anti-inflammatory treatment with dexamethasone in the chronic,
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collagen-induced arthritis (CIA)266. Thus, both chronic and acute mouse models of inflammatory
arthritis reveal a compelling role for GPSM3 involvement.
GPSM3-deficient mice have reduced CAIA that is associated with a decreased transcript
expression of the proinflammatory, monocyte-derived cytokines IL-6 and IL-1β, as well as of
monocyte-specific chemokine receptors in the joints239. TNF-α, IL-1β, and IL-6 are all produced
by monocytes/macrophages, which are recruited to the inflamed synovium by chemokines such
as CCL2/MCP-1 and CX3CL1/fractalkine, among numerous others224,225. GPSM3 deficiency
reduces monocyte chemotaxis toward CCL2, CX3CL1 and chemerin, and enhances etoposideinduced apoptosis ex vivo239, providing evidence that GPSM3 affects monocytes through the
regulation of chemokine-receptor signaling and its downstream intracellular sequelae. The
critical nature of monocyte infiltration and pathogenesis in autoimmune arthritis267 is further
underscored by the direct correlation between disease severity and the accumulation of
monocyte-targeting nanoparticles in the inflamed joint synovium, as observed recently by Kim et
al.268.
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1.4 Figures and Tables

Primary goal
Con-nued
Remission

Remission
High RA Disease
Ac-vity

Alternate goal
Con-nued Low
Disease Ac-vity

Low Disease
Ac-vity
Adapt treatment to disease severity
using a composite measure of
disease activity every 1-3 months.

Adapt treatment if state is lost
using a composite measure of
disease activity every 3-6 months.

Figure 1.1 – Algorithm for treatment of RA patients according to the treat-to-target activity. This
64
figure is adapted from Smolen et al. (2010) .The green arrows indicate the primary goal of remission,
while the alternative goal is indicated in red. Prior to reaching either goal, the patient is assessed for
disease activity every 1-3 months and treatment is adjusted according to the disease activity (dark
background). After reaching the initial goal, the patient is monitored every 3-6 months and treatment is
adjusted to maintain disease activity (light background).
DMARD-naïve
patient

MTX monotherapy

1.
2.
3.

Secondary therapy:
MTX + non-biologic DMARD
TNFi +/- MTX
Non-TNFi biologic +/- MTX

Failure of therapy 2:
4. Another TNFi biologic or
5. non-TNFi biologic +/- MTX

Failure of therapy 4:
Non-TNFi biologic or
Tofacitnib +/- MTX

Failure of therapy 5:
Another non-TNFi biologic or
Tofacitnib +/- MTX

Failure of therapy 1 or 3:
6. Another non-TNFi
biologic +/- MTX

Failure of therapy 6:
TNFi biologic or Tofacitnib
+/- MTX

Figure 1.2 – Algorithm for prescription-based therapies for RA. This figure is adapted from Singh et
65
al. (2015) . In this diagram MTX is considered the primary non-biologic, although other non-biologic
DMARD options are available. In the event of successful remission with treatment, no further therapeutics
are prescribed. If remission is not reached treatments are prescribed to maintain disease activity levels.
Abbreviations: MTX = methotrexate, DMARD = disease-modifying antirheumatic drug, TNFi = tumor
necrosis factor α inhibitor.
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Signaling molecule effects on neutrophil physiology
Priming
C5a
GM-CSF
IFNγ
Ig Complex
IL-1β
IL-8
TNF-α

Chemotaxis

Activation

Increase
Lifespan

MHCII
Presentation

X
X

X
X

X
X
X
X
X
X

Indirectly
Indirectly
X
Indirectly

X
X
X
X

X
X

Table 1.1 – The effects of various signaling molecules (first column) on neutrophil
physiology in inflammation. Adapted from Wright et al.81.
Neutrophil granule enzymes involved in tissue damage
Granule
Protein
Role in tissue damage
Azurophilic
Myeloperoxidase
Produces HOCl (from H2O2 + Cl-)269
(primary)
Elastase
Degradation of cartilage collagen and
elastin166
Cytochrome b558 (NOX2)
An isoform of the catalytic subunit of
NADPH oxidase270
Specific
Collagenase
Degradation of cartilage collagen166
(secondary) Gelatinase B (MMP9)
Degradation of cartilage collagen168
Gelatinase
Gelatinase B (MMP9)
Degradation of cartilage collagen168
(tertiary)
MMP25
Inactivates
extracellular
proteinases,
prolonging half-life of elastase and
cathepsin G271

Table 1.2 – A non-inclusive list of neutrophil granule molecules that affect the
pathogenesis of RA. The granule (first column), granule molecule (second column),
and function of the granule molecule in tissue damage (third column) are reported.
Adapted from Wright, et al. 201081
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Neutrophil cytokine production and function
Chemokine
Target
Function
C-C chemokines
CCL2136,272
Monocytes,
Chemoattractant
dendritic cells
CCL3112,272,128
TH1 cells
Chemoattractant
273
CCL4
T cells and Chemoattractant
monocytes
CCL17274,275
TH2 cells and Chemoattractant
dendritic cells
128
CCL18
Naïve T cells
Chemoattraction of naïve T cells
toward antigen presenting cells41
276
CCL19
B and T cells
Potent
chemoattractant
for
lymphocytes41
CCL20276
B and T cells
Potent
chemoattractant
for
lymphocytes277
C-X-C chemokines
CXCL1278
Neutrophils and Chemoattractant
monocytes
112
CXCL2
Neutrophils and Chemoattractant
monocytes
CXCL8128 (a.k.a. IL-8)
Neutrophils and Chemoattractant
monocytes
279 280
CXCL9 ,
TH1 cells
Chemoattractant
CXCL10128,274
TH1 cells
Chemoattractant
CXCL11280
TH1 cells
Chemoattractant
128
Soluble CX3CL1*
Leukocytes
Chemoattractant for CX3CR1+ cells
(e.g., monocytes and T cells)
Interleukins
IL-1β112
Multiple
Described in text
281
41
IL-4
Naïve T cells
Induces differentiation of naïve T cells
toward TH2 phenotype41
IL-17A282
Fibroblasts,
Induces production of numerous
synoviocytes,
cytokines
endothelial
(e.g., IL-6, IL-10, IL-12, CXCL1,
cells,
and CXCL2, CXCL8, CCL2, CCL5, PGE2;
macrophages283 reviewed in Benedetti & Miossec283)
IL-17B284
Fibroblasts284
Potentiates TNFα-induced production
of cytokines (i.e., G-CSF, IL-6, IL1β)284
279
IL-18*
NK cells, T Promotes release of IFN-γ and
cells,
and CXCR2 agonists (reviewed in Volin &
fibroblasts
Koch285)
286
287
IL-23
Naïve T cells
Promotes differentiation of naïve T
cells toward the TH17 lineage287
Others
TRAIL288
Multiple
Induction of caspase-8-dependent
apoptosis288
289
290
BLyS
B cells
Promotes B cell survival and
maturation to plasma cell lineage290
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APRIL291

B cells / Plasma Modulates late humoral immune
cells291
response
via
induction
of
immunoglobulin class switching and
survival signals291
CD40L292
B-cells41
Co-stimulatory ligand for B-cell
activation41
293
RANKL
Osteoclasts
Activation of bone resorption293
Matrix
Extracellular
Degradation of extracellular matrix
metalloproteinases294,295 matrix
promoting neutrophil migration
IFNγ184,183
Multiple41
Promotes macrophage activation,
MHC class II expression, TH1
adaptive immune response, and
antibody isotype switching to IgG41.
Neutrophil Granule Proteins
Collagenase166
Cartilage
Promotes
tissue
damage
and
collagen166
degradation of synovial cartilage296
Elastase166
Cartilage166 and Promotes tissue damage by cleaving
cytokines297
collagen and elastin296; activates
CCL15298 and chemerin299.
297
Cathepsin G
Cytokines
N-terminal truncation of CXCL5300,
CCL15298, and chemerin299 resulting in
full activation of these chemokines.
α-Defensins197
T
cells, Primarily an antimicrobial, but also
dendritic cells, recruits T cells and dendritic cells197
and fibroblasts
and has been shown to be a fibroblast
mitogen301.
302
LL-37
Dendritic
Antibacterial,
activates
dendritic
cells199,303
cells199,303
Myeloperoxidase188
Macrophages
Upregulates
reactive
oxygen
production in neutrophils and induces
production of reactive oxygen, TNF-α,
and IL-1 by macrophages189
GM-CSF and
Myeloid
Survival,
proliferation,
and
G-CSF274
progenitor
differentiation
of
pre-neutrophil
cells41
progenitors in bone marrow41.
86,304
Adapted from
Unless noted target cells and
function identified in41, or reviewed
in86,304,305.

Table 1.3 – A non-inclusive list of cytokines and signaling molecules shown to be
expressed at either the transcript or protein level in neutrophils. The signaling
molecule (first column), effector cell/tissue (second column), and function of signaling
molecule on effector cell (third column) are reported.
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Y

Y

ROS and
proteolytic enzymes

Y

Y

Fc Receptor

Y

Soluble antibody
or antibody complex

Fc Receptor

Y

ROS and
proteolytic enzymes

Autoimmune
antibody

Y

Cartilage or Synovial Tissue

Figure 1.3 – Diagram of neutrophil activation by soluble (above) or tissue-bound
(below) autoimmune antibodies. Interaction between Fc receptors on the neutrophil
and the Fc portion of autoimmune antibodies results in the release of granule
components (Table 1.3) into the extracellular space. This release of reactive oxygen
species (ROS) and proteolytic enzymes results in non-specific damage of local tissues
and propagation of the inflammatory response.
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Figure 1.4 – GoLoco motif-containing proteins. Expression pattern as reported by
the BioGPS gene expression atlas (http://biogps.org)265.

43

Figure 1.5 – Model for GPSM3 function in regulating Gi-coupled chemokine
receptors. Two of the three GoLoco motifs within GPSM3 (yellow) bind to Gαi·GDP
subunits235,236. Additionally, the LSL motif within GPSM3 interacts with Gβ subunits
toward their biosynthetic pathway in forming Gβγ dimers237. These interactions likely
regulate ligand-activated chemokine receptor signaling pathways, including Gαimediated inhibition of cAMP production by adenylyl cyclase, inositol phosphate
production from Gβγ-mediated activation of phospholipase-Cβ, and/or cell survival
signaling by Gβγ-mediated activation of class IB phosphatidylinositol-3’-kinase (PI3K)
leading to PKB/Akt phosphorylation.

Figure 1.6 – GPSM3 amino acid variation between transcript isoforms. The
Ensembl database259 predicts two distinct wild-type human GPSM3 proteins that have
different N-terminal polypeptide sequences and that correlate with different mRNA
transcripts.
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2.1 – Abstract

G protein signaling modulator 3 (GPSM3) is a regulator of G protein-coupled
receptor signaling, with expression restricted to leukocytes and lymphoid organs.
Previous

genome-wide

association

studies

have

highlighted

single-nucleotide

polymorphisms (SNPs rs204989, rs204991) in a region upstream of the GPSM3
transcription start site as being inversely correlated to the prevalence of rheumatoid
arthritis (RA) -- this association is supported by the protection afforded to Gpsm3deficient mice in models of inflammatory arthritis. Here, we assessed the functional
consequences of these polymorphisms. We collected biospecimens from 50 volunteers
with RA diagnoses, 50 RA-free volunteers matched to the aforementioned group, and
100 unmatched healthy young volunteers. We genotyped these individuals for GPSM3
(rs204989, rs204991), CCL21 (rs2812378), and HLA gene region (rs6457620)
polymorphisms, and found no significant differences in minor allele frequencies between
the RA and disease-free cohorts. However, we identified that individuals homozygous
for SNPs rs204989 and rs204991 had decreased GPSM3 transcript abundance relative
to individuals homozygous for the major allele. In vitro promoter activity studies suggest
that SNP rs204989 is the primary cause of this decrease in transcript levels.
Knockdown of GPSM3 in THP-1 cells, a human monocytic cell line, was found to disrupt
ex vivo migration to the chemokine MCP-1.
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2.2 – INTRODUCTION

Chemokine receptors comprise a subfamily of the G protein-coupled receptor
(GPCR) superfamily of transmembrane receptors that are expressed on a number of
leukocyte subsets and function predominantly to regulate chemotaxis1–5. Upon binding
their cognate chemokine agonists, chemokine receptors transduce signals by inducing
dissociation of their associated, intracellular Gi protein heterotrimers (Giα·GDP/Gβγ).
This process is highly regulated through additional intracellular proteins that act upon
the Giα subunit and ultimately affect the rate of signal inactivation4,6,7. In particular,
proteins containing one or more conserved GoLoco motifs are capable of sequestering
inactivated Giα·GDP, preventing its reassociation with Gβγ and GPCRs and thereby
disrupting continued Giα-induced signaling without quenching Gβγ-mediated signaling6–
10

. The importance of Gβγ-associated signaling to chemokine actions has recently been

highlighted by reports that specific Gβγ-activating compounds are sufficient to induce
neutrophil chemotaxis11 and, conversely, a Gβγ antagonist can inhibit fMLP-induced
chemotaxis12. GoLoco proteins may directly regulate signaling pathways required for
chemotaxis by sequestering Giα·GDP and prolonging Gβγ-mediated signaling
processes13,14, thereby exacerbating inflammation.

G protein signaling modulator 3 (GPSM3) contains two functional GoLoco motifs
and is restricted in its expression to leukocytes and myeloid-derived cells15,16. Gpsm3deficient mice exhibit a profoundly blunted course of joint damage in an acute, collagen
antibody-induced model of inflammatory arthritis16. Histologic analyses of affected
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synovial tissues indicate a relative acellularity of synovial cavities in Gpsm3-deficient
mice compared to wild type mice, which suggests a potential leukocyte migration deficit.
These findings suggest a role for GPSM3 in the development of inflammation in
rheumatoid arthritis, most likely through a key regulatory role on leukocyte chemotaxis
to the synovium17. However, a direct demonstration of such a role has yet to be
exhibited with human cells.

Genome-wide association studies (GWAS) have identified two single-nucleotide
polymorphisms (SNPs), rs204989 and rs204991, 5’ to the GPSM3 transcriptional start
site that are significantly less prevalent in individuals with rheumatoid arthritis (and other
autoimmune diseases; e.g., lupus and multiple sclerosis), implying a potential protective
effect of these minor gene variations18–20. Notably, rs204989 and rs204991 both exist
within the chromosome 6p21.3 band, a region previously attributed to a large portion of
the heritable aspect of RA; specifically, HLA gene region polyallelic haploblocks within
the chromosome 6p21.3 region represent some of the greatest risk factors for RA21
(reviewed in ref. 22). In particular, the biallelic HLA gene locus polymorphism, rs6457620
[C>G], has been identified as an RA risk factor in a meta-analysis of GWAS studies
investigating multiple populations in the Wellcome Trust Case Control Consortium
(WTCCC), North American Rheumatoid Arthritis Consortium (NARAC), and the
Swedish Epidemiological Investigation of Rheumatoid Arthritis (EIRA)23,24. Thus, the
potential exists for linkage disequilibrium between GPSM3 and HLA gene region
polymorphisms. In this study, we addressed whether GPSM3 SNPs result in a
detectable phenotype that explains their inverse association with rheumatoid arthritis.
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Furthermore, we assessed whether linkage disequilibrium with the known RA risk allele
in the HLA gene region, rs645762023,24, may affect the inverse association of GPSM3
SNP alleles with RA. Additionally, another RA risk allele, CCL21 rs2812378 [T>C],
located on an unlinked chromosome, was analyzed as both a negative control for
linkage and a positive control for RA disease risk24.

We recruited a group of 50

volunteers with a diagnosis of RA, 50 RA-free volunteers who were matched to the
aforementioned group by a ‘Bring-a-friend-to-clinic’ program, and 100 unmatched
healthy young volunteers to donate biospecimens for analyses. Based on the location of
the polymorphisms and previous reports of protection from inflammatory phenotypes in
human GWAS18–20 and Gpsm3-deficient mouse studies16, we hypothesized that
individuals homozygous for the minor alleles of rs204989 and rs204991 would exhibit
decreased whole-blood GPSM3 transcript abundance. Additionally, we predicted that
knockdown of GPSM3 would result in disruption of chemokine-induced migration in a
human monocytic cell line.
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2.3 – RESULTS

2.3.1 – GPSM3 SNPs rs204989 and rs204991, each previously associated by
GWAS with protection from rheumatoid arthritis, form a haploblock with rs204990

The cohorts recruited for this study included an initial set of 100 unmatched
healthy young volunteers, a group of 50 volunteers with a positive diagnosis of RA, and
50 RA-free volunteers matched to the aforementioned group by a ‘Bring-a-friend-toclinic’ program. Upon genotyping all 200 volunteers recruited for this study, we found
that GPSM3 SNPs rs204989 and rs204991, originally identified to be independently18–20
associated with protection from RA, are in complete linkage disequilibrium within this
population. Additionally, sequencing a 3.5-kb region 5’ to the GPSM3 transcriptional
start site in eight volunteers revealed a total of four polymorphisms in this region:
rs204989, rs204990, rs204991, and rs3096688 (Fig. 2.1A). All of these chromosome 6
SNPs have been previously identified in the NCBI Database of Single Nucleotide
Polymorphisms (dbSNPs)

25

. In this study, three of these GPSM3 SNPs (rs204989,

rs204990, rs204991) were seen to be inherited as a haploblock in complete linkage
disequilibrium; therefore, we defined all individuals homozygous for the minor (lower
frequency) alleles of all three SNPs as having the “m/m” genotype and all individuals
homozygous for the major (higher frequency) allele for all three SNPs as having the
“M/M” genotype (Fig. 2.1A).
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2.3.2 – The GPSM3 rs204989/rs204991 haploblock is associated with decreased
GPSM3 mRNA expression in whole blood
In disease-free homozygotes for the minor alleles of GPSM3 SNPs, whole bloodderived RNA contained only 75.9% (m/m; n = 11; 95% C.I. of ± 7.6%) of the average
GPSM3 transcript level present in homozygotes for the major alleles (M/M; n = 53; 95%
C.I. of ± 5.6%). This was a decrease of 24.1% (95% C.I. of 7.1% - 41.7%; t = 3.803; df =
62; p = 0.0003) for individuals with the m/m genotype (n = 11) relative to individuals with
the M/M genotype (Fig. 1B; n = 53). Heterozygous individuals (M/m genotype) exhibited
an average of 82.0% of the GPSM3 transcript abundance of the M/M genotype, but had
a marked amount of variability (data not shown; n = 6; 95% C.I. of ± 31.1%). In our
analyses of GPSM3 mRNA abundance, we excluded RA patient samples to avoid
potential confounding effects caused by anti-RA pharmacotherapy, as shown previously
by RNA-seq26,27. According to the 1000 Genomes Project28, the minor allele frequencies
(MAFs) in the general population of rs204989 and rs204991 are 23.3% and 23.4%,
respectively. In our volunteer populations, the chromosome 6 rs204989 and rs204991
SNPs occurred in a haploblock with a minor allele frequency (MAF) of 29% within the
unmatched healthy young cohort (n=100), 23% within the rheumatoid arthritis cohort (n
= 50), and 18% within the matched control (disease-free) cohort (n = 50). The MAF of
the chromosome 9 CCL21 gene locus polymorphism rs2812378 [T>C] is 30.1%
according to the 1000 Genomes Project28. In our recruited populations, the CCL21 gene
polymorphism MAF was 31.5% within the unmatched healthy young population (n =
100), 30.0% within the rheumatoid arthritis cohort (n = 50), and 25.0% within the
matched control cohort (n = 50). The MAF of the chromosome 6 HLA gene region
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polymorphism rs6457620 was 56.0% within the unmatched healthy young cohort (n =
100), 35.0% within the rheumatoid arthritis cohort (n = 50), and 45.0% within the
matched control population (n = 50). None of the differences in GPSM3 (p = 0.4839),
CCL21 (p = 0.5267), and HLA gene region (p = 0.1938) polymorphism MAFs between
the RA and matched, disease-free cohorts was statistically significant (Fig. 2.1C).

2.3.3 – The GPSM3 SNP haploblock is in weak linkage disequilibrium with HLA
SNP rs6457620, but the latter is unlinked to GPSM3 transcript abundance

Both the gene for GPSM3 and the HLA gene region SNP rs6457620 reside on
chromosome 6, presenting the possibility of linkage disequilibrium; however, over 0.5
megabases

of

DNA

sequence

separate

rs6457620

from

the

GPSM3

rs204989/rs204991 SNP haploblock25. In individuals homozygous for the GPSM3 SNPs
(M/M), the HLA gene region SNP MAF was 41.3% (Figure 2.2). In heterozygotes for the
GPSM3 SNPs (M/m), the HLA gene region SNP MAF was 56.3%, while homozygotes
for the minor alleles of GPSM3 SNPs (m/m) exhibited a 60.7% HLA gene region SNP
MAF. This distribution was significantly different from chance distribution of unlinked loci
(Fig. 2.2A; p = 0.0066), suggesting the presence of weak linkage disequilibrium and
consistent with data from the NCBI dbSNP

25

(Fig. 2.2D). Within the RA cohort, there

was significant variation from chance distribution of GPSM3 SNPs MAF when stratified
by HLA gene region SNP genotype (Fig. 2.2B; p = 0.0123), which was not observed
within the matched control group (Fig. 2.2C; p = 0.2739). However, when stratified by
HLA SNP rs6457620 genotype, GPSM3 transcript abundance in whole blood was not
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significantly different (Fig. 2.2E; F = 1.219; p = 0.3050); this result is in contrast to the
significant difference in GPSM3 transcript abundance observed when stratified by
GPSM3 SNP haploblock genotype (Fig. 2.1B).
2.3.4 – rs204989 of the GPSM3 SNP haploblock is solely linked to decreased
GPSM3 transcript abundance

A 3.5-kb region 5’ to the human GPSM3 transcription start site, spanning the
region of the GPSM3 SNP haploblock under study (Figure 2.1A), was subcloned into a
promoterless luciferase-reporter vector. Transfecting this construct into HEK293T cells,
we found the normalized firefly luciferase activity induced by the “minor/polymorphic”
GPSM3 promoter (pGL3-m; containing the minor rs204989/rs204990/rs204991
haploblock as well as the minor allele of SNP rs3096688) was 26.5% less than that of
the wild type promoter (pGL3-M; containing the major allele of all four SNPs) (p <
0.0001; Fig. 3A). To assess the relative effect(s) of each of the four minor SNP variants
within this GPSM3 promoter region, each individual polymorphism was separately
introduced to the wild type promoter by site-directed mutagenesis (i.e., rs204989 [C>T],
rs204990 [G>T], rs204991 [A>G], and rs3096688 [A>G]). Introduction of the minor allele
of rs204990 (p = 0.1435), rs204991 (p = 0.2136), or rs3096688 (p = 0.6618) did not
significantly alter the normalized firefly luciferase activity of the wild type promoter (Fig.
2.3A). In contrast, introduction of the minor allele of rs204989 [C>T] into the wild type
promoter significantly decreased promoter-induced luminescence (p < 0.0001; Fig.
2.3A); conversely, introduction of the major allele of rs204989 [T>C] into the
polymorphic promoter (“pGL3-m-989”) was found to restore wild type promoter-induced
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luminescence (p = 0.9384; Fig. 2.3B). Using the JASPAR transcription factor binding
profile database29, two potential transcription factor binding sites were found to overlap
with the site of the rs204989 SNP: namely, AP1 and C/EBPβ consensus binding sites
(Fig. 2.4).

2.3.5 – Decreased GPSM3 abundance leads to a deficit in migration towards
monocyte chemoattractant protein-1 (MCP-1) by the human monocytic THP-1 cell
line

The human monocytic THP-1 cell line has previously been shown to
endogenously express GPSM3

16

; we confirmed the presence of the GPSM3 ancestral

(“major”) alleles of rs204989 and rs204991 within this cell line (data not shown). We
established stable GPSM3 knockdown (and scrambled control) THP-1 cell lines (Fig.
2.5A), using previously validated shRNA-expressing lentiviral vectors directed against
GPSM3 (i.e., shRNA19 and shRNA20; ref.

47

). Using these stable THP-1 cell lines in

real-time Transwell plate migration assays, we measured vehicle-normalized relative
fluorescence units (RFU) over a 30-minute timeframe to quantify MCP-1/CCL2-induced
cell transmigration. After normalizing to vehicle-induced non-specific migration, the
GPSM3 knockdown cell lines shRNA19 and shRNA20 exhibited disrupted migration to
the chemokine MCP-1 (a.k.a. CCL2) relative to scrambled shRNA control lines (Fig.
2.5B); these migration differences were independent of any changes in transcript
abundance of the MCP-1 receptor (i.e., CCR2) between cell lines assayed (Fig. 2.5C; F
= 2.40; p = 0.119). This migratory deficit upon GPSM3 knockdown was observed both
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by a decrease in initial rate of migration (Fig. 2.5D) and by a decrease in maximum
transmigration-induced fluorescence achieved (Fig. 2.5E).

2.4 – DISCUSSION

Genome-wide association studies (GWAS) have empowered researchers to
investigate complex non-Mendelian genetic disorders, including RA; however, these
studies can be hampered by the identification of large numbers of noncoding variants
with unknown effects, reproducibility across multiple populations being uncertain, and
linkage with other risk alleles obscuring results30. In multiple GWAS reports, noncoding
variants 5’ to the transcription start site of GPSM3 (Fig. 2.1A) have been identified as
occurring less frequently in individuals with RA18–20. However, like many identified
variants, no functional consequence has been elucidated to explain this association. In
the current study, we addressed (1) genotype-dependent phenotypes of the identified
chromosome 6 GPSM3 SNPs, (2) potential linkage with rs6457620, a biallelic RA risk
allele with a large effect size in the HLA gene region on chromosome 6 (refs.

23,24

), and

(3) a functional effect of altered GPSM3 expression levels in a human monocytic cell
line.

We recruited 50 volunteers with confirmed RA diagnoses, 50 RA-free volunteers
matched to the arthritis group, and 100 younger healthy individuals to analyze
genotype-dependent functional consequences of GPSM3 SNP alleles. Our finding that
homozygotes for the GPSM3 SNPs (m/m) have lower GPSM3 transcript abundance in
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whole blood relative to homozygotes for the ancestral allele (M/M) (Fig. 2.1B) supports
the hypothesis first put forth from GWAS18–20 that there is a potential functional
consequence of the identified GPSM3 SNPs rs204989 and rs204991, namely protection
from development of rheumatoid arthritis; we have previously demonstrated16 that
lowered Gpsm3 expression in mice, as generated by gene knockout technology, results
in protection from collagen-autoantibody induced inflammatory arthritis.

While our present finding of lowered GPSM3 mRNA levels in the whole blood of
homozygotes bearing the GPSM3 SNP haploblock is consistent with GWAS and mouse
gene knockout studies, the observed frequencies of the rs204989/rs204991 haploblock
within the various genotyped groups are seemingly discrepant, given the trend toward
decreased GPSM3 minor allele frequency, albeit not significantly different, in the
disease-free matched control (MAF = 18.0%; n = 50) compared to the RA cohort (MAF
= 23.0%; n = 50). Considering the small sample size, the observed variability is not
remarkable in light of the reported minor allele frequency in the general population being
23.3%. Small sample size likely also affected our ability to assign statistical significance
to the trend of increased frequency of the positive RA risk allele (Fig. 2.1C), CCL21
gene rs2812378 [T>C] on chromosome 9 (i.e., unlinked to the human GPSM3 locus on
chromosome 6; ref. 24).

To address whether the GPSM3 SNP haploblock on chromosome 6 was serving
as a surrogate marker for a linked and causal (yet unrelated) chromosome 6 variation
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affecting GPSM3 mRNA abundance and/or RA disease status, additional genotyping
was performed on another chromosome 6 biallelic allele, specifically near the wellestablished risk region in the HLA gene region (reviewed by Holoshitz22 and Yuta, et
al.33). This RA risk allele, rs6457620 [C>G]23,24 is reported by RegulomeDB34 (based on
Hapmap2 metadata) to exist in complete linkage disequilibrium (D’ = 1.0; r2 = 1.0) with
another HLA region RA risk allele rs6457617 [C>T]31,32 in a population of Americans
with European ancestry (CEPH collection)35 that is very similar to the demographics of
our West Virginia-based sample population. Both polymorphisms (rs6457617 &
rs6457620) exist ~500 kb from the GPSM3 SNP haploblock (e.g., Fig. 2.2D). When
stratifying the HLA region-associated SNP genotype by GPSM3 SNP genotype, a
preferential coexistence is seen between the GPSM3 SNP haploblock minor allele and
the minor allele (G) of rs6457620 (Fig. 2.2). Upon further stratification by disease state,
we discovered the GPSM3 SNP alleles were more strongly associated with the minor
allele of rs6457620 (G) in our RA cohort when compared to the matched control cohort
(Fig. 2.2B vs. C). These findings suggest that the protective effect of the GPSM3 SNP
haploblock minor allele is most likely masked in our small-sized cohort by the large
effect size of the HLA gene region RA risk allele at rs6457620 (RA odds ratio of 2.5524)
or other RA risk-related HLA gene haploblocks in linkage disequilibrium21,33. Previous
GWAS studies have genotyped tens of thousands of ethnically-diverse volunteers to
identify the two GPSM3 SNPs rs204989 and rs204991 as inversely associated with RA
18–20

. Therefore, we hypothesize that our inability to reproduce previous GWAS findings

is most likely a consequence of the relatively small sample size we recruited for this
functional study of GPSM3 phenotypes and/or a founder effect among the local
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recruited volunteers36. Regardless, our finding of a genotype-dependent decrease in
GPSM3 mRNA abundance is supportive of the prior GWAS findings18–20, especially in
light of the protection from inflammatory arthritis exhibited by Gpsm3-deficient mice16.

To probe the molecular mechanism whereby presence of the minor allele of the
rs204989/rs204991 haploblock leads to decreased GPSM3 transcript levels in whole
blood, a 3.5-kb promoter region containing the haploblock region was tested for its
promoter activity upon transfection into HEK293T cells (used given low transient
transfection efficiency of the THP-1 cell line). There was a significant decrease in
promoter activity in the reporter construct containing all four 5’ SNPs versus the
ancestral sequence, in a direct parallel to decreased GPSM3 transcript abundance seen
in whole blood samples from individuals homozygous for the minor rs204989/rs204991
haploblock versus the ancestral (“major”) haploblock. The presence of rs204989 [C>T]
was found to be the sole determinant responsible for the reduction in GPSM3 promoter
activity. We did observe slight variability in the decrease in GPSM3 promoter-driven
luciferase activity between experiments, most likely due to experimental variability,
environmental factors (e.g., temperature differentially affecting firefly and Renilla
luciferase activity), and elapsed time between experiments. Regardless, all constructs
containing the minor allele of rs204989 [C>T] were not significantly different from the
construct with all 4 GPSM3 SNP alleles. To our knowledge, this is the first reported
functional connection between the GPSM3 rs204989 polymorphism and GPSM3
transcript abundance in human cells and human samples. The singular effect of the
rs204989 cytosine-to-thymine transition on GPSM3 promoter activity may reside in the
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disruption of the consensus DNA-binding motif of AP-1 and/or C/EBPβ; this hypothesis
is now the topic of future work.

A potential functional consequence of this genotype-dependent decrease in
GPSM3 abundance is dysregulated G protein-coupled receptor signaling via Giα6–10 – a
common signaling system used by chemokine receptors. Considering the restricted
expression of GPSM3 in leukocytes and lymphoid organs15,16 and the importance of of
Giα-coupled chemokine receptors in leukocyte migration during RA pathogenesis37, we
hypothesized that a reduction in GPSM3 expression in human monocytic THP-1 cells
would result in perturbed chemokine-dependent chemotaxis. Given the role of monocyte
chemoattractant protein-1 (MCP-1/CCR2) signaling in the recruitment of monocytes and
macrophages during inflammatory bouts in RA patients38,39, we elected to examine
MCP-1-induced chemotaxis. shRNA-induced knockdown of GPSM3 in THP-1 cells
disrupted Transwell migration (both initial rate and maximal migration) toward MCP-1,
but did not affect expression of its cognate receptor, C-C chemokine receptor 2 (CCR2)
(Fig. 5). Taken together, these data support a role for GPSM3 in supporting MCP-1induced migration of human THP-1 cells. We note that the knockdown efficiency of the
successful GPSM3-targeted shRNAs was significantly greater than the 24.1% decrease
found in individuals homozygous for the minor alleles of the GPSM3 SNP haploblock.
Therefore, we hypothesize that the functional effect of the rs204989 GPSM3 SNP in
vivo is most likely more subtle, yet it likely plays a role in the pathogenesis of RA as a
component of a complex genetic framework that is, to date, still being elucidated.
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Based on our collective results, the GPSM3 SNPs rs204989 and rs204991,
identified as protective against RA in prior GWAS studies, likely exhibit this protective
effect via linkage to rs204989 and its alteration of GPSM3 transcription. An rs204989mediated decrease in GPSM3 transcript level likely decreases GPSM3 protein levels
and thereby decreases chemokine-dependent leukocyte migration in inflammation.
RNA-seq ‘transcriptomic’ datasets report the GPSM3 mRNA as being expressed at an
appreciable level in all human leukocyte subsets examined (GEO accession
GDS62408)40, suggesting that decreased GPSM3 mRNA transcript caused by SNP
rs204989 may affect both the innate and adaptive immune responses that act
sequentially in the pathogenesis of rheumatoid arthritis37. Future work will initially
address whether the presence of rs204989 is functionally relevant in primary leukocytes
isolated from patient samples or in CRISPR-mediated introduction of rs204989 in
human leukocyte cell lines. Additionally, we will seek to establish whether one or both of
the candidate transcription factors (i.e., AP1 or C/EBPβ) are indeed involved in GPSM3
promoter regulation and whether such activity is directly affected by the major or minor
allele of SNP rs204989.
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2.5 – MATERIALS AND METHODS

2.5.1 – Subjects: A WVU IRB-approved case-control study (IRB protocol #1304033165)
recruited a total of 200 consenting local volunteers for buccal swabs and blood samples.
The volunteer population was subdivided into three groups of 100 young, healthy
control volunteers from among the WVU Health Sciences Center student population, 50
rheumatoid arthritis patients (ICD-9 diagnosed and anti-RF-positive), and 50
demographically matched controls. Inclusion criteria for the 100 healthy control
volunteers included (1) at least 18 years of age, (2) self-reported good health, and (3)
no family history of autoimmune disease. Inclusion criteria for the 50 rheumatoid arthritis
individuals included (1) at least 18 years of age, (2) positive ICD-9 diagnosis and (3)
rheumatoid factor positive. Inclusion criteria for the 50 demographically matched
controls included (1) at least 18 years of age, (2) not a blood relative of a volunteer
enrolled in the study, and (3) no family history of autoimmune disease. For buccal swab
samples, volunteers were instructed to vigorously swab the inside of both cheeks for 15
seconds on each side, and resultant samples were stored in a sterile nuclease-free
container at -80ºC. Blood samples were collected by a trained phlebotomist sequentially
into a K2EDTA tube (Becton Dickinson) and a PAXgene Blood RNA tube (BD); as per
manufacturer’s suggested protocol, the PAXgene Blood RNA tube was incubated at
room temperature for 120 minutes prior to archiving at -80 ºC.

2.5.2 – Isolation and Quantification of gDNA: Isolation of genomic DNA (gDNA) from
buccal swab samples was performed with the QIAamp DNA Blood Mini Kit (Qiagen) on
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a QIAcube automated nucleic acid extraction/purification instrument (Qiagen;
Germantown, MD). Briefly, buccal swabs were immersed in 400 µl of Buffer ATL
(Qiagen) and treated with proteinase K by incubation at 56 ºC for 10 minutes. Following
incubation, buccal swabs were removed, placed into QIAamp spin columns, and
centrifuged at 13,000 RPM for 1 minute on a tabletop microfuge. Buccal swabs were
then discarded. Cell lysates were then loaded into separate QIAamp spin columns as
per manufacturer’s suggested protocols; purified gDNA was automatically collected
using the custom QIAcube “buccal swab spin” protocol (Qiagen). Quantification of
human gDNA was performed with the Investigator Quantiplex Kit (Qiagen) using the
manufacturer’s suggested protocols. Briefly, buccal swab eluate was diluted 1:1 with
nuclease-free water. Quantitative PCR to measure eluate gDNA content was performed
using the Investigator Quantiplex Kit on a RotorGene Q-400 thermocycler (Qiagen) with
an initial denaturation phase at 95ºC for 60 seconds, followed by 40 cycles of 95ºC for 1
second and 60ºC for 10 seconds. DNA quantity was recorded as a mean of technical
replicates.

2.5.3 – SNP Genotyping of Subjects: SNP genotypes were determined using the Type-it
Fast Probe PCR Kit (Qiagen), TaqMan SNP genotyping probes, and primers for
rs204989 (GPSM3), rs204991 (GPSM3), rs2812378 (CCL21), and rs6457620 (HLA
gene

region)

(Life

Technologies;

cat.

#C_3293828_20,

C_2412452_20,

C_16113556_10, and C_29315329_10, respectively) using the manufacturer’s
suggested protocols. Briefly, equal masses of human gDNA were added to each
reaction and the manufacturer’s recommended cycling parameters were used to detect
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both major and minor alleles in multiplex qPCR reactions performed in technical
replicates on a RotorGene Q-400 thermocycler. Coded identifiers were used to blind
investigators of the disease state of volunteers until all samples had been genotyped.

2.5.4 – Isolation of Whole Blood RNA: To maintain homogeneity of sample treatment, all
RNA was extracted from archived whole blood collected into PAXgene Blood RNA
tubes with the PAXgene Blood RNA kit (Qiagen) using a modification of the
manufacturer’s suggested protocol. Briefly, when possible genotypes (M/M and m/m)
were prepared concurrently. Upon removal from cryostorage, PAXgene tubes were
incubated on a rocker at room temperature for 15-18 hours, centrifuged at 5,000 x g for
10 minutes at 4ºC, and the resulting cell pellet was resuspended in 4 ml of nucleasefree water. The solution was then centrifuged at 5,000 x g for 10 minutes at 4 ºC, and
the cell pellet was resuspended in 350 µl of the manufacturer’s resuspension buffer
(BR1). Isolation of whole blood RNA was performed using an automated QIAcube
workflow according to the manufacturer’s suggested protocol to minimize variability
between preparations. Eluted nucleic acids were quantified by absorbance at 260 nm
using a Nanodrop 2000 (Thermo Scientific) and assessed for purity using 260/280 nm
ratio of ≥1.8. Immediately following isolation, a sample (250 ng) of eluted nucleic acids
from each subject was used to synthesize complementary DNA (cDNA) with Thermo
Verso Reverse Transcriptase Kit (Thermo Scientific). cDNA was then diluted 1:5 and
used immediately for qRT-PCR analyses.
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2.5.5 – Quantitative Reverse Transcriptase PCR (qRT-PCR): A sample of cDNA,
derived from equal masses of RNA from each volunteer, was amplified in duplicate (with
an additional independent “no reverse transcriptase-treated” control) using the USB
VeriQuest Fast SYBR Green qPCR Master Mix (Affymetrix, Cleveland, OH) and
custom-designed, intron-spanning PCR primers (Supplemental Table S1 and Figure
S1). Cycling conditions were modified from the manufacturer’s suggested protocol to
establish linearity of transcript detection (Supplemental Figure S2A,B). Relative
quantification of gene expression was performed using the ΔΔCT method41, and the
specificity of each amplicon was verified by gel electrophoresis and melt curve tests
(e.g., Supplemental Fig. S2C).

2.5.6 – Cell lines and culture conditions: The human embryonic kidney 293T cell line
(HEK293T) was obtained from the American Type Tissue Collection (ATCC). Cell lines
were maintained at 37 ºC in a humidified atmosphere containing 5% CO2. The
HEK293T cell line was maintained in DMEM supplemented with 10% fetal bovine
serum, 100 IU penicillin, and 100 µg/ml streptomycin. Transient transfections of
HEK293T cells were performed as previously described

42

. Briefly, transfection of

monolayers grown to 60-70% confluence was performed by incubating cells 15-18
hours with Ca3(PO4)2 and plasmid DNA solution. The cell monolayers were then
washed twice with phosphate buffered saline (pH 7.4), then fresh medium was added.
THP-1 cells, from the ATCC, were maintained in an ATCC-modification of RPMI
medium supplemented with 10% heat-inactivated fetal bovine serum, 100 IU penicillin,
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100 µg/ml streptomycin, and 2 µg/ml puromycin. GPSM3 expression was stably
knocked-down in THP-1 cells via lentiviral transduction (under the WVU IBC protocol #
15-04-08) of Mission shRNA in the pLKO.1 vector (clones: TRCN0000036819 and
TRCN0000036820). An additional two THP-1 monoclonal cell lines were established
stably-expressing scrambled control (a gift from Dr. David Sabatini, ref.

43

; Addgene

plasmid # 1864). Briefly, transduction was performed at a multiplicity of infection of 10
using the spinoculation protocol (described in ref.

44

), transduced cells were selected

with 2 µg/ml puromycin, and monoclonal populations were established by limiting
dilution. All THP-1 monoclonal cell lines and HEK 293T cells were confirmed free of
Mycoplasma spp. and Acholeplasma spp. contamination (Supplemental Figure S3)
using Lookout® Mycoplasma PCR Detection kit following manufacturer’s protocols
(Sigma-Aldrich, St. Louis, MO).

2.5.7 – Cloning and mutagenesis of plasmids: DNA from plasmids pGL3-basic-luc2P
(Promega, Madison, WI) and pcDNA3.1(+) were digested at the HindIII and XhoI sites
using FastDigest enzymes and buffers (Thermo Scientific, Pittsburgh, PA), and
restricted DNA ends were phosphatase treated with calf intestinal alkaline phosphatase
(Promega, Madison, WI). Vectors were purified via extraction from a 1% agarose gel
(QIAquick, Qiagen). Sequences of the GPSM3 gene locus were retrieved from the NCBI
reference sequence (NC_000006.12 c32195523-32190766). A 5010-bp region of the
GPSM3 promoter was amplified from gDNA (“GPSM3 amplification primers”;
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Supplemental Table S2) from one individual with the major GPSM3 alleles (“pGL3-M”)
and another individual with all minor polymorphic alleles (“pGL3-m”); nested primers
(Supplemental Table S2) were used to amplify a 3512-bp span of this promoter region
(NC_000006.12 32192523 - 32196035) and thereby introduce flanking HindIII and XhoI
cut sites (“GPSM3 cloning primers”). The resultant amplicons were digested with HindIII
and XhoI, and ligated into both pGL3-luc2P and pcDNA3.1(+) vectors (Rapid DNA
ligation kit; Roche, Basel, Switzerland). Mutagenesis was performed using the
QuikChange Lightning Mutagenesis kit (Agilent Technologies, Santa Clara, CA) and
manufacturer’s suggested protocols with primers (Supplemental Table S3). Briefly,
mutagenesis of GPSM3 promoter inserts was performed within the pcDNA3.1(+) vector,
sequenced by the Sanger method to confirm mutagenesis, and then subcloned into
pGL3-luc2P vectors.

2.5.8 – Promoter-driven luciferase assay: HEK293T cells were transiently transfected
using the calcium phosphate method, as described previously42,45, with 5 µg of pGL3
firefly luciferase-based reporter vector and 1 µg of pRL-TK Renilla luciferase-based
reporter control vector (Promega, Madison, WI). Forty-eight hours following transfection,
the cells were assayed for both firefly and Renilla luciferase activities using the
manufacturer’s suggested protocol for the Dual-Luciferase Reporter Assay System
(Promega, Madison, WI). Briefly, cells were harvested, washed in PBS pH 7.4, and
lysed using the manufacturer’s “passive lysis” buffer. Using automatic injectors within a
Flexstation-3 (Molecular Devices, Sunnyvale, CA), firefly luciferase substrate was
added to the cellular lysate and luminescence was recorded in a white, clear-bottom 96-
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well plate for 10 seconds. Firefly luminescence was then quenched and Renilla
luciferase substrate was added to the lysate and luminescence was recorded for 10
seconds. Data were normalized to luminescence induced by Renilla luciferase activity
and reported as fold-change from pGL3-M transfected HEK 293T cells. All data are
representative of biologic triplicates.

2.5.9 – Transcription factor bioinformatics: The 3.5 kb of sequence 5’ to the GPSM3
transcription start site was acquired from the Genome Reference Consortium human
genome 38 (GRCh38) and imported into JASPAR29. Predictions of consensus binding
motifs for transcription factors were cut off at 20% dissimilarity.

2.5.10 – Transwell migration assay: THP-1 cells stably expressing either GPSM3knockdown shRNA or scrambled shRNA control were serum-starved in HBSS + 1%
BSA at 37°C for one hour and labeled with calcein-AM cell permeant fluorescent dye
(494 nm/ 517 nm). Cells were washed and suspended in HBSS + 1% BSA + 10 mM
HEPES, and 5 x 107 cells/ml were loaded into the upper well of a Falcon™ HTS
FluoroBlok 96-Multiwell Insert System chemotaxis chambers (Corning, NY). Cells were
allowed to migrate toward vehicle or 100 ng/mL MCP-1/CCL2 (R&D Systems,
Minneapolis, MN) in the lower chamber. Fluorescence was measured at 2 minute
intervals over the course of 60 minutes at 37°C using a Flexstation 3 microplate reader
(Molecular Devices, Sunnyvale, CA). All data are representative of biological triplicates
with technical replicates (i.e., n = 6).

104

2.5.11 – Statistical analyses: Descriptive data from the case-control cohort were
analyzed using SAS University Edition 3.1 (SAS Institute Inc., Cary, NC). Differences in
2 x 2 discrete variables were determined using Fisher’s exact test, while 2 x 3 discrete
variables were compared using the Fisher-Freeman-Halton exact test46. Regression
analyses in Transwell migration assays were performed using 4 parameter logistic
nonlinear regression analyses over the period of migration with post-hoc comparison by
one-way ANOVA of the unshared maximum and time to 50% migration parameters. All
nonlinear models were confirmed to have r-squared values >0.99, and accepted the null
hypothesis of the Shapiro-Wilk normality test (p ≥ 0.05). All other analyses were
performed in Prism 6.0 using a two-tailed independent t-test or one-way ANOVA with
Bonnferroni or Dunnett’s post-hoc tests where indicated.
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Figure 2.1. GPSM3 transcript abundance in whole blood from individuals
homozygous for the minor allele of the rs204989/rs204991 haploblock (the “m/m”
genotype) is significantly lower than in whole blood from individuals
homozygous for the major allele of the haploblock (the “M/M” genotype). (A)
Schematic representation of identified polymorphisms with respect to the predicted
transcription start site of the human GPSM3 gene. (B) Scatter plot representation of
GPSM3 mRNA abundance, measured in whole blood by qRT-PCR, as normalized to
106

the average level measured in M/M individuals. Individual results for homozygous major
allele samples (M/M; n = 53) are depicted by solid circles, and homozygous minor allele
samples (m/m; n=11) are depicted by open circles. An average decrease (Δµ) in
GPSM3 transcript abundance of 24.1% (t = 3.80, df = 62, p = 0.0003) was observed in
homozygous minor allele samples. Error bars represent S.E.M. (C) Descriptive statistics
of the three cohorts of volunteers genotyped in this study: Minor allele frequencies were
23% for rs204989 and rs204991 in the rheumatoid arthritis samples versus 18% in the
disease-free controls (Fisher’s exact test; p = 0.4839). Risk/minor allele frequency for
rs2812378 was 30.0% in the rheumatoid arthris samples versus 25.0% in the diseasefree controls (p = 0.5267). Risk/minor allele frequency for the HLA gene region biallelic
SNP rs6457620 was 35.0% in the rheumatoid arthritis samples and 45.0% in the
disease-free matched controls (p = 0.1938).
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Figure 2.2. Linkage of the GPSM3 SNP haploblock and the known RA risk allele in
the HLA gene region, rs6457620 [C>G], is more pronounced in RA samples than
controls, but this linkage does not result in a rs6457620 genotype-dependent
effect on GPSM3 transcript abundance in whole blood. (A) Descriptive statistics of
all 200 volunteers, including the RA (n = 50), disease-free matched control (n = 50), and
young healthy control volunteers recruited for the current study. These data are
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stratified by GPSM3 SNP haplotype, showing that the rs6457620 [G] risk allele
frequency amongst homozygous ancestral GPSM3 haploblock individuals (M/M) is
41.3%, heterozygous individuals (M/m) is 56.3%, and homozygous minor GPSM3
haploblock (m/m) is 60.7%. These data are significantly different from chance
distribution (Fisher-Freeman-Halton exact test; p = 0.0066). (B) Analyses of GPSM3
SNP haploblock linkage within RA samples stratified by rs6457620 genotype, again
exhibiting statistically significant difference from chance distribution (Fisher-FreemanHalton exact test; p = 0.0123). (C) Within the disease-free matched control samples,
GPSM3 SNP minor allele (m) frequency, as stratified by rs6457620 genotype, is not
significantly different from chance distribution as determined by Fisher-Freeman-Halton
exact test (p = 0.2739). (D) Graphical representation of minor allele frequencies (MAFs;
of European [‘eu’] population), physical distance (in basepairs), and linkage
disequilibrium (LD) value (as quantified by heatmap) between the three linked SNPs of
the GPSM3 SNP haploblock (rs204989, rs204990, rs204991) and the HLA gene region
SNP

rs6547620,

as

obtained

using

the

NIEHS

(http://snpinfo.niehs.nih.gov/) from NCBI dbSNP data (ref.

SNPinfo
25

webserver

). (E) Despite modest

linkage between GPSM3 SNP minor alleles (m) and the rs6457620 risk allele (G), there
is no effect of the genotype at HLA gene region SNP rs6457620 on GPSM3 transcript
abundance. Significance determined by one-way ANOVA with Bonferroni post-hoc.
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Figure 2.3. Functional consequences of SNPs rs204989, rs204990, rs204991, and
rs3096688 on GPSM3 promoter activity. (A) Functional results upon subcloning a 3.5
kb-region immediately 5’ to the GPSM3 transcription start site from M/M and m/m
genotype volunteers, leading to wild type (pGL3-M) and “minor”/polymorphic (pGL3-m)
promoter-driven expression of firefly luciferase in HEK293T cells. Luciferase activity is
reported as a ratio of GPSM3 promoter-dependent firefly luciferase activity (FLuc) to
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control Renilla luciferase activity (pRL-TK control vector) and normalized to the average
level measured from the wild type pGL3-M vector (set to 1.00; dotted line). Introduction
of independent minor alleles (denoted “+###”) into the wild type pGL3-M vector is seen
to differentially affect resultant firefly luciferase activity. (B) Restoration of the major
allele at rs204989 in the pGL3-m vector (i.e., “pGL-m-989”) restores wild type GPSM3
promoter activity. All data are compiled from three independent experiments. Error
measure is S.E.M. Significance was determined using one-way ANOVA after controlling
for multiple comparisons with Dunnett’s test using pGL3-M as the defined control.
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Figure 2.4. Putative transcription factor binding sites within the human GPSM3
promoter potentially disrupted by the minor allele of SNP rs204989 (arrows), as
predicted by the JASPAR database: (A) Fos/Jun (AP1) heterodimer; (B) C/EBP-β.
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Figure 2.5. Lentiviral-mediated shRNA knockdown of endogenous GPSM3
expression in the human monocytic THP-1 cell line disrupts migration toward
MCP-1 (A) Western blot showing whole lysate (40 µg) immunoreactivity with mouse
monoclonal anti-GPSM3 antibody 35.5.1 (ref.

47

) and with anti-β-actin as a loading

control. (B) Real-time Transwell migration analysis of indicated calcein-AM stained
THP-1 cell lines as shown by change in the ratio of MCP-1-induced to vehicle-induced
relative fluorescence units (RFU) over a 30 minute timeframe. (C) qRT-PCR data from
indicated stable knockdown or scrambled control THP-1 cell line total RNA
preparations. There was no significant difference in CCR2 mRNA abundance in the
THP-1 cell lines as determined by one-way ANOVA (F = 2.40; p = 0.119). (D)
Regression analysis-derived rate of THP-1 cell line transmigration over initial migratory
period; differences between each cell line was calculated by one-way ANOVA. (E)
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Regression analysis-derived maximum THP-1 cell transmigration over 30 minute
timecourse; differences between each cell line were calculated by one-way ANOVA. All
data are reported as means with error bars representing S.E.M.
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Supplementary Information

Genetic variations in GPSM3 associated with protection from
rheumatoid arthritis affect its transcript abundance
BJ Gall, A Wilson, AB Schroer, JD Gross, P Stoilov,
V Setola, CM Watkins, DP Siderovski
Supplementary Materials and Methods:
Quantitative Reverse Transcriptase PCR (qRT-PCR): Relative quantification of gene
expression was performed using the ΔΔCT method using the indicated formula and
primer pairs:
(!"#$ !"#! !"#" !" !" !"#$%"& !"#$%-!"#$ !"#! !"#" !" !" !"#$%&')
(!"#$ !"# !"#" !" !" !"#$%"& !"#$%-!"#$ !"# !"#" !" !" !"#$%&')

Relative mRNA abundance = 2

Table S2.1: Sequences of primers used in gene transcript detection
Primers:
B2M Fwd
B2M Rev
GPSM3 Fwd
GPSM3 Rev

Sequence (5’à 3’)
tgctgtctccatgtttgatgtatct
tctctgctccccacctctaagt (product=86 bp)
ctccaaactccaccactct
cagtctgcagggagagcag (product=114 bp)

Table S2.2: Sequences of primers used in subcloning GPSM3 promoter
Primers:
Amplification Primer Forward
Amplification Primer Reverse
Cloning Primer Forward
Cloning Primer Reverse

Sequence (5’à 3’)
tcaagcagtggtggttgaag
tgaggtccctacagggaatg
ggtggtaagcttcccctagaggggagaaactg
ggtggtctcgaggatatcggccctggctct

Table S2.3: Sequences of primers used in mutagenizing GPSM3 promoter
Mutagenesis Primers
rs204989 (CàT) sense
rs204989 (CàT) anti-sense
rs204989 (TàC) sense
rs204989 (TàC) anti-sense
rs204990 (GàT) sense
rs204990 (GàT) anti-sense
rs204991 (AàG) sense
rs204991 (AàG) anti-sense
rs3096688 (AàG) sense
rs3096688 (AàG) anti-sense

Sequence (5’à3’)
gtattcactatgcatcaagtgctttattacattattaatacatcaaccc
gggttgatgtattaataatgtaataaagcacttgatgcatagtgaatac
gtattcactatgcatcaagtgcttcattacattattaatacatcaaccc
gggttgatgtattaataatgtaatgaagcacttgatgcatagtgaatac
cttcctacctcagcctctcatttttccatatctatatctctta
taagagatatagatatggaaaaatgagaggctgaggtaggaag
ccccttgtctgcactaaactgtaagtttccaaaatgaaccc
gggttcattttggaaacttacagtttagtgcagacaagggg
ccgcctcagcctcccaaagtgctaggattac
gtaatcctagcactttgggaggctgaggcgg
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Supplementary Figures:

GPSM3-001

GPSM3-002

GPSM3-004

Figure S2.1. Schematic representation of the location of GPSM3 Fwd (à) and GPSM3
Rev (ß) primers relative to the predicted exon/intron architecture described for
established human GPSM3 gene transcripts (as per ENSEMBL database record
ENSG00000213654). Open rectangles, exons encoding 5’ or 3’ UTRs; closed
rectangles, exons encoding open-reading frame sequence.
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Figure S2.2. Template dilution-based tests of qRT-PCR primer efficiencies.
Threshold values for custom B2M (A) and GPSM3 (B) primers (Table S1) over log10
serial dilution of cDNA synthesized from whole blood RNA show similar primer
efficiencies. (C) PCR products from whole blood cDNA following qRT-PCR amplification
and electrophoretic separation performed on a 4-12% tris/borate/EDTA (TBE) gel: well 1
– DNA ladder, well 2 – GPSM3 SYBR Green PCR amplicon (114 bp predicted), well 3 –
B2M SYBR Green PCR amplicon (86 bp predicted).
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GPSM3 #2 (80 bp)

B

Figure S2.3. PCR confirmation of lack of Mycoplasma spp. and Acholeplasma
spp. contamination. PCR amplification of highly conserved 16S rRNA coding region
(lower band) and internal control DNA (upper band) was performed using Lookout®
Mycoplasma PCR Detection Kit (Sigma-Aldrich, St. Louis, MO), which is sensitive to 10
genomes per 1 µl. Performed by directly adhering to the manufacturer’s instructions.
Lane 1: (Positive control) PCR amplification of both the internal control (upper band)
and Mycoplasma orale DNA fragments (lower band). Lane 2: (Negative control) PCR
amplification of only the internal control. Lanes 3-7: (Culture supernatants) PCR
amplification of only the internal control.
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Under review – Genes & Immunity
BJ Gall1, AB Schroer1, JD Gross1, V Setola1,2, DP Siderovski1
1
2

Department of Physiology & Pharmacology and

Department of Behavioral Medicine & Psychiatry,

West Virginia University School of Medicine, Morgantown, WV, USA 26506-9229

Corresponding author:
David Siderovski, WVU Dept. of Physiology & Pharmacology
One Medical Center Drive, PO Box 9229, Morgantown, WV 26506-9229
Email: dpsiderovski@hsc.wvu.edu; Tel: 304-293-2418; Fax: 304-293-3850
Running title: GPSM3 affects migration of a neutrophil model
Keywords: arthritis; chemotaxis; G Protein Signaling Modulator 3; leukotriene B4;
neutrophils; SNP rs204989
Conflicts of Interest: The authors declare no conflict of interest.
Funding source: This work was supported in part by the National Institutes of Health
under Award Number U54GM104942.

123

3.1 - Abstract

G Protein Signaling Modulator 3 (GPSM3) is a leukocyte-specific regulator of G
protein-coupled receptors, which binds inactivated Gαi·GDP subunits, precluding their
reassociation with Gβγ subunits. GPSM3 deficiency protects mice from inflammatory
arthritis and, in humans, GPSM3 single nucleotide polymorphisms (SNPs) are inversely
associated with rheumatoid arthritis incidence; recently, these polymorphisms were
linked to one particular SNP (rs204989) that decreases GPSM3 transcript abundance.
However, the precise role of GPSM3 in leukocyte biology is unknown. Here we show
that GPSM3 is induced in the human promyelocytic leukemia NB4 cell line following
retinoic acid treatment, which differentiates this cell line into a neutrophil-like cell line
(NB4*). Reducing GPSM3 expression in NB4* cells disrupts their migration toward
leukotriene B4, a chemoattractant involved in initial recruitment of neutrophils to arthritic
joints, but not migration toward formylated peptides. Our results suggest that the
arthritis-protective

GPSM3

SNP

rs204989

may

act

to

decrease

neutrophil

chemoattractant responsiveness.
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3.2 - Introduction
Genome-wide association studies (1-3) have highlighted single-nucleotide
polymorphisms (SNPs rs204989 & rs204991) in a region upstream of the GPSM3
transcription start site as being inversely correlated to the prevalence of rheumatoid
arthritis (RA). This GPSM3 SNP association is supported by the protection afforded to
Gpsm3-deficient mice in an acute model of inflammatory arthritis (4). Histologic analysis
of synovial tissue from Gpsm3-deficient mice revealed a marked acellularity (4),
suggesting that protection from developing inflammation relies on a potential cellular
trafficking defect.
Neutrophils are leukocytes critical to the activation of inflammation in RA and
many other autoimmune-related diseases (reviewed in (5)). Neutrophils elicit this
function

following

their

initial

recruitment

by

early-phase

proinflammatory

chemoattractants. In RA, this early-phase recruitment is mediated primarily by
leukotriene B4 (LTB4), followed by a LTB4 positive-feedback loop in which recruited
neutrophils secrete LTB4 and additional chemoattractants (reviewed in (6)). To date,
work to identify the role of GPSM3 in disease pathophysiology has exclusively focused
on circulating monocytes, which compose less than 10% of circulating leukocytes (7).
However, mice made deficient in one of several monocyte chemokine receptors (i.e.,
CCR1, CCR2, and CCR5) do not exhibit significant protection from models of RA
inflammation (8); furthermore, mice depleted of Ly6Chigh monocytes have no change in
histopathology (9). Moreover, the initial class of leukocytes recruited to synovial tissues
in human arthritis is thought to be neutrophils, which migrate in response to a sequential
cascade of LTB4, IL-1β, and CXCR2 agonists (6). Further support for the primary role of
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neutrophils in initiating RA inflammation comes from protection afforded to mouse
strains that are deficient in various proteins required for the recognition or synthesis of
LTB4, including the LTB4 receptor BLT1 (10), 5-lipoxygenase activating protein (11), 5lipoxygenase (12), and leukotriene A4 hydrolase (12).
The LTB4 receptor, BLT1, is a G protein-coupled receptor linked to pertussis
toxin-sensitive Gi-subfamily heterotrimers (13), and therefore sensitive to potential
regulation by GoLoco motif-containing proteins (like GPSM3) that act as Gαi-selective
guanine nucleotide dissociation inhibitors (14). The role of GPSM3 in neutrophil function
has not previously been assessed. Here, we identify the expression of GPSM3 in an
immortalized cell line that can be differentiated towards neutrophil-like function, and
further identify a selective role for GPSM3 in its migration toward proinflammatory LTB4.

3.3 - RESULTS

3.3.1 - Identification of GPSM3 expression in the ATRA-differentiated NB4 cell
model of neutrophils

GPSM3 was undetectable within whole cell lysates of the human acute promyelocytic
leukemia NB4 cell line. However, upon treatment of NB4 cell cultures with all-trans
retinoic acid (ATRA), GPSM3 transcript (Fig. 3.1A) and GPSM3 protein (Fig. 3.1B)
increased in a differentiation-dependent manner concurrently with the established
differentiation marker CD11b. This ATRA-dependent induction of GPSM3 expression
also paralleled the acquisition of other markers of differentiated neutrophil function:
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specifically, the activity of intracellular oxidoreductase enzymes that can reduce
nitroblue tetrazolium to colored formazan dye (Fig. 3.1C) and morphologic changes
(Fig. 3.1D; e.g., invagination of the nucleus), both of which have been reported
previously in ATRA-differentiated NB4* cells (15).

3.3.2 - GPSM3 deficiency impairs LTB4, but not fMLP-induced migration

We established stable, monoclonal daughter lines from the parental NB4 cell line
using previously validated short hairpin RNA (shRNA)-expressing lentiviral vectors
directed against GPSM3 (16). After ATRA treatment, all daughter lines exhibited
equivalent upregulation of CD11b and equivalent expression of Gβ subunits (Fig. 2A,
right panel); therefore, the established interaction between GPSM3 and neosynthesized, free Gβ subunits (16) does not affect steady-state Gβ levels in this cell
line. In addition, all daughter lines exhibited equivalent induction of intracellular
oxidoreductase activity upon ATRA treatment (Fig. 3.2B, right panel). Four NB4*
monoclonal lines with successful knockdown of GPSM3 expression were each found to
have disrupted migration towards LTB4 in Transwell migration assays (Fig. 3.2C),
compared both to scrambled shRNA control lines and to a line expressing an ineffective
shRNA (i.e., daughter line NB4*-shRNA22.2; Fig. 3.2A&B). Diminished migratory
response to LTB4 was not correlated with any decrease in mRNA expression of the
high-affinity LTB4 receptor 1 (LTB4R1); for example, compared to the scrambled
shRNA control lines, only the NB4*-shRNA19.5 line exhibited a significant difference in
LTB4R1 mRNA expression (Fig. 3.2C inset, Δ = +56.5%, p < 0.0001) and this difference
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was an increase in expression. In contrast to the diminished migratory response
towards LTB4 elicited by GPSM3 knockdown, no significant differences were observed
in

formylated

peptide

(fMLP)-induced

migration

toward

a

number

of

fMLP

concentrations (e.g., Fig. 3.2D and S3.2), despite statistically significant differences
observed in mRNA expression of the high-affinity, Gi-coupled formylated peptide
receptor 1 (FPR1; Fig. 3.2D inset).

3.3.3 – The phospholipase C inhibitor, U73122, disruptes LTB4-induced migration

Inhibition of phosphoinositide 3-kinase (PI3K) or Mitogen-activated protein kinase
kinase (MKK), does not significantly affect LTB4-induced Transwell migration; however,
inhibition of phospholipase C (PLC) ameliorates LTB4-induced migration (Fig. 3.3).
When m-3M3FBS, a receptor-independent PLC activator, was added to the lower
chamber it was unable to restore migration of the shRNA 19.1 monoclone (Fig. 3.3).
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3.4 - DISCUSSION

Before its mRNA was cloned (17), GPSM3 protein was first detected in neutrophil
detergent-resistant fractions by mass spectrometry (18). More recently, RNA-seq
datasets indicate that human neutrophils have greater GPSM3 mRNA than all other
types of circulating leukocytes (e.g., NCBI GEO accession number GSE62408 (19)).
These findings sparked our interest in determining whether GPSM3 was functioning to
regulate aspect(s) of neutrophil biology. Using RNA-interference to negate the GPSM3
upregulation found to occur normally in the promyelocytic NB4 cell line upon ATRA
differentiation, we have now established that GPSM3 is required for the full migratory
response

of

a

neutrophil-like

cell

line

toward

pathophysiologically

relevant

concentrations of LTB4 (20). The migratory response to LTB4 is believed to be
dependent on the abundance of GPSM3 protein in these cells, given that the NB4*shRNA20 monoclonal lines were seen to have an intermediate level of GPSM3
knockdown efficiency and, in parallel, an intermediate migratory phenotype. Given our
findings here, we surmise that the synovial acellularity seen in anti-collagen antibody
challenged GPSM3-deficient mice (4) and the inverse association between RA
development and the GPSM3 expression-lowering SNP rs204989 (21) could be the
result of reduced neutrophil recruitment by LTB4.
During infections, neutrophil responsiveness to bacterial-derived formylated
peptides is mediated via formyl peptide receptors (22): i.e., GPCRs coupled to Gαicontaining heterotrimers in a similar fashion to LTB4 receptors. However, GPSM3
knockdown in NB4* cells does not affect migration initiated through the formyl peptide
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receptor across a gradient of concentrations (Fig. S3.2). We therefore conclude that
GPSM3 knockdown does not globally affect the chemotactic machinery of NB4* cells,
but

instead

leads

to

a

selective

abrogation

of

responsiveness

to

certain

chemoattractants, like LTB4 shown here. Future investigations will be directed at
identifying the specific signaling mechanism(s) regulated by GPSM3 that differentially
affect LTB4- vs fMLP-induced migration. The effect of GPSM3 deficiency on NB4*
LTB4-induced migration, coupled with the established role that LTB4 plays in the
pathogenesis of RA, supports the therapeutic potential of GPSM3-targeted inhibitors in
the treatment of RA, as we have proposed previously (21).

3.5 – MATERIALS AND METHODS

3.5.1 - Cell lines and culture conditions

The human acute promyelocytic leukemia cell line (NB4) was obtained from the Leibniz
Institute German Collection of Microorganisms and Cell Cultures. Preliminary studies
were performed on NB4 cells that were a generous gift from Dr. Sherman Weissman.
Cells were maintained at 37ºC in a humidified, 5% CO2 atmosphere in an ATCCmodification of RPMI medium supplemented with 10% heat-inactivated fetal bovine
serum, 100 IU penicillin, 100 µg/ml streptomycin, and 2 µg/ml puromycin. GPSM3
expression was stably knocked-down via lentiviral transduction (WVU IBC protocol 1504-08) as described previously (21). Additional NB4 cell lines were established
expressing a scrambled shRNA control (Addgene plasmid 1864). Briefly, transduction
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was performed at a multiplicity of infection of 10 using spinoculation (ref. (23));
transduced cells were selected with 2 µg/ml puromycin and monoclonal populations
established by limiting dilution. All NB4 lines were confirmed free of Mycoplasma spp.
and Acholeplasma spp. contamination using the Lookout® Mycoplasma PCR Detection
kit (Sigma-Aldrich, St. Louis, MO; Fig. S3.1). NB4 differentiation was performed as
previously reported (24) by treatment with complete media containing 1 µM all-trans
retinoic acid (Acros Organics, Geel, Belgium). Cell density was maintained between 4 x
105 and 1 x 106 cells/mL.

3.5.2 - Nitroblue Tetrazolium (NBT) reduction

Cells (5 x 105) were resuspended in PBS with 1 mg/ml NBT and 300 nM PMA, then
incubated at 37ºC and 5% CO2 for 30 minutes. Cells were then washed in PBS twice
and mounted on slides for visualization of 500 cells per cell population per experiment.
Formazan-positive (black), -intermediate (gray), and -negative (colorless) cells were
scored under brightfield microscopy.

3.5.3 - Wright-Giemsa staining
Cells were fixed with 100% methanol for 1 minute, then allowed to air-dry briefly. Cells
were then stained using Wright-Giemsa stain for 2 minutes, after which 1.5 volumes of
PBS, pH 6.8 was added, and the cells were allowed to incubate for another 2 minutes.
Cells were washed and visualized on an EVOS FL Auto microscope (Thermo Scientific,
Waltham, MA).
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3.5.4 - RNA isolation, cDNA synthesis, and quantitative reverse transcriptase PCR
(qRT-PCR)

RNA was extracted from ATRA-differentiated NB4 cells with the RNeasy kit (Qiagen).
Briefly, cells were centrifuged at 200 x g for five minutes, and the supernatant was
removed. Cells were then washed with 1X PBS and centrifuged again to remove
supernatant. The cell pellet was resuspended in 600 µl of the manufacturer’s lysis buffer
(RLT) with 1% β-mercaptoethanol. RNA isolation was performed using an automated
QIAcube workflow according to the manufacturer’s suggested protocol to minimize
variability between preparations. Eluted nucleic acids were quantified by absorbance at
260 nm using a Nanodrop 2000 (Thermo Scientific) and assessed for purity using a
260/280 nm cut-off ratio ≥1.8. Immediately following isolation, a sample of eluted nucleic
acids (250 ng) from each group of cells was used to synthesize complementary DNA
(cDNA) with the Thermo Verso Reverse Transcriptase Kit (Thermo Scientific). cDNA
was then diluted 1:5 and used immediately for qRT-PCR analyses. Samples of cDNA,
derived from equal mass of input RNA from each sample, were amplified in duplicate
(with an additional, independent, “no reverse transcriptase-treated” control) using the
USB VeriQuest Fast SYBR Green qPCR Master Mix (Affymetrix, Cleveland, OH) and
commercially-validated PCR primers (Qiagen, Hilden, Germany). Cycling conditions
were

established

following

the

manufacturer’s

suggested

protocol.

Relative

quantification of gene expression was performed using the ΔΔCT method (25) with βmicroglobulin chosen as the stable housekeeping gene.
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3.5.5 - Transwell migration assay

shRNA-expressing NB4 cell lines were serum-starved in HBSS + 1% BSA at 37°C for
one hour and labeled with calcein-AM cell-permeant fluorescent dye (ex. 494 nm/em.
517 nm). Cells were washed and suspended in HBSS + 1% BSA + 10 mM HEPES, and
2.5 x 106 cells/ml were loaded into the upper well of Falcon™ HTS FluoroBlok 96Multiwell Insert System chemotaxis chambers (Corning, NY). Cells were allowed to
migrate toward vehicle or 100 nM LTB4 or 100 ng/ml fMLP (R&D Systems, Minneapolis,
MN) in the lower chamber. Fluorescence was measured at 2-minute intervals over the
course of 60 minutes at 37°C using a Flexstation 3 microplate reader (Molecular
Devices, Sunnyvale, CA). All data are representative of biological triplicates with
technical replicates (i.e., n = 6).

3.5.6 - Antibodies and Western blot

Antibodies targeting GPSM3 (UNC Immunology Core; clone 35.5.1; 1:200 dilution),
CD11b (Developmental Studies Hybridoma Bank; clone H5A4; 1:200 dilution), panGbeta (T-20; Santa Cruz Biotechnology; 1:500 dilution) and β-actin (Sigma; 1:2000
dilution) were purchased from the indicated sources. Horseradish peroxidase (HRP)conjugated anti-mouse IgG was purchased from Sigma. Cells were lysed with ice-cold
RIPA buffer with protease inhibitor (ThermoScientific, Waltham, MA), sonicated on ice,
then clarified by centrifugation at 20,000 X g for 5 minutes. Protein content was

133

quantified by the Bradford protein assay (ThermoScientific, Waltham, MA) using BSA as
a standard. Lysates were diluted in Laemmli buffer (BioRad, Hercules, CA) and
resolved on 8-16% pre-cast SDS-polyacyrlamide gels (BioRad), transferred to
nitrocellulose membranes, immunoblotted with primary (overnight, 4ºC) and HRPconjugated secondary (1:2000 dilution, 2 h at room temperature) antibodies, and
visualized by chemiluminescence (ECL, ThermoScientific, Waltham, MA).

3.5.7 - Statistical analyses

Area-under-the-curve analyses of Transwell migration assay data were performed over
the period of migration with post-hoc comparison by one-way ANOVA and accepted the
null hypothesis of the Brown-Forsythe normality test (p ≥ 0.05). Significance was
reported as NB4*-shRNA monoclonal line response compared to those of scrambled 2
and scrambled 3 cell lines. Nonlinear modeling could not be used in these analyses
because r-squared values were <0.9. All analyses were performed in GraphPad Prism
6.0 using one-way ANOVA with Bonnferroni or Dunnett’s post-hoc tests where
indicated.
3.6 - ACKNOWLEDGEMENTS
The authors thank Dr. Sherman Weissman for his generous gift of the NB4 cell line at
the onset of these studies.
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3.7 Figures
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Figure 3.1 – GPSM3 transcript and protein expression are increased during alltrans retinoic acid (ATRA) differentiation of NB4 cells toward a neutrophil-like
physiology.
(A) GPSM3 mRNA abundance in NB4 cells over treatment time with 1 µM ATRA;
relative expression normalized to cells treated with vehicle (DMSO) for 120 hours. (B)
Levels of GPSM3 protein and the differentiation marker CD11b both increase with
ATRA-induced differentiation. (C) ATRA-induced differentiation over time increases the
neutrophil-specific ability to reduce nitroblue tetrazolium to formazan, as observed by a
steady increase in formazan-positive (dark) NB4 cells over time. (D) Wright-Giemsa
stained NB4* cells indicating the acquisition over time of ATRA-induced morphological
changes mimicking the nuclear invagination seen in neutrophil-like precursor cells.
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Figure 3.2 – GPSM3 deficiency disrupts NB4* cell migration toward LTB4.
(A) Immunoblot revealing undetectable GPSM3 and CD11b immunoreactivity within
whole cell lysates from all shRNA-expressing monoclonal cell lines when these lines
were mock-differentiated with vehicle only (0.01% DMSO; left panels). Immunoblot
revealing decreased GPSM3 immunoreactivity after 120 hours of all-trans retinoic acid
(ATRA) treatment of NB4* cells stably expressing GPSM3-targeted shRNAs shRNA19
or shRNA20 (right panels). (B) Nitroblue tetrazolium reduction assay indicating that
>90% of cells within each NB4-shRNA monoclonal cell line are incapable of reducing
nitroblue tetrazolium after mock-differentiation with vehicle only (0.01% DMSO; left bar
graph). Following differentiation with all-trans retinoic acid, >87% of differentiated NB4*
cells were capable of reducing nitroblue tetrazolium, irrespective of expressed shRNA
species (right bar graph). (C) Real-time Transwell migration towards 100 nM LTB4 over
60 minutes by indicated NB4* cell lines (after 120 hours of ATRA differentiation).
Significance (p < 0.05) determined by one-way ANOVA analyses of area under the
curve with Bonferroni post-hoc. (C insert) Post-differentiated NB4* transcript abundance
of the LTB4 receptor BLT1 (LTB4R); significance (p < 0.05) determined by KruskalWallis test (unequal group variances, Brown-Forsythe p < 0.05) with Dunn’s post-hoc.
All data plotted as mean ± S.E.M. (D) Real-time Transwell migration towards 100 ng/mL
fMLP over 60 minutes by indicated NB4* cell lines (after 120 hours of ATRA
differentiation). (D insert) Post-differentiated NB4* transcript abundance of the fMLP
receptor (FPR1); significance (p < 0.05) determined by Kruskal-Wallis test (unequal
group variances, Brown-Forsythe p < 0.05) with Dunn’s post-hoc. All data plotted as
mean ± S.E.M.

138

MEK: U0126

400

400

300

300

RFU

RFU

PI3K: LY294002

200
100
0

200
100

0

10

20

30

0

0

Time (min.)

10

20

30

Time (min.)

PLC: U73122
400

shRNA19.1 LTB4 + DMSO
scrambled 2 LTB4 + DMSO
scrambled3 LTB4 + DMSO
shRNA19.1 LTB4 + Inhibitor
scrambled2 LTB + Inhibitor
scrambled3 LTB + Inhibitor

RFU

300
200
100
0

0

10

20

30

Time (min.)

Figure 3.3 – LTB4-induced Transwell migration is disrupted by a phospholipase C
inhibitor, but not inhibitors of MEK or PI3K. Real-time Transwell migration of NB4*
cells, pretreated for 30 minutes with indicated inhibitor or vehicle (DMSO), towards 100
nM LTB4 in the presence of (A) 2 µM U73122 (PLC inhibitor), (B) 10 µM U0126 (MEK
inhibitor), or (C) 5 µM LY294002 (PI3K inhibitor)(Mean ± S.E.M.). Closed circles indicate
cells pretreated with vehicle for 30 minutes, and open circles indicate cells pretreated
with indicated inhibitor.
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SUPPLEMENTARY INFORMATION

Reduction of GPSM3 expression akin to the
arthritis-protective SNP rs204989 differentially
affects migration in a neutrophil model
BJ Gall1, AB Schroer1, JD Gross1, V Setola1,2, DP Siderovski1
1
2

Department of Physiology & Pharmacology and

Department of Behavioral Medicine & Psychiatry,
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West Virginia University School of Medicine, Morgantown, WV, USA 26506-9229

Figure S3.1. PCR confirmation of lack of Mycoplasma spp. and Acholeplasma
spp. contamination. PCR amplification of highly conserved 16S rRNA coding region
(lower band) and internal control DNA (upper band) was performed using Lookout®
Mycoplasma PCR Detection Kit (Sigma-Aldrich, St. Louis, MO), which is sensitive to 10
genomes per 1 µl. Performed by directly adhering to the manufacturer’s instructions.
Lane 1: (Positive control) PCR amplification of both the internal control (upper band)
and Mycoplasma orale DNA fragments (lower band). Lane 2: (Negative control) PCR
amplification of only the internal control. Lanes 3-9: (Culture supernatants) PCR
amplification of only the internal control, including HEK 293T cells previously tested to
be free of Mycoplasma spp. contamination. Lane 10: (Media control) PCR amplification
only the internal control from fresh media.
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Figure S3.2. GPSM3 deficiency does not decrease Transwell migration across a
concentration gradient of fMLP. Real-time Transwell migration towards fMLP over 60
minutes by indicated NB4* cell lines (after 120 hours of ATRA differentiation). fMLP
concentrations included (A) 250 ng / ml, (B) 100 ng / ml, (C) 50 ng / ml, (D) 10 ng / ml,
(E) 1 ng / ml, and (F) vehicle (DMSO).
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Chapter 4

Reduced transcript abundance of G protein
signaling modulator 3 by lipopolysaccharide
and α hemolysin in a monocytic cell line
This work is the result of a collaborative effort with Dr. Alex Duncan’s lab and is,
in part, currently published in:
Giguere, P. M., Gall, B. J., Ezekwe, E. A. D., Laroche, G., Buckley, B. K., Kebaier, C.,
Wilson, J. E., Ting, J. P., Siderovski, D. P. & Duncan, J. A. G Protein Signaling
Modulator-3 Inhibits the Inflammasome Activity of NLRP3. J. Biol. Chem. (2014).
doi:10.1074/ jbc.M114.578393
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4.1 – Abstract

NOD-like receptor family, pyrin domain containing 3 (NLRP3) is an
inflammasome protein that is released from an inactive complex of chaperones in
response to a wide variety of endogenous and pathogen-derived danger signals.
G protein signaling modulator 3 (GPSM3) is another leukocyte-restricted protein
that is a component of the complex that sequesters NLRP3 in the inactive state.
To initiate an NLRP3-dependent inflammasome response, cells must first be
‘primed’ to increase transcription of genes coding for components (e.g., NLRP3)
and substrates (e.g., IL1B) of the inflammasome. Using qRT-PCR and Western
blot, we identified GPSM3 transcript and protein abundance both decrease when
human

and

mouse

monocyte

cell

lines

and

cells

are

primed

with

lipopolysaccharide (LPS). Therefore, the decrease in GPSM3 transcription
probably reduces the stability of the complex of proteins that sequesters NLRP3
in an inactive state and results in an increase of NLRP3-dependent inflammasome
activity.

4.2 – Introduction

G protein signaling modulator-3 (GPSM3) is a newly identified signaling regulator
with prominent expression in myeloid lineage cells, and at lower relative levels in a
variety of lymphoid tissues 1. GPSM3 (a.k.a. AGS4 or G18;2,3) possesses two functional
“GoLoco motifs”

3

for binding inactive Gαi-GDP subunits and additionally binds to Gβ

147

subunits during their synthetic pathway towards forming mature Gβγ dimers 4; these
interactions with heterotrimeric G protein subunits are thought to underlie the effects of
GPSM3 on chemokine receptor signaling that is critical to the development of
inflammatory arthritis 1. We previously investigated the role of GPSM3 in NLRP3mediated IL-1β secretion, and further identified GPSM3 as a component of the
chaperone complex that maintains NLRP3 in an inactive state (Appendix 1). Thus,
establishing a negative regulatory function of GPSM3 on NLRP3-dependent IL-1β
generation in mice 5. NLRP3 priming with lipopolysaccharide (LPS) and activation with
S. aureus α hemolysin (HLA) have been shown to increase IL-1β secretion through
NLRP3-dependent caspase-1 activity

5,6

. Furthermore a greater increase of IL-1β

secretion is observed in Gpsm3-deficient mice 5. It is unknown how this treatment, that
activates the NLRP3 inflammasome, would affect the transcription of GPSM3 in human
or mouse cells endogenously transcribing GPSM3. Because GPSM3 is a negative
regulator of NLRP3 activity, prolonged priming and/or activation of the NLRP3
inflammasome may decrease transcript abundance of GPSM3 to increase the
sensitivity of the NLRP3 inflammasome. Here, we investigate the transcriptional
consequences of LPS and HLA treatment on the THP-1 human monocytic cell line.
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4.3 – Results and Discussion

4.3.1 – Increased Nlrp3 and Il1b transcript abundance in mouse BMDMs following
LPS and HLA treatment.

Despite the involvement of GPSM3 in the migration of innate immune cells and in
mouse models of RA 1, little is known about the regulation of GPSM3 transcription.
Treatment of mouse bone marrow-derived macrophages (BMDMs) with LPS alone or
HLA alone resulted in the increase in Nlrp3 and Il1b transcript abundance. BMDM
priming with LPS and activation with HLA resulted in an additional increase in transcript
abundance of Nlrp3 and Il1b. This increase was independent of Gpsm3 genotype (Fig.
4.1A and B). Therefore, GPSM3 is not required to increase the transcript abundance of
Nlrp3 or Il1b. The lack of effect of GPSM3 is likely due to the G protein-coupled
receptor-independent mechanisms of action of LPS and HLA, which act through toll-like
receptor 4 (TLR4; i.e., receptor tyrosine kinase)

7,8

and by forming pores in the cell

membrane 9, respectively. Nevertheless, GPSM3 deficiency increases secretion of IL1β in mouse peritonitis models and isolated BMDMs 5; therefore, GPSM3 probably
regulates IL-1β secretion as part of a protein complex rather than by regulation of
transcription.
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4.3.2 – LPS and HLA treatment decreases GPSM3 transcript and protein
concentration in human monocyte-like cells.

Considering the differences in mouse and human immune systems 10, the effects
of LPS on human THP-1 monocyte-like cell line was investigated to test similarities in
response between species. In THP-1 cells, treatment with LPS increased IL1B (Fig.
4.1D) and trended toward increasing NLRP3 transcript abundance (Fig. 4.1E). This
mimicked the increase in transcript abundance seen in mouse BMDMs. Although not
addressed, LPS probably primes THP-1 cells by increasing NLRP3 and pro-IL-1β
protein, thus increasing the amount of IL-1β secreted following activation of the NLRP3
inflammasome. LPS treatment of THP-1 cells also significantly decreased GPSM3
transcript abundance (Fig. 4.1C) and protein concentration (Fig. 4.1F). In the absence
of a priming event, NLRP3 activity is nominal (reviewed in

11

); therefore, priming is

required to mount an effective NLRP3-dependent response to various dangerassociated molecular patterns. When priming occurs prior to activation the translation of
additional proteins can potentiate NLRP3-dependent IL-1β secretion, with pro-IL-1β
protein detection in monocytes 30 minute after LPS priming

12

. Because GPSM3 is a

negative regulator of NLRP3-dependent IL-1β secretion 5, LPS-induced decreases in
GPSM3 transcript and protein abundance may result in increased sensitivity of NLRP3
to activation stimuli.
There is a greater magnitude of decrease of GPSM3 transcript abundance by
LPS pretreatment followed by HLA, a NLRP3 activator. Although, there is no difference
in GPSM3 transcript abundance of LPS or vehicle pretreated THP-1 cells prior to HLA
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treatment (Fig. 4.2). The additional decrease in GPSM3 transcript abundance is likely
relevant only during prolonged treatment with HLA, and may act to further decrease the
negative regulation on NLRP3 to prolong secretion of IL-1β. It is also likely that the
decrease in GPSM3 in the presence of bacterial LPS and HLA results in impaired
migration once the leukocyte reaches foci of bacterial infections

1

(Fig. 2.5 and 3.2).

Whether this is protective to the host or the bacteria has not been investigated, but
could act to prevent leukocytes from migrating away from bacteria.
In summary, LPS-induced increases in NLRP3 and IL-1β transcript abundance
are conserved between human and mouse myeloid cells and cell lines (Fig. 4.1A-E).
LPS treatment also decreases transcript and protein abundance of GPSM3 (Fig. 4.1C
and F), a negative regulator of the NLRP3 inflammasome activity. Therefore, decreases
in GPSM3 concentration likely increases the activity of the NLRP3 inflammasome by
reducing the inhibitory effect of GPSM3 (Fig. 4.3). Additional studies will be required to
determine if HLA-induced decreases in GPSM3 transcript abundance (Fig. 4.2) are
relevant in IL-1β secretion; however, induction of the NLRP3 inflammasome following
HLA treatment is probably too rapid for transcriptional changes to affect protein levels.
Nevertheless, continued interest in the affects of other NLRP3 priming agents will be of
interest. Particularly TNFα, which is involved in the pathology of a number of chronic
inflammatory states such as rheumatoid arthritis 13.
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4.4 – Materials and Methods

4.4.1 – Commercial antibodies, constructs, and other reagents. HRP-conjugated goat
anti-mouse and goat anti-rabbit antibodies were from GE Healthcare (Piscataway, NJ).
Monoclonal anti-GPSM3 antibody was produced by the UNC Antibody Core Facility and
has been previously described

14

. Recombinant S. aureus α hemolysin was generated

as previously described 15.

4.4.2 – Cell culture. The human THP-1 cell line was each obtained from the American
Type Culture Collection (ATCC) and maintained in ATCC-modification of RPMI-1640
media (Invitrogen, Carlsbad, CA), supplemented with 10% fetal bovine serum (Cellgro,
Manassas, VA) at 37°C in a humidified atmosphere containing 5% CO2.

4.4.3 – Ex-vivo transcriptional activation. BMDMs and THP-1 cells were resuspended in
serum-free RPMI 1640 and seeded in 24-wells plate at a density of 1x106 cells/ml/well.
LPS (100 ng/ml) was added for 3 hours. Subsequently, cells were stimulated with α
hemolysin (10 µg/ml) for 1 hour.

4.4.4 – Quantitative RT-PCR. THP-1 or bone marrow-derived macrophage (BMDM)
cells were activated as previously described with LPS (100 ng/ml) and/or α hemolysin
(10 µg/ml). Cells were harvested and lysed in buffer RLT (Qiagen) + 1% 2mercaptoethanol (Fisher Chemical) before immediately being placed on ice. RNA
extraction was performed using the Qiagen RNeasy kit following manufacturer’s
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instructions, and isolated RNA was DNase I treated and used to synthesize cDNA
immediately (Thermo Verso cDNA synthesis kit). Relative gene expression was
quantified using Veriquest Fast Probe PCR master mix (Affymetrix) and Taqman probes
(Life Technologies) for GPSM3, NLPR3, and pro-IL-1β normalized to multiplexed β2microglobin. Fold change in target gene expression was calculated using threshold
values by the 2-ΔΔCt method, described by Livak & Schmittgen

16

, and statistical

significance was determined by one-way ANOVA with Bonferroni post-hoc (p<0.05).
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4.6 – Figures
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Fig. 4.1. Transcriptional consequence of LPS treatment in mouse and human
leukocytes. Bone marrow derived macrophages (BMDMs) were generated from wild
type (WT) or Gpsm3-/- mice and primed with LPS for 3 hours with 100 ng/ml and/or
subsequently treated with α -hemolysin (HLA) for 1 hour, as indicated. Pro-IL-1β and
NLRP3 mRNA levels in each cell line were assessed using quantitative RT-PCR as
described in the materials and methods (panels A and B). THP1 cells were treated with
LPS (100ng/ml) or vehicle for 3 hours. GPSM3, Pro-IL-1β, and NLRP3 mRNA levels
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were assessed by quantitative RT-PCR (panels C, D, and E). Data are expressed in
pg/ml using the means ± S.E.M. of three different experiments (n=8-10); *p<0.05,
**p<0.01 and ***p<0.001 by one-way ANOVA.GPSM3, NLRP3, and actin (loading
control) protein levels were also assessed using immunoblot analysis with the indicated
antibodies (panel F). Samples from 3 independent experiments are shown.
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Fig. 4.2. Transcriptional consequence of a NLRP3 activation treatment on THP-1
cells. THP1 cells were treated with LPS (100ng/ml) or vehicle for 3 hours. Then treated
with α hemolysin (HLA) or vehicle for 1 hour. GPSM3 mRNA levels were assessed by
quantitative RT-PCR.
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Fig. 4.3. Model of GPSM3 regulation by lipopolysaccharide, and proposed
influence on NLRP3 inflammasome.

Formation of a network between GPSM3,

chaperones, and NLRP3 maintains the steady-state level of NLRP3 by stabilizing it
within the complex. Activation of the inflammasome requires two independent signals.
Toll-like receptors (TLR) and tumor-necrosis factor receptors (TNFR) are known to
trigger priming signals leading to up-regulation of NLRP3 and pro-IL1b through a NFkBdependent pathway as well as down regulation of GPSM3. The NLPR3 activation signal
is triggered by endogenous (‘danger-associated molecular patterns’; DAMPs) or
exogenous (‘pathogen-associated molecular patterns’; PAMPs) danger signals.
Activation of NLRP3 can also be mediated by bacterial pore-forming toxins such as the
alpha-hemolysin (HLA) of S. aureus. Activation of NLRP3 leads to formation of a
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Figure 8

multiprotein complex containing oligomerized NLRP3, the adaptor ASC, and caspase-1.
Once activated, caspase-1 cleaves pro-IL1b (and pro-IL-18), releasing the biological
active form of IL-1b (and IL-18) and thereby triggering inflammation and antimicrobial
activity.
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Chapter 5: Project insights and future directions

5.1 Functional consequences of GPSM3 gene variants in the clinical setting

Although a great deal of insight has been gained since the advent of minimally
biased genome-wide association studies (GWAS), there is much research that still
needs to be completed to fully elucidate the complex genetics of RA. A small sampling
of milestone GWAS achievements includes the identification of HLA-DRB1 haploblock
SNP tags, which are in linkage disequilibrium with risk haploblocks and may represent a
diagnostic mimic for expensive direct HLA typing in the future
discovery of risk alleles in peptidylarginine deaminase (PADI4)

3

1,2

. Additionally, the

supports the previous

discovery that PADI4 is involved in post-translational citrullination of proteins.
Citrullination of proteins, in RA, often precedes the production of anti-citrullinated
peptide antibodies (ACPA) that are often present in patient samples and are used as
part of the diagnostic panel of tests for RA 4. Despite the successes of GWAS, there are
a number of limitations of the technique, including the number of false-positive results
from multiple comparison statistics and linkage disequilibrium 5, which necessitate
additional confirmation studies, similar to what was performed in PADI4, to identify
causal gene variants from those simply associated with causal genetic or epigenetic
variants (e.g., Chapter 2). Once these causal gene variants are identified, additional
studies are then required to identify their biological significance before they can properly
be translated to a clinical setting as a genetic biomarker or identify the gene product as
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a therapeutic target. Multiple prior GWAS publications had identified two single
nucleotide polymorphisms (SNPs) within the GPSM3 gene locus as inversely
associated with a number of autoimmune diseases including RA, multiple sclerosis,
systemic lupus erythematosus, and ankylosing spondylitis in multiple populations
including European, North American, and Swedish cohorts

6–8

. The reproducibility of

these GPSM3 gene variants warranted further investigation, because Gpsm3-deficient
mice are afforded a significant protection from joint tissue swelling and proinflammatory
cell influx into synovial tissues in an acute model of collagen autoantibody-induced
inflammatory arthritis using the C57Bl/6 mouse strain 9, and in a chronic model of
heterologous collagen-induced inflammatory arthritis within the DBA-1 background
(unpublished; Billard, Gall, et al.). We sought to address the translational potential of
GPSM3 gene variants by initially confirming a functional consequence of inheritance of
GPSM3 gene variants (Chapters 2 & 5.1.1), and proposing additional valuable
experiments to identify the mechanisms of action of the identified GPSM3 gene variants
(Chapter 5.1.2).

5.1.1 – Study of GWAS-identified GPSM3 single nucleotide polymorphisms

To address transcriptional consequences of previously identified GPSM3 SNPs,
rs204989

7

and rs204991

6,8

, we addressed (1) disease state-dependent differences in

minor allele frequencies within a case-control cohort of RA patients and matched
controls, (2) transcriptional consequences of these SNPs, as well as (3) the potential
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genetic linkage of GPSM3 SNPs with other polymorphisms within the chromosome
6p21 region with large effect sizes (Fig. 5.1 10; e.g., HLA-DRB1 haplotypes) 11.
To minimize the chances of not identifying a transcriptionally relevant
polymorphism in linkage disequilibrium with the previously identified GPSM3 SNPs, we
performed Sanger sequencing of a 3.5 kb region 5’ to the GPSM3 transcription start site
that revealed the existence of a novel haploblock of 3 previously reported GPSM3
SNPs, rs204989 (MAF = 0.2328 12), rs204990 (MAF = 0.2330 12), and rs204991 (MAF =
0.2348

12

; Fig. 2.1A). All 200 volunteers recruited in this study were confirmed to have

the same minor allele (m) and the major allele (M) genotype for rs204989 and
rs204991, and all 8 volunteers that were Sanger sequenced were confirmed to have the
same genotype for each of the 3 GPSM3 SNPs

13

. We elected not to sequence the

coding region of the GPSM3 gene locus, even given that NCBI dbSNP

14

reports three

polymorphisms with a MAF ≥ 0.01 in that region. Of those three rs22694420 (MAF =
0.01) and rs117877134 (MAF = 0.01) are intronic and of low frequency, supporting a
lack of linkage disequilibrium. The final polymorphism, rs3134605 (MAF = 0.23), occurs
in the second exon of GPSM3 and has a similar frequency of rs204989/rs204991
haploblock, but is not predicted to be in strong linkage disequilibrium with said
haploblock
structure

16

15

. Furthermore, rs3134605 is not predicted to affect mRNA secondary

(Fig. 5.2), and results in a synonymous proline-to-proline mutation. The

effects of rs3134605 will need to be further investigated to better understand its effects
on GPSM3 mRNA stability, translation efficiency, and role in intron splicing. Precedence
has been set for synonymous mutations affecting mRNA stability (reviewed in

17

).

However, detecting the rs204989-dependent effect on transcription supports our
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hypothesis that rs204989 is responsible for the decreased GPSM3 transcript
abundance observed in whole blood.

Individuals with the m/m genotype of the GPSM3 SNP haploblock were shown to
have a 24.1% decrease in GPSM3 transcript abundance in whole blood relative to M/M
volunteers (Fig. 2.1B). The affect the m/m genotype has in the decreased GPSM3
transcript abundance, potentially mimics the some of the protection afforded by Gpsm3
deficiency in mouse models of RA. Both the GPSM3 SNP haploblock and genotypedependent decrease in transcript abundance were novel findings. From the genotypeassociated decrease in GPSM3 transcript and the 5’ location of the GPSM3 SNPs, we
developed the hypothesis that the presence of the minor alleles perturbed the normal
activity of DNA binding proteins, such as histones or transcription factors. We set out to
first test the hypothesis that these SNPs affected transcription factor interactions with
each of the GPSM3 SNP loci.
In determining the role of non-chromosomal protein interaction with the GPSM3
5’ region containing either the major (pGL3-M) or minor alleles (pGL3-m), we subcloned
this region into a luciferase vector with minimal promoter activity (pGL3-basic) and the
firefly luciferase open reading frame. When transiently transfected, the construct
containing the minor alleles (pGL3-m) resulted in a decrease in firefly luciferase activity
(Fig. 2.3). From these data, we hypothesize the presence of one or more GPSM3 minor
allele(s) resulted in a decrease in transcriptional activity of the subcloned region;
however, the presence of the GPSM3 SNP haploblock meant that we were unable to
assess the effects of individual SNPs on GPSM3 transcript abundance in collected
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whole blood, and therefore raised the question of which SNP(s) was/were causing this
identified genotype-dependent phenotype. This confounder was addressed using
mutagenesis in the in vitro promoter-driven luciferase model of transcriptional activity
(Fig. 2.3), where we identified a functional consequence for one of the SNPs, rs204989,
in the impaired transcriptional activity of the GPSM3 5’ region (Fig. 2.3A and Fig. 2.3B).
We concluded that the reduced transcriptional activity of the GPSM3 5’ region
containing the minor allele of rs204989 further supports our findings of genotypedependent decrease in GPSM3 transcript abundance in volunteers’ whole blood (Fig.
2.1B); however, these results were confounded by experimental limitations of our study.
We encountered difficulties in transfection of leukocyte cell lines (endogenously
expressing GPSM3) that are resistant to plasmid transfection, potentially via RIG-like
receptor- or TLR9-dependent immune activation and degradation of plasmid dsDNA
produced in E. coli, as reported previously in myeloid cell lines

18,19

. This resistance

resulted in low transfection efficiencies in the large reporter plasmids containing the 3.5
kb region 5’ to GPSM3 (>8 kb total size), and therefore yielded a low signal-to-noise
ratio when detecting luciferase activity in THP-1 cells (Fig. 5.3). Furthermore, the pGL3
plasmid used in these experiments lacked a eukaryotic resistance gene (e.g.,
Neomycin-resistance [neo]), which prevented the establishment of stable expressing
cell lines of each construct, although establishing stable monoclonal cell lines of each
construct would result in plasmid incorporation into the genome that could result in
chromatin-induced silencing.
To counter the difficulties in THP-1 electroporation/transfections, HEK 293T cells
were used. Although HEK 293T cells do not endogenously express GPSM3 protein or
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transcript, the activity of the non-genomic plasmid containing each of the GPSM3
promoters in HEK 293T cells suggests these cells have compatible transcription
machinery (i.e., transcription factors) to transcribe GPSM3, but there is a genomic
modification that silences its expression. Correlative bioinformatic data suggests the
GPSM3 locus is associated with transcriptionally active trimethylated histone H3 lysine
4 (H3K4me3)

20

in CD14+ monocytes endogenously transcribing GPSM3, but not HEK

293T cells in ChIP-Seq studies (Fig. 5.4)

21

. The association of the GPSM3 gene locus

with condensed regions of chromatin likely prevents endogenous transcription of
GPSM3 in HEK 293T cells. Thus, the use of chromatin-independent plasmids for
transcriptional activity in HEK 293T cells is most likely a viable alternative model that
mimics the genotype-dependent decreases in GPSM3 transcript abundance from whole
blood. In cell types that do transcribe the GPSM3 gene, we hypothesized the minor
allele of rs204989 disrupts transcription factor association and result in the observed
decrease in GPSM3 transcript abundance in whole blood (Fig. 2.1B). Based on the
JASPAR transcription factor database

22

, we predicted, the AP-1 or C/EBPβ

transcription factors were most likely to be affected by the minor allele of rs204989 (Fig.
2.4). AP-1 has been shown previously to undergo nuclear translocation in HEK 293T
cells

23,24

. However, a PubMed search (“[C/EBP] AND [beta] AND [HEK]”) did not return

a report showing C/EBPβ activity in HEK 293T cells. The paucity of findings indicating
C/EBPβ activity in HEK293T cells, led us to think the AP-1 transcription factor is
involved in differential GPSM3 transcription in m/m individuals. We do note that
transcription factors often bind to relatively promiscuous motifs (Fig. 2.4 and

25

) and in

certain conditions act to repress transcription. Therefore, the involvement of individual
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transcription factors in GPSM3 transcription requires substantial follow-up in cells
endogenously transcribing GPSM3 (Chapter 5.1.2a).
In our case-control cohort we report the GPSM3 minor allele frequencies
(predicted to be ‘protective’) were trending toward being greater in the RA cohort (Fig.
2.1C). This trend was the opposite of reports in GWAS in large multiethnic cohorts

6–8

.

We found it surprising that the genotype-dependent decreases in GPSM3 transcript
abundance and promoter activity (believed to be ‘protective’ in RA) were not reflected
by decreased minor allele frequencies of GPSM3 SNPs in our RA cohort (Fig. 2.1C).
Our findings are confounded by the known limitations of small population genetic
association studies

26

and potential founders’ effect within our local population

27

. With

the IRB restrictions, we could not increase recruitment to address the small population
size in what was designed to be a primarily functional study. Instead we attempted to
address potential linkage of the GPSM3 SNPs with rs6457620 [C>G] 28,29 (Odds Ratio =
2.55 29), an established RA risk locus ~500 kb from the GPSM3 SNPs in the HLA region
of chromosome 6p21.3 (Fig. 5.1). This HLA region SNP was chosen because of the
repeated association of HLA region polymorphisms with RA, and to counter the critique
that GPSM3 SNPs may associate with RA due to linkage disequilibrium with the HLA
region. We found an association between the GPSM3 SNP minor alleles with the minor
allele of rs6457620 that was greater than chance distribution within the RA cohort (Fig.
2.2B), but was not statistically different in the matched cohort (Fig. 2.2C). These
findings are contrary to RegulomeDB metadata

30

that reports minimal linkage exists

between the GPSM3 SNP loci and rs6457620. This observed association between
GPSM3 SNPs and the HLA SNP in our RA population was likely a result of a small
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sample size or Founder’s effect. Regardless, the coexistence of these two minor alleles
in our RA population, but not the matched controls, may have masked the protective
benefits of the GPSM3 SNPs minor alleles by the larger effect size of rs6457620 in the
RA cohort (reviewed by Holoshitz 11 and Yuta, et al. 31).

From the combined results of: (1) decreased GPSM3 transcript abundance in
whole blood samples (Fig. 2.1B) and (2) ex vivo analyses of GPSM3 5’ region
transcriptional activity (Fig. 2.3), we conclude that the GPSM3 SNP rs204989 [C>T] is
impairing transcription factor binding (Fig. 2.4) likely resulting in the observed decrease
in GPSM3 transcript abundance in whole blood samples of individuals with the m/m
genotype. This conclusion is based on our findings of: (1) decreases in activity of
GPSM3 promoters with the minor allele of rs204989 in HEK293T cells was markedly
similar to the decrease in whole blood GPSM3 transcript abundance, and (2) because
transfection of non-genomic plasmids does not assess normal histone or epigenetic
regulation of gene expression. Confirmation of this hypothesis will be the aim of future
studies (Chapter 5.1.2a).
Considering the small effect size of rs204989 on GPSM3 transcript abundance,
the minor allele of rs204989 in RA may be considered as a clinical biomarker of RA risk
as part of a larger genetic panel in conjunction with some of the over 100 confirmed RA
risk alleles

32,33

(reviewed in

31

). Regardless, rs204989 is: (1) inversely correlated with

RA in multiple, large, multiethnic cohorts

6–8

, (2) does result in a decrease in GPSM3

transcript abundance in whole blood (Fig. 2.1B), (3) Gpsm3-deficient mice are protected
from two models of inflammatory arthritis (unpublished and 9), and (4) GPSM3 depletion
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disrupts human leukocyte cell line migration toward chemoattractants relevant in RA
(Figs. 2.5 and 3.2C). Therefore, GPSM3 may rather be a target for pharmaceutical
inhibition to provide therapeutic benefits in RA patients, rather than a genetic marker.
This portion of my thesis represents a link between our lab group’s previous findings of
protection from arthritis-like paw swelling in Gpsm3-deficient mice and begins to
translate them to humans with natural GPSM3 polymorphisms resulting in deficiency of
GPSM3 transcript in whole blood.

5.1.2 – Future directions for rs204989

Future directions for GPSM3 genetics research will be important to confirm our
findings reported in chapter 2. To address this I propose two individual aims: to identify
transcription factors affected by rs204989 (5.1.2a) and to determine the consequences
of the minor allele of rs204989 in leukocyte biology (5.1.2b).

5.1.2a – Identification of transcription-relevant proteins affected by rs204989

Rationale – 5.1.2a Experiments 1-3: The plasmid-based techniques, employed to
assess the role of rs204989 on transcription of GPSM3, focused exclusively on HEK
293T cells and factors independent of epigenetics. Although the plasmid-based model
in HEK 293T cells is most likely effective in determining transcriptional activity of the
GPSM3 promoter, follow-up is required to determine which transcription-relevant
protein’s function is affected by the minor allele of rs204989. In an attempt to identify
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potential DNA:protein interactions that are disrupted by rs204989, future studies will
most likely require (5.1.2a Experiment 1) electrophoretic mobility shift assays (EMSA),
(5.1.2a Experiment 2) electrophoretic mobility super-shift assays (EMSSA), and (5.1.2a
Experiment 3) transcription factor pull down assays 34.
5.1.2a Experiment 1: Initially EMSA will be employed to confirm that oligonucleotide
probes, containing the major allele of rs204989, associate with a nuclear protein within
NB4* and THP-1 cell line nuclear extracts. We will synthesize a biotin-conjugated
oligonucleotide sequence that corresponds to either the major or minor allele of
rs204989. This oligonucleotide will be incubated with nuclear extract from THP-1 or
NB4* cells, then the mixture will be resolved on a polyacrylamide gel. Based on the
decreased luciferase activity of plasmids containing the minor allele of rs204989 (Fig.
2.3), there will likely be a shift in migration patterns of the oligonucleotides incubated
with nuclear extracts that correspond to a nuclear protein association with the
oligonucleotide. If no transcription factor can be identified, ChIP-qPCR analyses can be
performed to determine relative differences between the major and minor allele of
rs204989 with respect to active (e.g., H3K4me3
35

20,21

) versus inactive (e.g., H3K27me3

) states of histones; selection of histone methylation or acetylation states to interrogate

in these experiments will be based on publically-available ChIP-seq datasets. This line
of experimentation would be nearly identical to 5.1.2a experiment 3, and address
whether association with inactive chromatin (heterochromatin) is different in the major
and minor alleles of rs204989. Therefore, explaining the decreased transcript
abundance in clinical samples, without a rs204989-localized nuclear protein extractbinding event per se.
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5.1.2a Experiment 2: Identification of the transcription-relevant proteins can be
completed via EMSSA with anti-c-fos (part of AP-1 heterodimer) and anti-CEBP/β
antibodies (predicted in fig. 2.4)

22

. Antibody binding with these proteins would create a

supershifted band pattern that would confirm the protein associated with the
oligonucleotides representing the major or minor allele of rs204989. Differential EMSA
and EMSSA results from oligonucleotide probes containing the major versus minor
alleles of rs204989 would be indicative of disruption of transcription factor binding. From
the decreased promoter-driven luciferase activity of rs204989-containing promoters, we
predict the oligonucleotide containing the minor allele of rs204989 would have
decreased intensity. If neither antibody induces a super-shifted migration pattern, an
additional bioinformatics search will be used to identify additional potential transcriptionrelevant proteins that may be associating with this oligonucleotide sequence.
5.1.2a Experiment 3: Primary human leukocytes can then be used to confirm differential
association of the transcription-relevant protein association with the rs204989 locus can
be completed with chromatin immunoprecipitation (ChIP). This immunoprecipitation
would utilize antibodies specific for proteins identified in (5.1.2a Experiment 2) EMSSA
to precipitate chromosomal DNA associated with that protein. The collected precipitate
is then analyzed by qPCR determination of relative abundance of the rs204989 locus
co-precipitated from volunteer leukocytes with either the M/M or m/m genotype36. We
predict the relative DNA abundance co-precipitated from whole blood of the m/m
genotype will be less than the M/M genotype. Future identification of a transcription
factor or chromatin interaction at this locus would validate our previous findings of an
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apparent decrease in GPSM3 promoter activity and develop a more in-depth
understanding of transcriptional control of GPSM3.

Rationale – 5.1.2 Experiment 4: Little is known of processes that regulate the
transcription of GPSM3. Findings in the literature suggests that lipopolysaccharide37 and
methotrexate (GEO: GSE35455) both decrease relative GPSM3 transcript, but it is
inconclusive as to whether that is a GPSM3 promoter repression or a dilution of
transcript. Identification of a bona fide transcription factor interaction with GPSM3
promoter elements would provide more conclusive understanding of GPSM3
transcriptional regulation. This would also confirm the findings in 5.1.2 experiments 1-3,
by testing how activators or inhibitors of this transcription factor affect GPSM3 transcript
and protein concentration differently in the presence of the minor allele of rs204989.
5.1.2 Experiment 4: Insight into proteins involved in transcription whose binding
to DNA is impaired by the minor allele of rs204989 may lead to additional follow-up
experiments to determine natural and synthetic molecules that regulate transcription of
GPSM3. To identify a molecule that affects GPSM3 transcription, we would search
previous literature for compounds that affect the activity of transcriptional protein(s),
identified in the proposed EMSA and ChIP experiments, that associate with the major
allele of rs204989. For example, if AP-1 is found to differentially associate with the
major vs minor allele of rs204989, we could treat NB4* and THP-1 cells with an AP-1
activator, like flagellin (a TLR5 agonist)
inhibitor (e.g., SR 11302

39

38

, in the presence or absence of an AP-1

) to confirm AP-1 specificity. If GPSM3 transcript or protein

levels are affected by this treatment, we can then perform the same experiment using
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either primary leukocytes (e.g., neutrophils and monocytes) or CRISPR/Cas9-modified
NB4* and THP-1 cell lines of the M/M and m/m genotypes, to see if there are differential
effects of these treatments. This experiment would test our hypothesis that the minor
allele of rs204989 affects transcription factor binding, and further our understanding of
regulation of GPSM3 transcription.

5.1.2b – Determine the consequences of rs204989 in leukocyte recruitment

Rationale – 5.1.2b Experiment 1: Our current understanding is that the GPSM3
SNP rs204989 modulates GPSM3 gene transcription level, but we have yet to answer
what effects the SNP-dependent decrease in transcription has on the function of
leukocytes. Classical protein biochemistry has revealed that the GoLoco motifs within
GPSM3 act to sequester inactive Gαi·GDP, preventing its reassociation into the Gαβγ
heterotrimer to transact GPCR signaling

40,41

. An important class of Gαi-coupled

receptors in leukocytes is the chemokine receptor class, which initiate various
processes including chemotaxis
states

43,44

42

and activation of adhesion molecule high affinity

. Previous studies indicated that Gpsm3+/- mice (i.e., heterozygous for

GPSM3 deficiency) are afforded an intermediate level of protection from an acute model
of inflammatory arthritis 9; our conclusion, based on these data, is that a ~50% decrease
in GPSM3 protein expression is still protective from RA-like inflammation in mice. In
unpublished data there is a time sensitive component to GPSM3 detection by Western
blot; therefore, it appears that GPSM3 protein is fairly labile and steady-state GPSM3
protein levels are sensitive to changes in transcript abundance. Therefore, rs204989
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may decrease transcription of GPSM3 in humans enough to (1) decrease steady-state
concentrations of GPSM3 protein and (2) confer some protection from RA. However,
the effect a 24% decrease in GPSM3 mRNA will have on steady-state GPSM3 protein
levels is unknown. Furthermore, we cannot directly translate the protection afforded to
Gpsm3+/- mice in CAIA to humans, because there are marked differences between
mouse and human immunology that must be considered (e.g., differences in blood cell
subset composition

45

and in chemokine receptor expression

46

). Therefore, it is

important to address how the minor allele of rs204989 affects normal leukocyte
physiology in relevant human models (e.g., ex vivo leukocyte isolation or CRISPR/Cas9
genome editing).
5.1.2b Experiment 1: With prior approval from the WVU IRB, isolation of primary
neutrophils and monocytes from M/M and m/m volunteers would be possible by
negative selection of peripheral blood leukocyte. We will seek assistance from the WVU
Flow Cytometry core to confirm leukocyte cell type purity. With primary leukocytes from
these individuals, the effect that the minor allele of rs204989 has on GPSM3 protein
abundance in leukocytes can be determined. Assuming the decrease in GPSM3
transcript correlates to a decrease in GPSM3 protein, assessment of leukocyte
physiology can be performed using these primary leukocytes with previously reported
techniques including Transwell migration toward neutrophil chemoattractants (e.g.,
LTB4 and IL-8), and adhesion of chemokine-activated leukocytes (e.g., with LTB4 and
IL-8) to activated vascular endothelial cells. The latter of which would require
collaboration with a lab group with experience in vascular endothelial cell to leukocyte
interaction, like the Nurkiewicz lab. If the isolation of primary cells were not feasible, an
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alternative approach would be to use CRISPR/Cas9-mediated gene editing to introduce
the minor allele of rs204989 into NB4* and THP-1 immortalized cell line models,
confirmed to be M/M genotype (unpublished), for use in the same experiments.
However, the phenotypic effects of the minor allele of rs204989 may be too small to be
detected at the sensitivity of a Transwell migration assay. Additionally, as discussed
previously (Chapter 1), leukocytes in vivo are subject to a number of additional barriers
to migration including (1) vascular shear stress, (2) vascular endothelial cells, (3)
extracellular matrix, (4) cartilage, and (5) synovial tissues and fluid. Alternatively,
modifications to the Transwell experimental design may be more representative of
physiologic conditions and quantitate any minor differences more effectively. To better
mimic some of these barriers in vitro, modifications can be made to the current
Transwell migration assay by the addition of Matrigel (a basement membrane extract) to
the upper chamber of the Transwell plate. A cultured monolayer of vascular endothelial
cells (i.e., human umbilical vein endothelial cells [HUVEC]) will overlay the Matrigel. The
addition of relevant chemoattractants to the lower chamber will mimic the
transendothelial and trans-extracellular matrix migration required for these cells to
migrate into inflamed synovial tissues. With the additional barriers to migration, this
modified assay will also likely be more sensitive to small changes in migration rate
resulting from a minor disruption in signaling owing to the rs204989 allele, potentially
undetectable in static Transwell migration assays. Additionally, rs204989-dependent
effects on migration may still be relevant in the context of vascular flow and/or additional
RA risk factors.
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5.2 – GPSM3 function in leukocytes

GPSM3 has previously been shown to function in GPCR signaling as a guanine
nucleotide dissociation inhibitor for Gαi/o subunits: i.e, the protein’s GoLoco motifs
sequester inactive Gαi/o-GDP subunits inhibiting their reassociation with Gβγ subunits
41,47

. This process is believed to prolong Gβγ-mediated signaling 9, which has been

shown to be important in the migration of leukocytes toward proinflammatory signals
44,48,49

.
The highly restricted expression pattern of GPSM3 to leukocytes and lymphoid

organs led us to hypothesize that GPSM3 acts as a regulator of chemokine receptor
signaling – one of the most highly expressed classes of Gαi-coupled GPCRs in
leukocytes

50

. Furthermore, our laboratory’s work resulted in the discovery that the

minor allele of rs204989 (i.e., one of the GWAS-identified GPSM3 gene locus
polymorphisms) resulted in a decrease in GPSM3 transcript abundance in cells from
whole blood (Fig. 2.3). Although our laboratory’s collaborative work points to a role for
GPSM3 in the pathogenesis of RA in mouse models

9

and in negative regulation of

NLRP3 (appendix I) 37, the effects of GPSM3 deficiency on human leukocytes has yet to
be evaluated.
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5.2.1 – GPSM3 deficiency affects neutrophil and monocyte cell line migration
toward select chemoattractants

Depletion of GPSM3 from the human THP-1 monocyte-like cell line disrupts
migration toward a gradient of proinflammatory MCP-1 (Fig. 2.5B). The decreased
migration to MCP-1 was not elicited by changes in mRNA expression of the MCP-1
cognate receptor, C-C chemokine receptor 2 (CCR2) (Fig. 2.5D). MCP-1 is a
chemokine known to induce migration of primary monocytes in RA

51,52

. However,

inhibition of MCP-1 signaling through CCR2 has had little success in clinical trials

53

,

likely because of the redundant functions of CCR1 51 and CCR5 51 agonists in monocyte
/ macrophage recruitment to synovial tissues. Importantly, the role of a single
chemokine in monocyte migration was studied, in isolation of the pathophysiologic
conditions where many chemoattractants may be present. However, the advantage that
GPSM3 deficiency has over mouse Ccr2 knockout models
mouse

monocytes

have

significantly

decreased

54

, is that Gpsm3-deficient

migration

toward

multiple

proinflammatory chemokines (i.e., soluble fractalkine, chemerin, MCP-1) or trending
toward being decreased (i.e., macrophage inflammatory protein-1α, RANTES)

9

.

Although these studies are in mouse monocytes, a similar global deficit in migration is
likely replicated in human monocytes. Therefore, disruption of GPSM3 expression or
function in RA patients may result in inhibition, or reduction in, monocyte migration to
inflamed synovial tissues in response to multiple pathophysiologic chemoattractants.
This type of inhibition has not been found with previous clinical trials with single
monocyte chemokine receptor inhibitors 51,55.
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However, our findings of impaired in vitro migration in GPSM3 deficient primary
mouse monocytes did not completely explain the protective phenotype seen in acute
and chronic models of arthritis. In mouse models of arthritis, prior recruitment of other,
more abundant, peripheral blood cell types (e.g., neutrophils) may be capable of
initiating inflammation in the synovial tissues without monocyte migration

54,56–59

. From

these data and the previous mouse model data showing Gpsm3 deficiency protects
mice from acute and chronic induced-arthritis models, we predicted neutrophils would
express GPSM3 and deficiency of GPSM3 would result in an impaired GPCRdependent migratory phenotype. Five observations led us to consider neutrophils as
another leukocyte that expresses GPSM3 including (1) the established involvement of
neutrophils in the development of human rheumatoid arthritis (Chapter 1.2)
GPSM3 transcript in neutrophils from RNA-seq datasets
protein in bovine neutrophils

62

50

60,61

, (2)

, (3) the detection of GPSM3

, (4) higher than expected levels of GPSM3 transcript

abundance in whole blood vs isolated monocytes (Fig. 2.1B), and (5) the shared
myeloid lineage of monocytes and neutrophils 45.
In the immortalized NB4 cell line model of ATRA-differentiated neutrophil-like
cells (NB4*), we showed that GPSM3 transcript and protein concentrations increase
with differentiation towards a neutrophil-like state (Fig. 3.1). Similar to the THP-1
monocyte-like cell line, GPSM3-deficient NB4* cells exhibit an impaired migration
toward LTB4, a proinflammatory chemoattractant (Fig. 3.2B). The critical involvement of
LTB4 in the early migration of neutrophils in RA

56–58,63–66

, may represent the strongest

connection between GPSM3 depletion and near acellularity of synovial tissues in mouse
models of arthritis

9

. Furthermore, disruption in neutrophil function by decreased
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migration may represent another protective function for individuals with the genetic
variant, rs204989, shown to influence GPSM3 transcript abundance (Chapter 2).
However, the clinical relevance of rs204989 (and its apparent ~25% reduction in
GPSM3 expression) may be small, due in part to the observed GPSM3-dependent
disruption of migration (i.e., shRNA19-mediated knockdown being more complete and
phenotypically more obvious versus shRNA20-mediated knockdown being less
complete and phenotypically less robust; Fig. 3.2B). Additionally, the decrease in static
Transwell migration may be amplified in vivo. At the whole organism level,
chemoattractant signaling is required to adhere to vascular endothelial cells44,67, release
enzymes to degrade extracellular matrix molecules68, and to migrate. If GPSM3
deficiency decreases each of these responses, there will likely be an additive or
synergistic effect that is not modeled in this study, but will be addressed in future
experiments (Chapters 5.2.1b and 5.2.2a).
Regardless, the clinical relevance of the rs204989-dependent 24.1% decrease
in GPSM3 transcript should be considered. In the THP-1 cell line, LPS treatment for 3
hours was shown to decrease transcript abundance by 25% (Fig. 4.1C) and that
resulted in a reduction of protein concentration (Fig. 4.1F), thus a natural reduction of
24.1% in whole blood likely decreases protein concentration in these individuals. Such a
reduction of GPSM3 may not impair Transwell migration of proinflammatory leukocytes
enough to be considered as a single RA-relevant genetic factor regardless of additional
effects (e.g., adhesion); however, rs204989 may be useful as part of a genetic
screening panel in conjunction with other RA genetic risk factors

31

. Based on our

present collection of data, we believe a more promising avenue for GPSM3 is as a
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target for inhibition by small molecule compounds, which could disrupt chemoattractant
signaling of proinflammatory cells. This inhibition of signaling through multiple
chemoattractants simultaneously would likely result in decreased migration. Inhibited
signaling may also decrease other chemoattractant-dependent processes, for example
tight leukocyte adhesion44,67 and matrix metalloprotease release68 in RA.
However, this assumption may not pertain to all chemoattractant receptors,
because GPSM3 deficiency did not decrease migration toward N-formylmethionineleucyl-phenylalanine (fMLP; Fig. 3.2C). N-formylated peptides (e.g., fMLP) can be
released from eukaryotic cell mitochondria in necrosis; therefore, may be involved only
in the late-phase (e.g., once significant necrosis begins) of inflammation

56,69

. In host

defense from bacteria, N-formylated peptides are typically a bacterial-derived
chemoattractant peptide involved in leukocyte recruitment. The ability of GPSM3deficient NB4* cells to migrate toward formylated peptides may represent a novel cell
response, that is likely due to the constitutively high numbers of formylated peptide
receptors on neutrophils

50

. This could turnover a large amount of G proteins at once,

thus resulting in Gβγ signaling sufficient to induce migration in the absence of GPSM3
sequestering inactive Gα subunits. Thus, inhibition of GPSM3 by small molecules could
have little effect on neutrophil migration toward certain bacterial infections

70

, and spare

the patient from global immunosuppression and risk of infection as is currently found
with RA biologics.
Additionally, we must consider the effects of GPSM3 deficiency in the chronic,
collagen-induced antibody (CIA) model of inflammatory arthritis. It has been shown that
CIA is dependent on lymphocytes (reviewed in

71

), which is further supported by the
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model’s requirement to be conducted with certain strains of mice (e.g., DBA-1) that
express specific haploblocks of mouse MHC
human HLA

74

72,73

(e.g., H-2q and H-2r) or transgenic

(e.g., HLA-DR1) on lymphocytes. Considering GPSM3 is expressed in

lymphocytes75 and GPSM3 deficiency protects mice from the lymphocyte-dependent
CIA model (unpublished), GPSM3 may also influence normal B- and T-lymphocyte
physiology. Thus, the GPSM3-deficient mouse may be afforded an additional level of
protection from the adaptive immune response in RA. This is supported by observations
of GPSM3 expression in human lymphocytes and immortalized lymphocytic cell lines
9,75

, as well as the impaired migration observed in mouse lymphocytes deficient in

GPSM1, a functionally similar GoLoco motif protein

76

. Research into the functions of

GPSM3 in lymphocyte migration and response to autoantigens may represent another
potential avenue for further investigations, which is currently beyond the scope of this
project. In summary, GPSM3 may be a highly desirable target for small molecule
inhibitors. In the clinical setting, GPSM3 inhibition in RA could circumnavigate the
failures of previous single chemokine receptor-targeted therapeutics

51,77

by working

downstream of multiple chemokine receptors (e.g., LTB4 and MCP-1) and cell types
(e.g., neutrophils and monocytes).
Beyond the role of GPSM3 in the migratory behaviors of monocytes and
neutrophils, our collaborators have shown that GPSM3 deficiency in mouse bone
marrow-derived macrophages (BMDMs) results in increased IL-1β release after priming
with lipopolysaccharide (LPS) and subsequent treatment with NLRP3-activating
compounds such as S. aureus α-hemolysin (HLA) (Fig. 4.5A-C). This inhibitory effect of
GPSM3 on NLRP3 function is presumably mediated through a direct or indirect
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interaction between the leucine-serine-leucine motif of GPSM3 and the 8th leucine-rich
region of NLRP3 (LRR; Fig. 4.2C, 4.3, and 4.4), as part of a larger NLRP3-inactivating
complex. Our experimental contributions to this work support the notion that GPSM3
deficiency does not affect the transcriptional upregulation of Nlrp3 nor pro-il1b in LPS
+/- HLA treated GPSM3 deficient mouse BMDMs (Fig. 4.6A and B). Thus GPSM3 acts
to regulate NLRP3 protein activity independent of transcriptional changes. We also
showed an increase in NLRP3 and pro-IL-1β mRNA abundance in THP-1 human
monocyte-like cells upon LPS treatment, while GPSM3 transcript and protein
abundance decreased (Fig. 4.6C and D). Thus, the inhibitory effect of GPSM3 on
NLRP3 function is a post-transcriptional event. The findings that GPSM3 deficiency
increases release of IL-1β supports the role of GPSM3 as a negative regulator of
NLRP3 activity; however, any apparent increase in IL-1β levels is not manifested as
exacerbated inflammation in the challenged GPSM3-deficient mouse. In contrast,
protection afforded GPSM3-deficient mice to collagen- and collagen-autoantibody
models of inflammatory arthritis runs counter to the known proinflammatory effects of IL1β in RA (e.g., the clinicial effectiveness of the anti-IL-1 biologic anakinra

78

and the

blunted course of chronic inflammatory arthritis exhibited by IL-1β-/- mice

79

).

Furthermore, development of collagen-induced arthritis in mice is not altered in either
NLRP3-deficient or caspase-1-deficient mice

80

. Therefore, chronic arthritis models are

probably dependent on IL-1β production but not dependent on IL-1β from the NLRP3
inflammasome. The disruption of leukocyte migration in GPSM3-deficient mice probably
resulted in an apparent inability of proinflammatory cells to reach the synovial tissues.
Therefore, cells releasing NLRP3-dependent IL-1β in the synovial tissues were
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presumably restricted to resident tissue leukocytes that are present in relatively small
numbers compared to what is seen in inflamed tissues. This small number of cells
would result in a small net change of synovial IL-1β levels upon GPSM3 loss and would
likely not overcome the effects of GPSM3 deficiency in curbing migration toward
proinflammatory chemoattractants. To better understand the clinical effects of GPSM3
on NLRP3 activity, additional studies will need to be performed in human-derived cells.

5.2.2 – Future directions

In summary of 5.2.1, we have shown a role for GPSM3 in the migratory
phenotypes of neutrophil- and monocyte-like leukocytes toward some (but not all)
proinflammatory chemoattractants. These studies have confirmed a similarity between
immune cell dysfunction in our GPSM3-deficient mouse strain and in GPSM3-depleted,
human-derived cell lines. Although these are correlative data, they may represent a
causal link between GPSM3 SNP frequency and the prevalence of RA in large
populations. A role for GPSM3 as a negative regulator of NLRP3 activity in mouse cells
has also been identified. To address questions that still remain about the function of
GPSM3 in the immune system, I propose two individual aims: to investigate cell
migration-relevant phenotypes that are differentially affected by GPSM3 deficiency
(5.2.2a), and to discover the effects GPSM3 deficiency has on NB4* and THP-1
adhesion to activated vascular endothelial cells (5.2.2b).
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5.2.2a – Investigate chemoattractant-relevant functions that are differentially
affected by GPSM3 deficiency

Rationale – experiment 1 (different migration patterns toward LTB4 and fMLP):
Our findings that GPSM3 deficiency disrupts LTB4 migration, but not fMLP-induced
migration, was unexpected (Fig. 3.2B and C). Two possibilities exist here: (1) high
amounts of formylated peptide receptors in neutrophils turn over enough G proteins to
negate the role of GPSM3 in prolonging Gβγ signaling (i.e., excess of signaling Gβγ
subunits) or (2) an uncharacterized mechanism within fMLP signaling is acting that is
not present for LTB4 signaling. One mechanism may be altered Gβ stability. In support
of this hypothesis, GPSM3 has been shown to associate with neosynthesized Gβ
subunits in intact cells, and with each Gβ isoform (i.e., Gβ1-4) in heterologous
overexpression studies

81

. This observation led to the conclusion that GPSM3 acts as a

chaperone for neosynthesized Gβ subunits

81

. However, GPSM3 knockdown in NB4*

cells had no omnibus effect on steady-state Gβ protein levels. Considering the different
isoforms of Gβ have significantly different efficacy at activating some effector molecules,
like PLCβ isoforms

82,83

, GPSM3 may affect the stability and signaling availability of

certain Gβ isoforms preferentially in vivo. Based on the Gβ isoform that couples to the
receptor, some receptors may be more affected by GPSM3 depletion thereby affecting
cell migration differently.
Experiment 1: To address the (1) first hypothesis (i.e., high number of receptors
minimizes the necessity of GPSM3) we plan to partially inhibit formylated peptide
receptor 1 signaling using either shRNA or small molecule inhibition (e.g.,
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BVT17318784). This experiment may determine if fewer responsive receptors may result
in decreased migration in GPSM3-deficient cells. To follow up on the (2) second
hypothesis (i.e., a GoLoco-independent function of GPSM3 is affecting signaling), we
propose restoring expression of either wild-type GPSM3 or variant GPSM3 species with
lentiviral transduction of various loss-of-function mutations (e.g., crippling one or more
of the GoLoco motifs responsible for Gαi·GDP binding, or the LSL motif involved in the
Gβ and NLRP3 interaction). Given that the shRNA19 hairpin used to knockdown
GPSM3 expression in NB4* cells targets the 3’UTR rather than the open-reading frame,
we have the ability to restore plasmid-based GPSM3 expression without interference
from the shRNA. Further experiments would be dependent on the results of which
GPSM3 mutant(s) do(es) not restore wild-type levels of migration. Alternatively, we can
investigate the Gβ stability hypothesis using Gβ-isoform specific antibodies to determine
if there are any changes to specific Gβ isoform levels, indicative of decreased stability in
the absence of GPSM3 function.
Rationale – experiments 2 and 3 (physiologic leukocyte migration): Another
aspect of leukocyte migration that needs to be addressed is the role GPSM3 might play
in GPCR signaling within a physiologically relevant conditions. Leukocyte recruitment to
inflamed synovium in pathophysiological conditions requires migration toward multiple
chemoattractants (experiment 2) and through multiple barriers that were not present in
Transwell assays (experiment 3). To address this, a modified Transwell migration assay
will be developed coating the Transwell membrane with Matrigel and vascular
endothelial cells, to mimic basement membrane and vascular endothelial respectively.
The requirement of chemoattractant signaling for adherence to vascular endothelial
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cells44 and to release enzymes to degrade extracellular matrix68 may mean GPSM3
deficiency affects multiple processes involved in leukocyte transmigration to inflamed
tissues85. Therefore, GPSM3 deficiency could prevent proinflammatory leukocyte
migration with greater magnitude than had been seen in previous simple Transwell
migration assays, although this hypothesis has yet to be addressed directly.
Experiment 2: To address the role GPSM3 plays in migration toward various
chemoattractants we propose sequential experiments. First, we propose investigating
the effects of GPSM3 deficiency in leukocyte migration towards additional diseaserelevant chemoattractants (e.g., complement factor 5a, CXCL8), to better understand
the broader effects of GPSM3 function in neutrophil-like cells and their migratory
responsiveness. Additional investigation in the role GPSM3 plays in multiple chemokine
signaling can be performed in collaboration with the WVU Department of Orthopedics, if
they are able to collect RA and osteoarthritis patient synovial fluid (SF) for future
studies. Following characterization of the chemokine content of SF samples, diluted RA
or osteoarthritis SF will serve as the chemoattractant on the bottom well of a Transwell
plate, with control and GPSM3-deficient NB4* or THP-1 cells in the upper chamber.
Alternatively, THP-1-derived macrophage conditioned media could act as another
source of multiple chemokines. With knowledge of how GPSM3 affects migration toward
multiple chemoattractants, we may be able to glean further knowledge of its signaling
function.
Experiment 3: A modified Transwell migration assay will be used to address the
effects of GPSM3 deficiency on migration through more physiologic barriers (e.g.,
vascular endothelial cells and basement membrane). To mimic the physiologic
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vasculature, a sequential layering on the Transwell membrane of Matrigel, a basement
membrane extract, and TNF-α activated vascular endothelial cells will be used. THP-1
or NB4* cells will be induced to migrate to the lower chamber by MCP-1 or LTB4,
respectively. If GPSM3 deficiency results in a decrease greater than what was observed
in simple Transwell migration assays, we will further investigate the chemoattractantinduced matrix metalloprotease activity (i.e., measure basement membrane degradative
enzyme activity)68 and adhesion to vascular endothelial cells (i.e., interaction prior to
transendothelial migration; experiment 4) (reviewed in

85

). Physiologic migration of

leukocytes in RA is directly addressed in Chapter 1.2.2. A decrease in Transwell
migration is expected in GPSM3 deficient cell lines based on (1) decreased migration in
simple Transwell migration assays (Fig. 2.5B and 3.2C), (2) requirement of
chemoattractant signaling in adhesion to vascular endothelial cells44, and (3)
involvement of chemoattractant signaling in protease release during migration through
extracellular matrix68.

Rationale – experiment 4 (adhesion to vascular endothelial cells): A cascade of
events must occur for leukocyte recruitment to tissues to occur; for example, prior to
any migration, circulating leukocytes must first adhere to vascular endothelial cells
proximal to inflamed tissues. Initial, GPCR-independent, sequential, weak interactions
with constitutively expressed binding molecules occur to promote neutrophil “rolling”. In
vessels supplying inflamed tissues (e.g., arthritic synovial tissues), chemokines and
cytokines from the underlying tissue are transported and bound to the luminal surface of
vascular endothelial cells by glycoaminoglycans

86

. Endothelial-bound chemokines
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induce of β2-integrins to adopt a high-affinity conformation allowing firm adhesion of
leukocytes, thus allowing transendothelial migration toward inflamed tissues to begin
87,88

. This activation of β2-integrins occurs via intracellular signaling networks – reported

in recent studies to be mediated (in part) through G protein βγ signaling

44

, which is

hypothesized to be prolonged by the Gαi·GDP-sequestering action of GPSM3. It is
important to address whether there is a GPSM3-dependent effect on leukocyte firm
adhesion, because adhesion is an obligatory first step to leukocyte recruitment;
therefore, an impairment in adhesion of GPSM3-deficient leukocytes may have an
additive or even synergistic effect with the observed impairment in migration on total
leukocyte recruitment in vivo.
Experiment 4: In collaboration with the Nurkiewicz laboratory, establishment of
an ex vivo flow chamber is possible to assess NB4* and THP-1 cell adhesion to
activated Human Umbilical Vein Endothelial Cells (HUVEC). Use of TNF-α, an activator
of endothelial cells, will be used to activate HUVEC cells, and pretreatment of NB4* or
THP-1 cells with a relevant chemoattractant will activate the high-affinity state of β2integrins. Physiological shear stress for post-capillary endothelial cells will be
established, and time-lapsed images of the flow of NB4* or THP-1 cells across the
activated HUVECs will be reviewed to quantify rolling versus adherent cells, as shown
previously in

89

. Alternatively, GPSM3-deficient mice can be used for intravital

microscopy to determine if there is an effect on adhesion in vivo. If there is not a
significant effect of GPSM3 deficiency on leukocyte firm adhesion, this would be a novel
finding that would be valuable to present alongside our existing data indicating the effect
of GPSM3 deficiency on migration. A decrease in leukocyte cell line adhesion is
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expected, because of the requirement of chemoattractant signaling in leukocyte firm
adhesion44.

Rationale – experiment 5 (phagocytosis of bacteria): Before proposing GPSM3
as a therapeutic target for RA, potential advantages over current treatments should be
considered. The most effective treatment is currently “combination therapy” with a
disease-modifying antirheumatic drug (DMARD), like methotrexate90, and a biologic, the
most popular being the TNFa inhibitors91 (e.g., etanercept, adalimumab). However, this
therapeutic strategy is hindered by an increased risk of serious infections92,93, due in
part to the systemic immunomodulatory role of TNFa94–96. Given this limitation,
considering how GPSM3 functional deficiency (i.e., shRNA) affects responses to
bacterial challenges is important. In mouse models Gpsm3-deficient mice exhibit
abrogated joint inflammation following induction of either acute collagen antibodyinduced arthritis (Fig. 1) or chronic collagen-induced arthritis (Fig. 2); moreover, these
mice show no overt signs of increased risk of infection during normal animal
husbandry9,97. GPSM3 deficient NB4* cell lines are also capable of migrating toward
formylated peptides, which are involved in leukocyte migration toward bacteria (Fig.
3.2D). Thus, these data suggest that GPSM3 may represent a therapeutic target for
pharmaceuticals that are both RA-specific and lack the risk of decreased bacteriainduced immune responses associated with the currently used TNFa inhibitors98.
Experiment 5: To address the effects of GPSM3 deficiency on phagocytosis of
bacteria, bacterial particles labeled with a pH-sensitive fluorescent marker will be used.
To model a physiologic tissue environment, cell models will represent the differentiated

190

state of neutrophils (NB4*) and tissue macrophages (differentiated THP-1*) within
peripheral tissues when functioning in host defense99,100. The co-culture of labeled
bacterial particles with NB4* or macrophage differentiated THP-1 cells (THP-1*) will
allow the leukocyte cell models to phagocytize bacterial particles within phagosomes.
These phagosomes will then acidify and activate pH-sensitive fluorophores on the
bacterial particles. Measurement of fluorescence in real-time will allow quantification of
the effect of GPSM3 deficiency on phagocytosis. Only minimal disruption of
phagocytosis in GPSM3 deficient cells is expected, based on: (1) the dramatic
downregulation of GPSM3 expression (to undetectable levels) seen during the
differentiation pathway to mature macrophages,9 an important tissue phagocyte, (2)
phagocytosis is driven primarily by Gαi-independent signaling processes (e.g., Toll-like
receptors, integrins)101,102, and (3) normal fMLP-induced migration in GPSM3 deficient
cell lines.
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5.3 – Figures

Figure 5.1 –Manhattan plot of association statistics highlighting all autosomal loci
associated with rheumatoid arthritis in this study. The P values of association to
ACPA-positive rheumatoid arthritis from the meta-analysis of the Immunochip and
GWAS data are shown. Known and newly identified rheumatoid arthritis risk loci are
shown in red and black, respectively. The GPSM3 gene locus exists ~500 kb from the
MHC region (P < 10-100), and may explain some of the inverse association with RA.
Three associated loci (identified by asterisks) only reach P < 5 × 10−8 when both ACPApositive and ACPA-negative cases are included in the analysis. The dashed gray line
indicates genome-wide significance (P = 5 × 10−8). Figure and legend adapted from
Eyre, et al.10.
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Figure 5.2 – Predicted lack of mRNA structural consequences of GPSM3 SNP
rs3134605 [A>G]. Bioinformatic prediction using RNAfold

16

of GPSM3 mRNA

secondary structure reveals there are no predicted changes in transcript structure. The
location of rs3134605 is indicated in both structures by the black arrow.
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Compiled (N=3; n=8)
THP-1 cells transfected with pRL-TK and
indicated plasmid (2.24x1011 copies/transfection).
Data normalized to RLuc activity (Mean with SEM).

p < 0.0001

Normalized Luminescence
(FLuc Activity / RLuc Activity)

30

p = 0.0135
% Difference = 27.2%
p = 0.761

20

10

0

THP-1 pGL3-M

THP-1 pGL3-m

THP-1 pGL3-basic

Figure 5.3 – Functional consequences of SNPs rs204989, rs204990, rs204991, and
rs3096688 on GPSM3 promoter activity in THP-1 promyelocytic cells. Functional
results upon subcloning a 3.5 kb-region immediately 5’ to the GPSM3 transcription start
site from M/M and m/m genotype volunteers, leading to wild type (pGL3-M) and
“minor”/polymorphic (pGL3-m) promoter-driven expression of firefly luciferase in THP-1
cells. Luciferase activity is reported as a ratio of GPSM3 promoter-dependent firefly
luciferase activity (FLuc) to control Renilla luciferase activity (pRL-TK control vector).
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A

B

HEK 293 H3K4me3

CD14+ Monocyte H3K4me3

Figure 5.4 – Publically available HEK 293T and CD14+ monocyte H3K4me3 ChipSeq data, from Thurman, et al.21, for (A) HEK 293T and (B) CD14+ monocytes,
retrieved from NCBI (NC_000006.12 GRCh38.2). Red boxes highlight the GPSM3 gene
locus, light green boxes are GPSM3 untranslated regions (UTR), dark green boxes
represent coding regions of the GPSM3 locus, and blue peaks represent the number of
fragments per kilobase of transcript per million mapped reads (FPKM). The amplitude of
the blue peaks represent the likelihood that genomic regions are associated with
trimethylated H3K4.
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Chemoattractant

Concentration Concentration
in RA SF
in OA SF
(pg/ml) ± S.D. (pg/ml) ± S.D.
2.6 ± 0.9
1.5 ± 1.0

Eotaxin / CCL11
Growth-related oncogene
101.4 ± 164.0
alpha (GROα) / CXCL1
IL-8 / CXCL8
161.2 ± 187.4
Monocyte chemotactic
75.7 ± 147.1
protein 1 (MCP-1) / CCL2
Regulated on activation,
normal T-cell expressed
7.0 ± 6.6
and secreted (RANTES) /
CCL5
Leukotriene B4 (LTB4) / 5,
214,320 ±
12-di-HETE
190,171
# = patients with non-inflammatory arthritis.

P value
0.003

4.9 ± 6.6

0.033

8.2 ± 14.5

< 0.0001

30.3 ± 18.9

0.073

1.4 ± 37.9

0.021

52,583 ±
28,612#

0.0003

Table 5.1 – Chemoattractant concentrations in synovial fluid samples of patients
with rheumatoid arthritis (RA) and osteoarthritis (OA), adapted from Hampel, et
al.103 and Klickstein, et al.104. For the first 5 chemoattractants 10-20 ml of synovial fluid
(“SF”) were collected during total knee alloarthroplasy. Chemokine concentration was
performed with 9-plex chemokine array (Quansys Biosciences; Logan, UT, USA). For
LTB4, synovial fluid was collected by aspiration from knee joints, and HETE was
purified and quantified by high-performance liquid chromatography (HPLC).
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Appendix 1

G protein signaling modulator 3 inhibits the inflammasome activity of
NLRP3
This work is the result of a collaborative effort with Dr. Alex Duncan’s lab, to
which I contributed the data and interpretation of figure 6, as well as assistance in
manuscript review. I take no credit for any other experimental findings. This work
is currently published in:
Giguere, P. M., Gall, B. J., Ezekwe, E. A. D., Laroche, G., Buckley, B. K., Kebaier, C.,
Wilson, J. E., Ting, J. P., Siderovski, D. P. & Duncan, J. A. G Protein Signaling
Modulator-3 Inhibits the Inflammasome Activity of NLRP3. J. Biol. Chem. (2014).
doi:10.1074/ jbc.M114.578393
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A1.1 – Abstract
Inflammasomes are multi-protein complexes that regulate maturation of the
interleukin 1β-related cytokines IL-1β and IL-18 through activation of the cysteine
proteinase caspase-1. NOD-like receptor family, pyrin domain containing 3
(NLRP3) protein is a key component of inflammasomes that assemble in
response to a wide variety of endogenous and pathogen-derived danger signals.
Activation of the NLRP3-inflammasome and subsequent secretion of IL-1β is
highly regulated by at least three processes: transcriptional activation of both
NLRP3 and pro-IL-1β genes, non-transcriptional priming of NLRP3, and final
activation of NLRP3. NLRP3 is predominantly expressed in cells of the
hematopoietic lineage. Using a yeast two-hybrid screen, we identified the
hematopoietic-restricted protein ‘G protein signaling modulator-3’ (GPSM3) as an
NLRP3-interacting protein and a negative regulator of IL-1β production triggered
by NLRP3-dependent inflammasome activators. In monocytes, GPSM3 associates
with the C-terminal leucine-rich repeat domain of NLRP3. Bone marrow-derived
macrophages lacking GPSM3 expression exhibit an increase in NLRP3-dependent
IL-1β, but not TNF-α, secretion. Furthermore, GPSM3-null mice have enhanced
serum and peritoneal IL-1β production following Alum-induced peritonitis. Our
findings suggest that GPSM3 acts as a direct negative regulator of NLRP3
function.
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A1.2 – Introduction

Phagocytic mononuclear cells such as monocytes and macrophages respond to
host and environmental cues through numerous signal transduction pathways to
coordinate inflammatory responses. The release of IL-1β and IL-18 from these cells
plays a major role in inflammatory responses to challenge with infectious agents and in
aseptic inflammatory conditions

1

. These cytokines are produced as inactive

cytoplasmic pro-cytokines and require specialized proteolytic processing and secretion
mechanisms in order to be released as biologically active molecules. The proteolytic
processing is carried out by a specific cysteine proteinase, caspase-1 2. Caspase-1 is
synthesized as an inactive pro-enzyme and activation of procaspase-1 is tightly
regulated 3. Multiprotein complexes known as inflammasomes activate caspase-1 in
response to numerous pro-inflammatory stimuli 4. While all inflammasomes activate
caspase-1, inflammasomes are assembled from various core protein components, each
of which has a defined range of triggers.

Inflammasome activation of procaspase-1 is ultimately responsible for proteolytic
processing of the precursors of IL-1β and IL-18 into mature, active cytokines 4. In
addition to procaspase-1, inflammasomes are known to contain other cellular proteins,
including the adapter proteins ‘Apoptotic Speck protein containing a Card’ (or ASC) and
Cardinal (also known as CARD8 or TUCAN), as well as a NOD-like receptor (NLR)
protein family member 4. The mammalian genome encodes approximately 23 NLR gene
family members, each defined by a conserved tripartite protein structure of a variable
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number of leucine-rich repeat at the carboxyl terminus, a central nucleotide-binding
oligomerization domain, and an amino-terminal effector domain. Most NLR effector
domains are either caspase activation and recruitment domains (CARD), leading to the
designation NLRC, or pyrin domains, leading to the designation NLRP

5

. The

immunologic signaling pathways within which many of these NLR proteins participate
have been elucidated both through genetic disease associations and through cell
biological and biochemical analyses of their function 6.

Of all inflammasome-forming proteins, NLRP3 is activated by the broadest range
of stimuli and has been implicated in the pathogenesis of a wide array of
autoinflammatory conditions, sterile inflammatory conditions, and infectious diseases.
Monosodium urate and calcium pyrophosphate crystals, underlying causes of the sterile
inflammatory arthritides gout and pseudogout, cause the activation of caspase-1 and
secretion of IL-1β; macrophages from NLRP3-deficient mice fail to secrete IL-1β in
response to either stimuli 7. Additionally, crystals linked to various other pathologic
inflammatory processes are known to signal through NLRP3, including asbestos, silica,
and β-amyloid fibrils

8-10

. Aluminum hydroxide (Alum), a vaccine adjuvant used in

humans, also stimulates the release of NLRP3-inflammasome-processed cytokines.
NLRP3-deficient

mice

have

blunted

immunologic

responses

to

vaccinations

accompanied by aluminum hydroxide, suggesting that NLRP3 plays an important role in
the adaptive immune response in this setting as well

10,11

. In addition, several

biochemical moieties produced by infectious disease agents or host inflammatory
processes, named pathogen-associated molecular patterns (PAMPs) and damage-
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associated molecular patterns (DAMPs), are known to activate the NLRP3-dependent
inflammasome; PAMPs and DAMPs include pore-forming toxins, pathogen-related RNA
and DNA species, host cell-derived ATP and DNA, and hyaluronan generated from
cellular damage

12

.

Activation of the NLRP3 inflammasome in response to these

diverse stimuli is controlled by a series of transcriptional and post-transcriptional
mechanisms that include upregulation of NLRP3 and involvement of the chaperonin
HSP90 and the deubiquitinase BRCC3 13-15.

Some of us have recently described functional studies of G protein signaling
modulator-3 (GPSM3), a newly identified signaling regulator with prominent expression
in myeloid lineage cells, and at lower relative levels in a variety of lymphoid tissues
GPSM3 (a.k.a. AGS4 or G18;

17-18

) possesses two functional “GoLoco motifs”

18

16

.

for

binding inactive Gαi-GDP subunits and additionally binds to Gβ subunits during their
synthetic pathway towards forming mature Gβγ dimers

19

; these interactions with

heterotrimeric G protein subunits are thought to underlie the effects of GPSM3 on
chemokine receptor signaling that is critical to the development of inflammatory arthritis
16

. More recently, we have described GPSM3 as also interacting directly with the

adaptor protein 14-3-3

20

. To identify additional interacting partner(s) that might be

involved in GPSM3-mediated signalling regulation, a yeast two-hybrid screen was
performed using full-length GPSM3 as bait. This screen 19 identified one clone encoding
a C-terminal fragment of NLRP3. Based on their co-expression in myeloid lineage cells
and the discovery of their potential association by yeast two-hybrid screening, we
investigated the role of GPSM3 in NLRP3-mediated IL-1β screening, we investigated
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the role of GPSM3 in NLRP3-mediated IL-1β production and further characterized this
association using biochemical approaches. Our data indicate a modulatory function of
GPSM3 on NLRP3-dependent IL-1β generation.

A1.3 – Results

A1.3.1 – GPSM3 interacts with the C-terminal end of NLRP3

Yeast two-hybrid screening for potential GPSM3-associated proteins within a
commercial, 106 clone human leukocyte cDNA library identified NLRP3, a critical
component of the monocyte inflammasome complex, as a potential GPSM3-interacting
protein. Fig. 4.1A shows the growth under auxotrophic selection of yeast transfected
with the cDNA encoding full-length GPSM3 fused to the Gal4 DNA binding domain (bait)
and the NLRP3-transcriptional activation domain fusion encoding the partial NLRP3
clone initially retrieved in the screen (prey). Sequence analysis of this prey clone
revealed the last four leucine-rich repeats of NLRP3 (a.a. 831-979) in frame with the
Gal4-transcriptional activation domain (Fig. 4.1B). To further characterize this
interaction, cDNA encoding HA epitope-tagged NLRP3 and FLAG epitope-tagged
GPSM3 were co-transfected in HEK293 cells which do not express either protein
endogenously. Full-length NLRP3, as well as its C-terminal fragment (a.a. 831-979),
were each efficiently co-immunoprecipitated with GPSM3 using anti-Flag antibodies
(Fig. 4.1C and D, respectively).
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Our group has previously described different point mutations to GPSM3 that
abolish specific interactions with its known heterotrimeric G protein binding partners:
Gαi·GDP and monomeric Gβ subunits. For example, mutation to phenylalanine of two
arginines at positions 81 and 152, within the critical triad sequences of the first and third
GoLoco motifs, completely abolishes direct interaction with Gαi·GDP subunits (herein
described as the ‘RF mutant’)

22

(Fig. 4.1B). Moreover, the point mutations

58

LSL60-to-

PLP, within a leucine-rich motif upstream of the first GoLoco motif, dramatically reduce
the association of GPSM3 with monomeric Gβ subunits (herein described as the ‘LSL
mutant’)

19

(Fig 4.1B). While the RF mutation did not perturb co-immunoprecipitation

between GPSM3 and NLRP3, the LSL mutation decreased the ability of GPSM3 to
interact with full-length and truncated NLRP3 (831-979) suggesting a common
interacting protein or shared binding site (Fig. 4.1C and D, last lane), in a fashion similar
to that observed for the GPSM3/Gβ interaction

19

. To demonstrate that the

GPSM3/NLRP3 association is not an artifact of protein overexpression, coimmunoprecipitation of endogenous NLRP3 and GPSM3 was performed from the
human monocytic cell line, THP-1. A sheep polyclonal anti-NLRP3 antibody was used to
immunoprecipitate

endogenous

NLRP3

and

associated

proteins.

The

immunoprecipitated complexes were analyzed for the presence of GPSM3 using
immunoblot with a mouse monoclonal anti-GPSM3 antibody

20,22

. Immunoprecipitation

with anti-NLRP3 antibodies led to capture of detectable endogenous GPSM3 as well as
NLRP3, while mock immunoprecipitation failed to capture either protein (Fig. 4.1E).
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A1.3.2 – Mapping the GPSM3-interaction site(s) within NLRP3

To further characterize the GPSM3/NLRP3 interaction, bioluminescence
resonance energy transfer (BRET) was used to identify the minimal GPSM3-interaction
domain within NLRP3. Full-length GPSM3, fused to the resonance donor Renilla
Luciferase (RLuc-GPSM3) was co-expressed with fusion proteins comprising various
domains of NLRP3 fused to the acceptor fluorescent protein GFP10 (GFP10-NLRP3,
Fig. 4.2A). Any interaction between RLuc-GPSM3 and the NLRP3 domain-GFP10
fusion proteins brings the luciferase donor and GFP acceptor proteins into close
proximity, allowing energy transfer. Cellular co-transfection with a fixed quantity of
RLuc-GPSM3 plasmid and a titration of increasing amounts of GFP10-NLRP3 (fulllength) plasmid generated a saturable signal (Fig. 4.2B) with a maximum net BRET ratio
of 0.3. Furthermore, when the RLuc-GPSM3 fusion contained the LSL mutation, the
BRET signal with GFP10-NLRP3 was lost (Fig. 4.2B). Fig. 4.2C summarizes BRET
experiment results between RLuc-GPSM3 and a variety of GFP10-NLRP3 truncation
constructs (Fig. 4.2A). Expression of RLuc-GPSM3 with GFP10 fusion protein encoding
solely the Pyrin domain of NLRP3 (Fig. 4.2C) gave no observable BRET signal.
Truncation of individual leucine-rich repeat (LRR) domains, starting from the Cterminus, revealed the importance of the last LRR (aa 911-932) to the GPSM3/NLRP3
interaction, as ~50% of the signal was lost following its removal. However, a GFP10
fusion protein encoding both the pyrin and NBD domains (GFP10-NLRP3 536 stop) also
produced ~50% of the total netBRET signal (Fig. 4.2C).
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This BRET-based evidence of interaction with the N-terminal region of NLRP3
was not expected, given that the cDNA clone retrieved from the yeast two-hybrid screen
contained only the last 4 LRRs of NLRP3 and interaction between GPSM3 and this Cterminal NLRP3 fragment was confirmed by reciprocal co-immunoprecipitation (Fig 4.1).
One possible explanation for also detecting a GPSM3 interaction with the NLRP3 Nterminal region is that the NBD domain is known to interact with the C-terminal LRR
portion, forming an intramolecular hairpin-like structure

26

. It is thus possible that, within

this cellular context, the NBD domain of NLRP3 interacts with endogenous NLR
proteins that might also interact with GPSM3. To determine whether GPSM3 could
interact with the NLRP3 C-terminus without bridging by the NLRP3-NBD domain, we
made a GFP10 fusion construct expressing only the C-terminal LRRs of NLRP3
(GFP10-NLRP3-LRR). Additionally, a truncation of the GFP10-NLRP3-LRR fusion
lacking the last LRR (a.a. 911-932) was generated. As expected, the construct
containing all the C-terminal LRRs (i.e., NLRP3 without its pyrin and NBD domains) was
sufficient to generate a robust BRET signal (Fig 4.2D). Removal of the final LRR
abolished the BRET signal, confirming that the last LRR is required for interaction with
GPSM3. Removal of the residual C-terminal extension beyond the final LRR domain
(i.e., “NLRP3 934 stop”) had no effect on the GPSM3/NLRP3 interaction as measured
by BRET (Fig. 4.2D). The interaction between GPSM3 and the GFP10-NLRP3-LRR
fusion protein was also confirmed by co-immunoprecipitation. As also observed in the
BRET assay, the coimmunoprecipitation of GPSM3 and the GFP10-NLRP3-LRR fusion
protein was disrupted by deletion of the last LRR domain, but not the residual Cterminal amino acids (Fig. 4.3).
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A1.3.3 - Subcellular localization of the GPSM3/NLRP3 interaction

We employed a third protein-protein interaction assay, bimolecular fluorescence
complementation (BiFC), to confirm the interaction between GPSM3 and NLRP3 as well
as to study the localization of their complex, using previously described methods

20,22

.

The N-terminal portion of the yellow fluorescent protein (YFP) was fused to full-length
GPSM3 (“YN-GPSM3”) and the C-terminal part of YFP was fused to full-length NLRP3.
When expressed alone or with the non-fused counterpart, no detectable fluorescence
was measured. However, when both fusion proteins were expressed together (YNGPSM3 + NLRP3-YC), a fluorescent signal was detectable in transfected cells (Fig.
4.4). As further confirmation of the co-immunoprecipitation and BRET results (Figs. 4.2
and 4.3), the LSL mutation in GPSM3 greatly reduced the BiFC signal (Fig. 4.4A). The
YN-GPSM3/NLRP3-YC complex was seen to form punctate structures throughout
transfected cells as observed by fluorescence microscopy (Fig. 4.4B). Ectopic
expression of the GFP10-NLRP3 fusion, which is fluorescent without binding the
GPSM3 partner, was also observed to form similar punctate structures, suggesting that
the GPSM3 interaction does not trigger this subcellular localization phenomenon nor
perturb the localization of overexpressed NLRP3 (Fig. 4.4B). These large dots are likely
oligomers of NLRP3 similar to those observed by others using immunofluorescence
based studies of overexpressed NLRP3 or activation of native NLRP3 in NLRP3expressing cells 27-29.
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A1.3.5 – Functional effects of the GPSM3/NLRP3 interaction on NLRP3-dependent
IL-1β secretion

To test the hypothesis that the GPSM3 interaction regulates NLRP3 function and
inflammasome

activation,

bone

marrow-derived

generated from GPSM3-deficient mice

16

macrophages

(BMDMs)

were

and IL-1β secretion quantified following

inflammasome activation. Inflammasome-dependent IL-1β secretion requires initial
priming using lipopolysaccharide (LPS) to induce pro-ILβ synthesis

30,31

. Following LPS

stimulation, different inflammasome activators were added and mature IL-1β secreted in
the medium was quantified. Activators of the NLRP3-dependent inflammasome
including ATP, α-hemolysin (aHL), and Alum induced robust IL-1β secretion with a
significant increase in IL-1β secretion in Gpsm3-/- mice after 4 hours of stimulation
compared to littermate control mice (Fig 4.5A-C left panels). As expected, NLRP3deficient mice showed no observable IL-1β secretion (Fig. 4.5A-C left panels).
Inflammasome activation is known to trigger release of IL-1β but not that of cytokines,
like TNF-α, not dependent on Caspase-1 activation

25

. TNF-α was also quantified in the

culture supernatants from these stimulated macrophages and found to be secreted to
the same extent by all three-mouse genotypes (Fig. 4.5A-C right panels); these results
suggest that GPSM3 regulation of cytokine secretion is specific for those dependent on
NLRP3-mediated Caspase-1 activation.

The specificity of GPSM3 for the NLRP3 inflammasome signalling pathway was
also tested using dsDNA stimulation, an AIM2-inflammasome activator 32, and a flagellin
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derived peptide known to activate the NLRC4-inflammasome

33

. BMDMs isolated from

AIM2-, NLRC4- and NLRP3-deficient mice were used as controls. At 18 hours posttreatment, dsDNA was found to induce a similar release of IL-1β secretion in BMDMs
from WT mice as compared to Gpsm3-/- mice. As predicted, BMDMs from Aim2 -/- mice
failed to secrete IL-1β upon dsDNA stimulation; notably, NLRP3-deficient BMDMs were
found to have increased IL-1β release compared to BMDMs from WT control and
Gpsm3-/- mice (Fig. 4.5C). Similarly, BMDMs from Nlrc4 -/- mice showed a significant
decrease in IL-1β secretion in response to flagellin, as expected

33

(Fig. 4.5D).

Importantly, GPSM3-deficient and WT BMDMs responded equally to dsDNA and
flagellin as an inflammasome stimulator (Fig. 4.5D-E), suggesting that GPSM3
regulation of inflammasomes is limited to the NLRP3-inflammasome.

To explore the involvement of GPSM3 in NLRP3-dependent inflammasome
activation in a more physiological context, we employed a model of Alum-induced
peritonitis and quantified resultant IL-1β production from peritoneal lavage and blood
serum. Gpsm3-/-, Nlrp3-/- and wild type littermate control mice were first pretreated
intraperitoneally (i.p.) with LPS and subsequently injected two hours later with Alum, an
NLRP3-dependent inflammasome activator

25

. Peritoneal exudate and peripheral blood

were both collected and cytokine content quantified. We observed that mature IL-1β
secretion was higher in the lavage and serum of Alum-treated Gpsm3-/- mice compared
to WT controls, whereas blunted IL-1β secretion was observed from Nlrp3-/- mice (Fig.
4.5F).
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To explore the mechanism by which GPSM3 regulated NLRP3-dependent IL-1β
secretion, we undertook studies of NLRP3, IL-1β, and GPSM3 expression in
macrophages and THP1 human monocytic cells. WT and Gpsm3-/- macrophages
exhibited equivalent induction of NLRP3 and Pro-IL-1β mRNA after treatment with LPS
and/or α-hemolysin (Fig. 4.6A and B), further indicating that GPSM3 alters IL-1β
secretion through post-transcriptional regulation of NLRP3. In THP1 cells, priming with
LPS led to increased Pro-IL-1β mRNA and decreased GPSM3 mRNA expression (Fig
4.6C-E). GPSM3 protein levels were also found to be decrease after treatment with LPS
(Fig. 4.6F), suggesting that priming by LPS relieves GPSM3 mediated inflammasome
inhibition in part through down regulation of the protein.

A1.3.5 – The GPSM3/NLRP3 complex includes HSPA8 and is independent of the
GPSM3/14-3-3 interaction

The chaperonin proteins HSP90, SGT1 34-36, and HSP70 37, 38 (reviewed in 39) are
known to be essential in regulating NLRP3-inflammasome activation. Cellular heat
shock diminishes NLRP3-inflammasome mediated Caspase-1 activation, suggesting
that these chaperonins are part of an inactive, basal-state NLRP3-containing complex
40

. The scaffolding protein RACK1 (“receptor for activated C kinases 1”), is required for

the functioning of a HSP90-, SGT1-, and HSP70-containing chaperonin complex in rice
which regulates innate immune signalling through nucleotide binding leucine-rich repeat
(NB-LRR)-type R proteins (the rice orthologs of mammalian NLR proteins) and other
innate immune signalling systems

36,41,42

. Our yeast two-hybrid screen identified the
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heat shock protein HSPA8 (also known as HSC70 or HSP73) and RACK1 as additional
GPSM3-interacting proteins, suggesting that GPSM3 may be involved in chaperoninmediated regulation of NLRP3 function. We thus co-expressed Flag-tagged GPSM3
and HA-tagged NLRP3 in the presence or absence of HA-HSPA8 and HA-RACK1 for
co-immunoprecipitation analyses. Immuno-precipitation of GPSM3 revealed formation
of a complex comprising GPSM3, NLRP3 and HSPA8 but excluding RACK1 (Fig. 4.7A).
Co-expression of HSPA8 increased complex formation between GPSM3 and NLRP3;
surprisingly, co-expression of RACK1 also increased GPSM3-NLRP3 complex
formation, and co-expression of RACK1 and HSPA8 was found to act synergistically on
complex formation. The LSL mutant of GPSM3, previously found to have a greatly
reduced interaction with NLRP3 (Fig. 4.1), also failed to interact with HSPA8 (Fig. 4.7A
and B, lane 7), suggesting a common binding site or partner. In addition,
overexpression of RACK1 and HSPA8 was found to increase fluorescence signal
between YN-GPSM3 and NLRP3-YC as observed using the BiFC assay (Fig. 4.7B).
This result supports the idea of a synergistic effect of RACK1 and HSPA8 on GPSM3NLRP3 complex formation.

We recently described GPSM3 as interacting directly with the adaptor protein 143-3

20

. Given that numerous heat shock proteins are known to interact or form a

complex with 14-3-3 proteins, including HSPA8

43

, we tested whether 14-3-3 proteins

were involved in complex formation between GPSM3, HSPA8, and NLRP3. As
previously described

20

, mutation of a critical serine 35 within the 14-3-3-binding site of

GPSM3 abolishes interaction with 14-3-3. However, the GPSM3 S35A mutant was seen
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to associate with HSPA8 and NLRP3 identically as wild-type GPSM3 (Fig. 4.7C), while
completely abolishing the 14-3-3 interaction, as previously reported 20.

A1.4 – Discussion

Activation of NLRP3 by various danger signals contributes to pathologic
inflammatory responses that drive a number of disease states

12

. Presumably the

capacity to generate potent pathologic inflammatory responses has led to the evolution
of a multistage activation process to rein in NLRP3 inflammasome activity in order to
minimize inappropriate inflammation-driven pathologies. An unbiased screen for
proteins that interact with GPSM3 identified a potential interaction with NLRP3. Our
present results support an endogenous and physiologic interaction between NLRP3 and
GPSM3, and the notion that GPSM3 exerts a negative regulatory effect on the function
of NLRP3. GPSM3 has previously been found to contribute to the induction of acute
inflammation in a collagen antibody-induced arthritis mouse model of acute
inflammatory arthritis. This pro-inflammatory effect is likely mediated by the influence of
GPSM3 on monocyte apoptosis and chemotaxis in response to several G protein
coupled receptor-activating chemokines

16

. This proinflammatory role of GPSM3 does

not contradict the negative regulation of the NLRP3 inflammasome that we now
describe because induction of collagen antibody-induced arthritis has previously been
shown as independent of NLRP3 inflammasome activation

44,45

, and additional GPSM3-

dependent impairment of leukocyte recruitment may offset the increase NLRP3 activity.
Our current data suggests that GPSM3 has pleiotropic effects on immune signaling

227

pathways and that, in addition to modulation of G protein coupled receptor signaling, it
is also able to regulate NLRP3 inflammasome activation.

Using a combination of methodologies, we have shown that GPSM3 interacts
with the distal C-terminal region of NLRP3 and absolutely requires the last leucine-rich
repeat domain (LRR8). No structural information is yet available for either protein;
therefore, we cannot exclude other determinants within NLRP3 that are also important
for this association. The LRR domains of NLR proteins are generally believed to serve
as ligand-binding domains for these innate immune sensors. Although the structure of
the LRR domain of NLRP3 has not yet been elucidated, the LRR domains of NLR
proteins are believed to associate with the NBD domain forming a horseshoe tertiary
structure akin to other LRR-containing proteins. Crystal structures of the LRR portion of
different TLR receptors have been elucidated in the presence of different molecular
ligands including dsRNA

46

, LPS

47

, and lipoprotein

terminus of the NLR protein NLRX1

49

48

, as well as the dsRNA-binding C-

. It is possible that GPSM3 interferes with the

ability of NLRP3 to interact with activating ligands through interaction with the final LRR
domain of NLRP3. A horseshoe tertiary structure for the LRR domains, if also present
within NLRP3, might allow intramolecular interaction of the C-terminal LRR domains
with the N-terminal NBD domain to facilitate the formation of a closed inactive state,
similarly to that described by the NLRC4 crystal structure

50

. The observed residual

BRET signal between GPSM3 and NLRP3 constructs lacking the LRR domains raises
the possibility of an endogenous NLR protein bridging truncated (LRR-lacking) NLRP3
mutants and GPSM3

51

. However, one could also speculate that, if GPSM3 is capable
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of simultaneously interacting with both the amino-terminus and the LRR domain of
NLRP3, such an interaction could inhibit release of the NLRP3 amino terminus and LRR
domain, thereby locking the protein in an inactive form. Further experiments are clearly
required to determine if either one of these mechanisms is involved in the inhibition of
NLRP3 by GPSM3.

A two-step regulatory circuit for cellular IL-1β secretion, in which pro-IL-1β is
induced by TLR stimulation and NLRP3 inflammasome-mediated Caspase-1 activation
is induced by a distinct second signaling event, has been a widely accepted model

52

.

The first step, or “signal 1,” of regulation of inflammasome-mediated IL-1β secretion is a
cell surface receptor-induced NF-kappaB transcriptional activation event that can be
initiated by various TLR-activating stimuli or by numerous cytokine receptors. TLR
stimulation primes cells for IL-1β secretion by enhancing pro-IL-1β production and by
increasing production of NLRP3, which is a very low abundance protein under basal
conditions. Our data indicate that as mRNA transcript abundance of NLRP3 and pro-IL1β increase, the transcript of the negative regulator GPSM3 is decreased as well (Fig.
4.6).

A heterogenous group of stimuli then provide “signal 2”, leading to post-

transcriptional activation of NLRP3 (reviewed in

52

). The activation of NLRP3 by “signal

2” is now known to further require a post-transcriptional deubiquitination event that is
catalyzed by the DUB class of deubiquitinases

53

. These data suggest that, in its basal

state, NLRP3 is ubiquitinated. A complex containing HSP90 and the ubiquitin ligase
subunit SGT1 is required for NLRP3 signaling in mammalian cells, and these proteins
may be involved in the baseline ubiquitination of NLRP3 that has been previously
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observed

39

. We have now presented data demonstrating that one other chaperonin

protein, HSPA8, is also found in complex with NLRP3 and GPSM3. These data suggest
the possibility of a third mechanism by which GPSM3 inhibits NLRP3 activation: namely,
that GPSM3 exerts its negative regulatory effect on NLRP3 by helping to bring it to a
basal Heat Shock protein ubiquitination/chaperonin complex. Based on our present
study and recent advances in the field, we propose a refined model of basal NLRP3
regulation (Fig. 4.8). The role of GPSM3 in promoting NLRP3 inactivation and whether
this negative regulatory pathway can be exploited therapeutically in cases of pathologic
NLRP3 activation remain areas for further study.

A1.5 – Materials and Methods

A1.5.1 – Commercial antibodies, constructs, and other reagents. Horseradish
peroxidase (HRP)-conjugated anti-hemagglutinin (HA) monoclonal antibody (clone
3F10) was obtained from Roche Diagnostics. Anti-Flag M2 antibody, and agaroseconjugated anti-Flag M2 antibody were purchased from Sigma. HRP-conjugated goat
anti-mouse and goat anti-rabbit antibodies were from GE Healthcare (Piscataway, NJ).
Anti-GFP Abfinity antibody was from Invitrogen. Mouse monoclonal anti-NLRP3 clone
cryo-2 was from Adipogen (San Diego, CA) and sheep polyclonal anti-NLRP3 from R&D
systems (Minneapolis, MN). Monoclonal anti-GPSM3 antibody was produced by the
UNC Antibody Core Facility and has been previously described

20

. All cDNAs used in

this manuscript were cloned in the pcDNA3.1 backbone vector (Invitrogen, Carlsbad,
CA), with Flag- or HA- epitope tag sequences included in the forward PCR primer to
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produce N-terminal tagged open-reading frames as described previously

20

.

Recombinant S. aureus α hemolysin was generated as previously described

21

.

Aluminum Hydroxide suspension (Imject Alum) was purchased from Thermo Scientific.

A1.5.2 – Cell culture and transfection. Human embryonic kidney 293 (HEK293) and
THP-1 cell lines were each obtained from the American Type Culture Collection (ATCC)
and maintained in DMEM or RPMI-1640 media (Invitrogen, Carlsbad, CA), respectively,
supplemented with 10% fetal bovine serum (Cellgro, Manassas, VA) at 37°C in a
humidified atmosphere containing 5% CO2. Transient transfections of cell monolayers
grown to 75–90% confluence were performed using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instructions.

A.5.3 – Immunoprecipitation and immunoblotting. Cells were lysed with ice-cold lysis
buffer (20 mM HEPES, pH 7.5, 1 mM EDTA, 150 mM NaCl, 1% NP-40, and Complete
protease inhibitor cocktail tablets (Roche, Indianapolis, IN)) at 4°C on a rocker platform
for 30 min. Lysates were clarified by centrifugation at 16,000 x g for 15 min at 4°C and
quantified by the bicinchoninic acid (BCA) protein content assay (Pierce, Rockford, IL).
For immunoprecipitation, lysates were incubated with specific antibody for 2 hours at
4°C followed by overnight incubation with protein-A/G agarose (Santa Cruz, Santa Cruz,
CA), or directly incubated with agarose-conjugated anti-Flag M2 antibody overnight.
Pelleted antibody/bead complexes were then washed three times with lysis buffer and
proteins eluted in Laemmli buffer. Eluted proteins or lysate samples were resolved on 412% precast SDS-polyacrylamide gels (Novex/Invitrogen), transferred to nitrocellulose,
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immunoblotted using primary and HRP-conjugated secondary antibodies, and
visualized by chemi-luminescence (ECL, GE Healthcare).

A1.5.4 – Bioluminescence resonance energy transfer (BRET). HEK293 cells were
seeded in 12-well plates (3.5 x 105 cells/well) and transfected with fixed amount of
RLuc-GPSM3 or RLuc-GPSM3 LSL mutant vector DNA (50 ng) and increasing amounts
of GFP10-NLRP3 vector DNA (0-1500 ng) and corresponding (decreasing) amounts of
pcDNA3 empty vector (1500 to 0 ng) to obtain a saturation curve. The others BRET
assays were performed by transfecting cells with 50 ng of the RLuc fusion proteinexpressing vector with 750 ng of GFP10-fusion protein expressing vector as indicated.
24h post transfection, cells were washed once, harvested and resuspended in BRET
buffer (phosphate-buffered saline with 1 mM CaCl2, 0.5 mM MgCl2, 0.1% glucose) and
distributed in white 96-wells microplates. BRET was initiated by adding coelenterazine400a at a final concentration of 5 m 0 Measurements of emitted light were collected on
a Mithras LB-940 plate-reader (Berthold Technologies) using a BRET2 filter set.

A1.5.5 – Bimolecular fluorescence complementation (BiFC). Fusion constructs were
made similar to those previously described

22

: namely, a fusion of the N-terminal

fragment (a.a. 1-158) of yellow fluorescent protein (YN) to the N-terminus of full-length
GPSM3 (“YN-GPSM3”) and the C-terminal fragment (a.a. 159-238) of YFP (YC) to the
C-terminus of NLRP3 (“NLRP3-YC”). HEK293 cells were transfected with an equal
amount of plasmids encoding the fusion proteins YN-GPSM3 and NLRP3-YC, and cells
were incubated at 37°C for 24 h. Total DNA quantity was normalized using empty
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pcDNA3.1 vector DNA. To measure fluorescence from formed complexes, transfected
cells were washed, harvested and resuspended in PBS. BiFC signal was acquired using
a Mithras LB-940 plate-reader using an excitation/emission filter set of 485 nm and 510
nm. The level of expression of each fusion protein was quantified by western blotting
using a polyclonal antibody directed against the GFP.

4.5.6 – Immunofluorescence microscopy. HEK293 cells were seeded in a 12-well plate
and transfected with 0.4 mEK293 cells were seeded in aNLRP3-YC. The following day,
cells were transferred to a poly-D-lysine (PDL)-coated coverslip in a 6-well plate and
grown overnight. Cells were then fixed with 4% paraformaldehyde plus PBS for 10 min
at room temperature. Coverslips were mounted using Vectashield mounting medium
containing DAPI (Vector Laboratories, Burlingame, CA) and examined by inverted
epifluorescence microscopy (Olympus IX70) using a 40× objective.

4.5.7 – Mice. Gpsm3 -/- mice were generated as previously described

16

. Nlrp3 -/- mice

were a kind gift from Dr. John Bertin (Millennium Pharmaceuticals) and were further
backcrossed at UNC to achieve nine generations of backcrossing onto the C57BL/6
background. Nlrc4 -/- mice were produced using C57BL/6 embryonic stem (ES) cells
and were a kind gift from Dr. Vishva Dixit (Genentech)

23

. Aim2 -/- mice were generated

using C57BL/6 ES cells by inGenious Targeting Laboratory (Ronkonkoma, NY)
(manuscript in preparation).
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A1.5.8 – Bone marrow-derived macrophages (BMDMs) isolation and culture. BMDMs
were prepared from 9-12 weeks old mice. Briefly, femurs and tibiae were removed from
CO2 euthanized mice. Both ends of the bones were cut and bone marrow cells were
extracted by flushing with DMEM medium containing 10 % FBS using a syringe with a
27-gauge needle. Cell suspension was filtered through a 75 ml cell strainer and then
centrifuged and resuspended in RBC lysis buffer (150 mM NH4Cl, 10 mM KCO3, 0.1
mM EDTA pH 7.4) for 10 minutes on ice. Cells were washed in complete medium and
finally resuspended at a density of 4x106 cells/ml in macrophage-conditioned medium
(DMEM containing 10 % FBS and 20 % L-929 culture supernatant as source of M-CSF).
Cells were seeded in 10-cm tissue culture plate (4x106 cells/plate) in 10 ml final volume.
Three days later, 10 ml of fresh macrophage conditioned medium was adde d and
replaced with 10 ml fresh medium at day 6 and day 8. Cells were collected from culture
dishes at day 8 by washing once with PBS and treated with 5 ml Accutase (Sigma) for 5
minutes at 37°C.

A1.5.9 – Ex-vivo inflammasome activation assay. BMDMs were resuspended in serumfree RPMI 1640 and seeded in 24-wells plate at a density of 1x106 cells/ml/well. LPS
(100 ng/ml) was added for 3 hours. Subsequently, cells were stimulated with NLRP3’s
inflammasome activators as indicated: ATP (5 mM), α hemolysin (10 µg/ml) and
Aluminum hydroxide (130 µg/ml Imject™, Pierce) for 1 hour. For AIM2 inflammasome
activation, dsDNA (2 µg/ml, poly(dA:dT)/Lyovec™, Invivogen) was used and cells
treated for 15 hours. For NLRC4 inflammasome activation, LPS treated macrophages
were then transduced with 250 ng/ml flagellin (Invivogen) using Profect-P2 (1.25 µl/ml,
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Targeting Systems) as described by Miao and colleagues

24

for 1 hour. Cultures

supernatant were collected after centrifugation at 13,000 xg for 10 min and cytokines
(IL-1β and TNFα) were measured by enzyme-linked immunosorbent assay (ELISA) as
described by Craven et al. 21.

A1.5.10 – Quantitative RT-PCR. THP-1 or bone marrow-derived macrophage (BMDM)
cells were activated as previously described with LPS (100 ng/ml) and/or α hemolysin
(10 µg/ml). Cells were harvested and lysed in buffer RLT (Qiagen) + 1% 2mercaptoethanol (Fisher Chemical) before immediately being placed on ice. RNA
extraction was performed using the Qiagen RNeasy kit following manufacturer’s
instructions, and isolated RNA was DNase I treated and used to synthesize cDNA
immediately (Thermo Verso cDNA synthesis kit). Relative gene expression was
quantified using Veriquest Fast Probe PCR master mix (Affymetrix) and Taqman probes
(Life Technologies) for GPSM3, NLPR3, and pro-IL-1β normalized to multiplexed β2microglobin. Fold change in target gene expression was calculated using threshold
values by the 2-ΔΔCt method, described by Livak & Schmittgen, and statistical
significance was determined by one-way ANOVA with Bonferroni post-hoc (p<0.05).

A1.5.11 – In vivo peritonitis experiments. Gpsm3-/-, Nlrp3-/- and wild type littermate
control mice were first pretreated intraperitoneally (i.p.) with LPS (20 mg/kg) and
subsequently injected two hours later with 350 µg Alum (Pierce), an NLRP3-dependent
inflammasome activator

25

. Peritoneal exudate and peripheral blood were both collected

and peritoneal cavity rinses with 3 ml of PBS (i.p. lavage) and both samples mixed

235

together and cytokine content quantified as described previously for ex vivo assay.
Cardiac puncture was used to bleed mice. Serum was collected from coagulated blood
that has been centrifuged.
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Fig. A1.1. Identification of NLRP3 as a GPSM3-interacting protein. (A)
Saccharomyces cerevisiae were co-transformed with indicated bait plasmids (either
expressing the Gal4p DNA binding domain alone [pAS2-1] or as a fusion with full-length
GPSM3 [pAS2-1/GPSM3]) and prey plasmids (either expressing the Gal4p activation
domain alone [pGAD424] or as a fusion with the C-terminus of NLRP3
[pACT2/NLRP3]). Transformed yeast were plated onto synthetic defined agar (Yc)
lacking leucine (Leu-, to select for the prey plasmid) and tryptophan (Trp-, to select for
the bait plasmid); growth on Yc Leu- Trp- medium demonstrates incorporation of both
bait and prey plasmids (left panel). Growth on Yc Leu- Trp- medium also deficient in
adenine (Ade-) and histidine (His-) indicates a positive protein-protein interaction (right
panel). (B) Domain architecture of NLRP3 comprising the pyrin domain, nucleotidebinding domain (NBD), and eight leucine-rich repeats (LRRs) in comparison to the
242

truncated domain structure for the NLRP3 fragment identified in the yeast two-hybrid
screen. Additionally represented is the domain structure of GPSM3 comprising the three
GoLoco motifs (GL1-GL3) and locations of point mutations used in this study. Amino
acid numbering for each domain is based on data from UniProt identifier Q96P20
(NLRP3) and Q9Y4H4 (GPSM3). (C-D) HEK293 cells were transiently co-transfected
with plasmids expressing HA-tagged full-length NLRP3 (a.a. 1-979; panel C) or an
NLRP3 C-terminal fragment (a.a. 831-979; panel D), along with Flag-tagged GPSM3,
either of wildtype sequence (‘WT’), R81F + R152F double mutant (‘RF’; abrogates
GPSM3/Gai·GDP interaction) or the LSL mutant in which the GPSM3 amino-acids
L58SL were mutated to PLP to eliminate the GPSM3/Gb interaction as previously
described. Immunoprecipitation (IP) of GPSM3 was performed using agaroseconjugated anti-Flag M2 antibody and co-immunoprecipitating proteins were detected
by immunoblotting (IB) with anti-HA epitope tag antibody. (E) Whole cell lysates from
THP-1 cells were immunoprecipitated with anti-NLRP3 goat polyclonal antibody or with
Protein-A/-G agarose beads alone. GPSM3 was subsequently detected using an antiGPSM3 mouse monoclonal antibody (clone 35.5.1) and NLRP3 was detected with antiNLRP3 mouse monoclonal antibody. Results shown are representative of two
independent experiments.
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Fig. A1.2. Characterization of the GPSM3/NLRP3 interaction using
bioluminescence resonance energy transfer (BRET). (A) A constant amount of
wildtype (or LSL mutant) RLuc-GPSM3 fusion expression vector was co-transfected into
HEK293 cells with increasing amounts of GFP10-NLRP3 fusion expression vector; the
resultant net BRET ratio was plotted as a function of the acceptor/donor ratio. (B) Cterminal truncation mutants were used to identify the minimal determinants within
NLRP3 required for the interaction with GPSM3. A stop codon was inserted by
mutagenesis after each domain of the GFP10-NLRP3 fusion construct (as indicated)
and subsequently tested in the BRET assay upon co-expression with RLuc-GPSM3. (C)
The leucine-rich repeat domains were fused to GFP10 (called “GFP10-NLRP3 LRR”)
and used in the same BRET experiment.
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Figure A1.3. Co-immunoprecipitation of GFP10-NLRP3 protein constructs with
GPSM3. Flag-tagged GPSM3 was co-transfected with the same GFP10-NLRP3 fusion
proteins used to map the interaction by BRET (Figure 2) and immunoprecipitation was
performed using anti-Flag M2 agarose-conjugated antibody; co-immunoprecipitated
proteins were detected by immunoblotting with an anti-GFP antibody.
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Figure A1.4. Analysis of the GPSM3/NLRP3 interaction using bimolecular
fluorescence complementation (BiFC). (A) HEK293 cells were transfected with
plasmids expressing YN-GPSM3 (a.a. 1-158 of YFP fused to GPSM3) and NLRP3-YC
(NLRP3 fused to a.a. 159-238 of YFP) and the fluorescence of reconstituted YFP
fluorophore was measured at 24 hours post-transfection. Cells were harvested and
fluorescence quantified on a plate reader. Total DNA used for transfection was
normalized using empty pcDNA3.1 vector DNA. Data are expressed as relative
fluorescence units (RFU) using the means ± S.E.M. of at least three different
experiments; *p<0.05, **p<0.01 and ***p<0.001 by one-way ANOVA. (B)
Epifluorescence microscopy images of HEK293 cells transfected with plasmids
expressing the two YFP protein fusions YN-GPSM3 and NLRP3-YC (top panel) or the
GFP10-NLRP3 alone (bottom panel).
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Fig. A1.5. GPSM3 deficiency leads to selective enhancement of the activation of
the NLRP3-dependent inflammasome in macrophages and in a mouse NLRP3
dependent peritonitis. Bone marrow derived macrophages (BMDMs) were generated
from wild type (WT), Gpsm3-/- and Nlrp3-/- mice (panels A, B, and C), or with wild type
(WT), Gpsm3-/-, Nlrp3-/-, Nlrc4-/- and Aim2-/- mice (panels C and D), and primed with
LPS for indicated times at 50 ng/ml before treatment with specific NLR inducers. ATP at
1 mM, Staphylococcus aureus a-hemolysin (HLA) at 10 ug/ml and aluminum hydroxide
and potassium salts (Alum) at 130 ug/ml were used to activate the NLRP3inflammasome. Mouse macrophages were also separately transfected with dsDNA to
activate AIM2 or flagellin peptide to activate NLRC4, as described in the Materials and
Methods section. Cell culture supernatant was collected following treatment and
secreted IL-1b and TNF-a quantified by ELISA as indicated. Twelve week old, wild type
littermate (WT), Gpsm3-/- and Nlrp3-/- mice were each initially primed by an
intraperitoneal injection of LPS (20 mg/kg) and subsequently injected 2 hours later with
350 mg of Alum (or saline vehicle, as indicated). Peritoneal exudate was collected and
the peritoneal cavity rinsed with 3 ml of PBS (“i.p. lavage”) and IL-1β content quantified
by ELISA (panel E). Blood was collected and serum IL-1β was quantified by ELISA
(panel F). Data are expressed in pg/ml using the means ± S.E.M. of three different
experiments (n=8-10); *p<0.05, **p<0.01 and ***p<0.001 by one-way ANOVA.
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Fig. A1.6. Pro-IL-1β and GPSM3 are reciprocally regulated during LPS-induced
inflammasome priming. Bone marrow derived macrophages (BMDMs) were
generated from wild type (WT) or Gpsm3-/- mice and primed with LPS for 3 hours with
100 ng/ml and/or subsequently treated with α -hemolysin (HLA) for 1 hour, as indicated.
Pro-IL-1β and NLRP3 mRNA levels in each cell line were assessed using quantitative
RT-PCR as described in the materials and methods (panels A and B). THP1 cells were
treated with LPS (100ng/ml) or vehicle for 3 hours. GPSM3, Pro-IL-1β, and NLRP3
mRNA levels were assessed by quantitative RT-PCR (panels C, D, and E). Data are
expressed in pg/ml using the means ± S.E.M. of three different experiments (n=8-10);
*p<0.05, **p<0.01 and ***p<0.001 by one-way ANOVA.GPSM3, NLRP3, and actin
(loading control) protein levels were also assessed using immunoblot analysis with the
indicated antibodies (panel F). Samples from 3 independent experiments are shown.
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Fig. A1.7. The heat shock protein HSPA8 is involved in the interaction between
NLRP3 and GPSM3. (A) To assess potential roles of HSPA8 and RACK1 in the
interaction between NLRP3 and GPSM3, HEK293 cells were transiently co-transfected
251

with plasmids encoding Flag-tagged GPSM3, HA-tagged NLRP3, HA-tagged HSPA8,
and/or C-terminal HA-tagged RACK1. Immunoprecipitation (IP) of GPSM3 performed
using agarose-conjugate anti-Flag M2 antibody revealed the presence of HSPA8 in the
complex, but the absence of RACK1, when immunoblotted with anti-HA. (B) HEK293
cells were transfected with plasmids expressing YN-GPSM3 and NLRP3-YC in the
presence or absence of RACK1 and HSPA8 and the fluorescence of reconstituted YFP
fluorophore was measured at 24 hours post-transfection. Cells were harvested and
fluorescence quantified on a plate reader. Total DNA used for transfection was
normalized using empty pcDNA3.1 vector DNA. Data are expressed as relative
fluorescence units (RFU) using the means ± S.E.M. of at least three different
experiments; *p<0.05, **p<0.01 and ***p<0.001 by one-way ANOVA. (C) To assess the
role of the known GPSM3 interactor 14-3-3, HEK293 cells were similarly co-transfected
with Flag-tagged wildtype GPSM3 or GPSM3 R35A mutant (a loss-of-function mutant
abolishing interaction with 14-3-3; ref. (20)) and HA-tagged HSPA8 and HA-tagged 143-3.
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Fig. A1.8. Model of NLRP3 regulation by GPSM3. Formation of a network between
GPSM3, chaperones, and NLRP3 maintains the steady-state level of NLRP3 by
stabilizing it within the complex. Activation of the inflammasome requires two
independent signals. Toll-like receptors (TLR) and tumor-necrosis factor receptors
(TNFR) are known to trigger priming signals leading to up-regulation of NLRP3 and proIL1b through a NFkB-dependent pathway as well as down regulation of GPSM3. Nontranscriptional priming of NLRP3 allows inflammasome activation upon detection of the
activation signal. The NLPR3 activation signal is triggered by endogenous (‘dangerassociated molecular patterns’; DAMPs) or exogenous (‘pathogen-associated molecular
patterns’; PAMPs) danger signals. Activation of NLRP3 can also be mediated by
bacterial pore-forming toxins such as the alpha-hemolysin (HLA) of S. aureus.
Activation of NLRP3 leads to formation of a multiprotein complex containing
oligomerized NLRP3, the adaptor ASC, and caspase-1. Once activated, caspase-1
cleaves pro-IL1b (and pro-IL-18), releasing the biological active form of IL-1b (and IL18) and thereby triggering inflammation and antimicrobial activity.
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